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ABSTRACT
Immunization is a powerful approach for the prevention and control of infectious disease,
however despite the successes of modem vaccine development, there remain several notable
obstacles for the advancement of vaccine-mediated improvements in global healthcare. Many of the
current limitations in vaccine availability and administration are the result of obligate needle-based
delivery, which in addition to contributing to reduced speed, ease, and compliance in administration,
has been shown to contribute to reduced overall safety due to needle re-use and needle-based
injuries. Needle-based vaccine delivery to immunologically passive tissues such as muscle may limit
efficacy, thus motivating the targeting of more inherently potent immune-competent sites. These
inherent limitations of needle-based vaccination on global health have led to a strong impetus to
develop needle-free vaccination strategies which have the potential to improve vaccine efficacy and
availability, enhance the ease, speed, and safety of vaccine administration, and reduce vaccination-
associated costs world-wide.
Here we present the design and preclinical testing of several parallel materials strategies for the non-
invasive delivery of subunit vaccines to the skin. We have utilized laser ablative micro-molding of
poly(dimethylsiloxane) to generate bioresorbable poly(lactide-co-glycolide) micro-structured skin
patches bearing -100 micron-scale needles arrayed across their surface. Upon topical application,
these 'microneedle arrays' are able to safely, and painlessly insert into the immune-competent
epidermal skin layers to generate microscopic conduits through which otherwise impermeant
vaccines and therapeutics are able to passage into the body.
We have leveraged this approach in combination with layer-by-layer (LbL) directed assembly to
generate vaccine-loaded conformal coatings on the surface of these microneedle arrays, which are
then delivered into the skin through topical patch application. The construction of coatings
containing antigen-expressing plasmid DNA (pDNA), together with immune-stimulatory RNA, and
degradable cationic polymers provided tunable control over vaccine dosage, rapid and effective
vaccine delivery in murine and primate skin models, and potent immunogenicity against a model
HIV antigen in mice. In this case, DNA vaccine delivery was able to elicit strong functional CD8' T
cell and humoral responses matching or exceeding the potency of in vivo electroporation, currently
the most promising approach for clinical DNA delivery in humans. Further efforts have explored the
use of LbL for encapsulation and delivery of soluble and particulate protein subunit vaccines, giving
enhanced generation of diverse and potent humoral responses in mice.
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In other work, we have developed an approach enabling rapid delivery of micron-scale degradable
polymer matrices or hydrogel depots using dissolvable composite microneedle structures for the
delivery of vaccines with programmable kinetics. These efforts have demonstrated the potential of
persistent vaccine release on tuning immune potency following non-invasive microneedle delivery,
including induction of potent effector and memory CD8* T cell responses and more powerful and
diverse antigen-specific humoral responses.
Finally, we have developed an approach for simple loading and delivery of clinically advanced
recombinant adenoviral vaccine vectors from sugar-glass coatings on bioresorbable microneedles.
Formulation in microneedle coatings improved vaccine stability at room temperature and preclinical
testing of these vaccine patches in mice and nonhuman primates demonstrated equivalent
immunogenicity compared to parenteral injection, eliciting strong systemic and disseminated
mucosal CD8' and CD4* T cell responses to a model HIV antigen. These cellular responses were
correlated with a similarly potent systemic and mucosal humoral response, together suggesting the
utility of this approach for non-invasive adenoviral immunization in a model close to humans.
Together these results strongly demonstrate the potential of materials engineering strategies for the
effective formulation, delivery, and release of recombinant vaccines by microneedle patches
targeting the skin. In addition to the significant practical advantages enabled by microneedle
delivery including improved safety, convenience, and storage, we have shown that advanced
formulation strategies paired with controlled release are able to initiate humoral and cellular adaptive
immunity more potently than possible through parenteral injection. Comprehensive tests in both
mice and primates have suggested that these principles may be broadly applied to enhance various
recombinant vaccination strategies potentially targeting numerous disease targets. Finally, initial
tests performed in nonhuman primates have indicated the promise of engineered microneedle
approaches for successful translation to humans. Overall, these findings provide a strong basis for
the continued development of similar vaccination strategies for the comprehensive transformation of
conventional vaccination enabling significant vaccine-mediated improvements in global health.
Thesis Supervisor: Darrell J. Irvine
Title: Professor of Biological Engineering and Materials Science and Engineering
Thesis Supervisor: Paula T. Hammond
Title: David H Koch Professor of Chemical Engineering
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1. BACKGROUND
1.1. The Need for, and Challenge of Developing New Generation Vaccines: HIV-1 as a Case Study
There are a reported 3 million new cases of HIV infection worldwide every year and despite the
success of combinatorial anti-retroviral therapies, greater than 2 million people die annually from
HIV-related causes.1 In addition, although anti-retroviral therapies have found success in
preventing the progression of HIV in infected individuals, these therapies are not curative, and
because these drugs are prohibitively expensive they are not readily available in the developing
world. The WHO reports that the developing world continues to bear a disproportionate share of
the global burden of HIV infection, with greater than 35% of new infections and 38% of HIV-
related deaths occurring in sub-Saharan Africa during 2007.1 Furthermore, recent statistics
demonstrate a rapid increase in new HIV-infections across the Indian subcontinent and Southeast
Asia. The devastating individual and societal consequences of this infection, together with the
deficiencies of current treatment options, specifically for those most acutely effected, makes the
development of an effective vaccine against HIV of critical importance.
However, despite decades of scientific effort in pursuit of this objective, there remain significant
scientific challenges facing current vaccine development efforts. Among these are
considerations originating from the unique transmission and replication mechanisms of HIV-1,
such as the need to generate both protective mucosal and systemic immunity, as well as effective
cellular and humoral immune responses.2 In addition, the molecular mechanisms of HIV-1
replication are inherently inaccurate and this results in extraordinary diversity among viral
isolates.2 3 Therefore, any potential strategy for an effective vaccine against HIV-1 must have
the flexibility to successfully address this inherent antigenic diversity. To date, traditional
approaches for generating effective antiviral immunity such as administration of live attenuated
virus, have either proven unsuccessful in immunizing against HIV-1, or are too dangerous given
the high rate of viral mutation. Alternative vaccination strategies such as the delivery of
recombinant peptide antigen or plasmid DNA constructs have met with limited success, partially
due to their relatively lower immunogenicity in humans.4 5 The combination of these approaches
for antigen delivery with administration of immuno-stimulants such as cytokines or adjuvants,
has demonstrated their potential to increase vaccine-elicited immune responses. 6 Therefore, it
seems likely that future improvements to this paradigm may lead to more effective protection
conferred by immunization. Specifically, approaches that increase plasmid transfection
efficiency or improve immunogenicity of protein subunit or plasmid DNA constructs, 7-9 as well
as the development of new non-viral vectors should drastically improve the magnitude and
duration of vaccine-elicited immune responses.
1.2. Potential Advantages of Needle-free Vaccination
Vaccines currently represent a significant strategy for the control of infectious disease on a
global level. However, despite the successes of modem vaccine development, there remain
several notable obstacles for the advancement of vaccine-mediated improvements in global
healthcare. Among these are factors which limit vaccine availability, such as cost and the need
15
for cold storage,10-12 or vaccine efficacy and compliance, such as the ease and speed of vaccine
delivery. Many of the current limitations in vaccine availability and administration are the
result of obligate needle-based delivery, which in addition to contributing to reduced speed, ease,
and compliance in administration, has been shown to contribute to reduced overall safety due to
needle re-use and needle-based injuries. 14-17 The inherent limitations of needle-based vaccination
on global health, together with emerging concern over global pandemic disease, has led to a
strong impetus to develop materials platforms supporting needle-free vaccination strategies
which have the potential to improve vaccine availability, enhance the ease, speed, and safety of
vaccine administration, and reduce vaccination-associated costs world-wide. 13'1 8
1.3. Transcutaneous Vaccine Delivery as a New Paradigm for Immunization
1.3.1. The Skin is Inherently Immuno-competent
Given the inherent drawbacks of needle-based vaccination, one promising alternative is
immunization through transcutaneous delivery of antigen/adjuvant, thereby inducing protective
immunity.19-23 The skin is the primary interface between the body and the environment and, as
such, is inherently endowed with natural immune competencies for the purpose of serving as the
first defense against microbial pathogens. For example, the anatomical structure and cellular
composition of the skin is in many ways ideal for immuno-surveillance and the initiation and
orientation of the adaptive immune response. On a cellular level, the skin represents a rich
immunological environment containing resident epidermal and dermal dendritic cells (DCs),
macrophages, T and B lymphocytes, and NK cells (Figure 1-1, reviewed in 24). In addition,
epidermal keratinocytes, the major cellular component of the skin, are active in detecting
invading pathogens through expression of germ-line encoded pattern recognition receptors
(PRRs) such as Toll-like receptors (TLRs). 25,26 Keratinocytes also constitutively or inductively
secrete many inflammatory cytokines that allow them to serve as instigators of inflammation.27,28
Skin-resident DCs have been shown to serve in a variety of immune-sentinel roles including
antigen uptake2 9 ,3 0 and migration to draining lymph nodes,31 antigen presentation, and
mediation of inflammatory state through cytokine and chemokine secretion. 33-35 Together with
skin-resident macrophages, keratinocytes and DCs represent a sensitive network for detection of
inflammatory signals, and transmission and processing of those signals to interface with and
orient the adaptive immune response.
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aFigure 1-1. Resident antigen presenting cells form an immune-sentinel network in the skin.
(a-b) Confocal micrographs of dissected murine skin showing the sentinel network of MHC-II-
GFP-expressing antigen presenting cells (green). (a)MHC-II-GFP cells reside in the epidermal
and dermal tissue dispersed in a dense network and (b) are able to colocalize with vaccine
delivered into the skin (blue).
1.3.2. Transcutaneous Immunization Indicates the Potential of Cutaneous Vaccine Delivery
The transcutaneous delivery of antigen and adjuvant has been recently explored for the purpose
of immunization with great success (reviewed in 36). For example, many instances of co-
administration of antigen with cholera toxin or heat-labile toxin from Escherichia coli have
produced potent cellular and humoral immune responses to both peptide
37
,
38 and genetic 39'40
vaccine formulations. In addition, transcutaneous application of antigen with adjuvant has been
shown to induce both IgG and IgA antibodies41,42 as well as cellular responses43 in mucosal
secretions in mice and more recently in human clinical trials.20 These effects were amplified in
cases where potent adjuvants were co-administered with either peptide or DNA vaccines 44,45
resulting in protective immunity in several cases of pathogenic challenge. 39 These studies,
although serving as a strong proof of principle for the potential efficacy of skin-based
immunization, are dependent upon the use of separate mechanical disruption of the stratum
corneum, as well as strong adjuvants that present significant associated safety concerns in the
context of translation to human clinical application. Therefore, although transcutaneous
immunization represents a significant opportunity for improving vaccine efficacy, further
progress is needed to ensure safe, convenient, consistent, and cost-effective methods for delivery.
1.4. Microneedles are a Promising Platform for Cutaneous Delivery
Recent work in the area of microneedle fabrication (arrays of needles less than a millimeter in
length) has demonstrated the utility of these materials for safe, efficient, and pain-free disruption
of the stratum corneum, promoting transcutaneous delivery of a variety of therapeutics and other
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bio-active materials (Figure 1-2).46-49 To date, various fabrication strategies have been
employed to create solid microneedles from silicon, metal, and various polymers 50' 5 1 and these
have been applied for cutaneous delivery primarily through (i) application of liquid formulations
to pretreated skin,5 2,5 3 through (ii) the transfer of dried, surface-coated materials from
microneedles upon application, 48'54'55 or more recently, through (i) the application of rapidly
dissolving microneedles encapsulating materials for delivery to the skin.56 -59 Although these
approaches have combined to provide a convincing proof of concept for the application of
microneedle arrays in cutaneous delivery, there are several issues, which must be considered to
allow microneedle-based delivery to address a more broad range of clinical applications. One
significant issue is the fact that current microneedle delivery approaches are deficient in
providing control over the kinetics of materials delivery. Delivery through the transfer of dried
surface-based coatings, as well as application of liquid formulations to microneedle treated skin,
provides therapeutics in a single bolus. Microneedles designed to rapidly dissolve upon
application effectively accomplish the same kinetic timeline for materials delivery. Therefore,
these approaches cannot begin to address clinical situations in which extended or controlled
release is important for improving therapeutic effect. In addition, although rapidly dissolving
microneedles begin to address the need for solid state stabilization of biologically sensitive
materials, thereby avoiding the cost of reliance upon the cold-chain and improving global
availability, there is still a need to combine this with more rigorous methods of materials
encapsulation that will allow for methodical design of materials formulation for delivery. This is
specifically true in the case of vaccination, where the recent push towards strategies utilizing
combinations of recombinant antigen and adjuvant requires a more modular approach to allow
for the necessary flexibility and control needed for rational design of vaccines.
1.0 cm
Figure 1-2. PLGA microneedle patches for transcutaneous delivery
Photograph of a microneedle array fabricated from poly-lactide-co-glycolide (PLGA), a
biodegradable FDA-approved plastic (left). Upon application to the skin, these microneedle-
arrays can safely and painlessly create microscopic channels for vaccine delivery into the body.
A scanning electron microscope image of a similar microneedle array (right) shows the presence
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of uniform needles only 0.5mm in length. This prevents access to blood vessels and nerves
deeper within the skin upon topical microneedle treatment.
1.5. Polyelectrolyte Multilayers (PEMs) Provide Robust Control over Surface-based Delivery
1.5.1. PEMs are a Robust and Flexible Approach to Surface Modification
To address the technological insufficiencies of current strategies for formulating vaccines for
delivery by microneedles, we have pursued layer-by-layer (LbL) nano-layer construction, a film
fabrication approach capable of nano-scale control over coating composition and modular
tunable incorporation of multiple constituents important for vaccine efficacy, delivery, and
storage. The surface-based directed-assembly of complimentary polymers through LbL
adsorption is a well-established method for the deposition of multi-component polymer thin
films. This approach takes advantage of complimentary functionality, such as electrostatic
charge or hydrogen bond status, in constituent materials to allow for deposition of thin films onto
surfaces in which film growth is achieved through iterative exposure to materials of alternating
character (Figure 1-3).
Extensive work in the area of polyelectrolyte multilayer (PEM) directed-assembly has
demonstrated the potential for simple and versatile materials encapsulation into conformal thin
films providing robust control over materials release, solid-state stabilization of environmentally-
sensitive encapsulated materials, and nanometer-scale control over film structure and
composition. 60-64 Control over film structure and composition is generally achieved through the
selection of polyelectrolyte materials, the specific conditions of directed-assembly, and the
number of bi-layers deposited. As film structure and composition are inherent determinants of
film behavior, these factors also provide a robust handle for controlling materials encapsulation
and release. In addition, because the entire process is aqueous-based, the LbL technique is
readily extensible to a variety of diverse natural and synthetic materials, specifically potentially
sensitive biologically active materials. Finally, this approach is ideally suited for application to
substrates of complex geometry, enabling the formation of conformal composite films on
irregular surfaces. Together these factors make the LbL technique an attractive and versatile
platform for rational assembly of functional multi-layered films with broad utility in a variety of
biological and medical applications.
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Figure 1-3. LbL is simple, bio-friendly, and scalable
(a) Schematic of electrostatic LbL directed-assembly for generation of polymer surface films
through iterative exposure to materials of complimentary charge. (b) Surface films are created
through sequential adsorption of charged polymers through electrostatic attraction with
concomitant reversal of surface charge yielding (c) surface films of defined nano-scale polymer
composition and structure.
1.5.2. Poly-f-amino Esters Allow for Controlled Release from Hydrolytically Degradable PEMs
Past efforts to design PEM systems capable of controlled release of biological materials has led
to the development of PEM film architectures utilizing a family of hydrolytically degradable
poly-cations known as poly-p-amino esters (PBAEs). First developed by Lynn and Langer in an
effort to create an improved vector for non-viral gene delivery, PBAEs have previously been
shown to be biocompatible, degradable over a time-scale of hours to days, are capable of
mediating efficient transfection of cells in vitro, and have adjuvant activity when co-delivered
with DNA vaccines.7'65-69 In addition to their straightforward synthesis, PBAEs are readily
degradable by hydrolysis of the ester bonds in their backbone to yield bio-compatible by-
products, all of which have been observed to have no detrimental effect on cell growth or
metabolism in vitro. In all cases, PBAEs show differential degradation kinetics depending on pH
conditions. Specifically, degradation is observed to occur with a much lower half-life at pH 7.4
than at pH 5.1, with the half-life of polymer-1, a representative PBAE, being approximately one
hour or eight hours at pH 7.4 and 5.1 respectively. Finally, PBAEs have been shown to
effectively complex with plasmid DNA through electrostatic interactions at physiologically
relevant conditions, and this has led to improved transfection in vitro.
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These characteristics have led to the extensive use of PBAEs for self-assembly into degradable
PEMs. PBAEs have been shown to readily self-assemble with a variety of poly-anions, and to
deconstruct in aqueous conditions via parallel disassembly and degradation of the constituent
polymers, giving gradual top-down erosion, the kinetics of which can be robustly tuned through
the combinatorial selection of constituent PBAE and poly-anion pairs. In particular, polymer-1,
has been used recently by Irvine and Hammond to fabricate LbL films with controlled erosion
and tunable drug release,64 and by others to fabricate PEM films promoting the controlled release
of plasmid DNA from surfaces for potential gene delivery applications.67'70'71
1.5.3. DNA PEM Self-Assembly is a Promising Approach for Surface-based Gene Delivery
The localized and controlled delivery of plasmid DNA from surfaces has been the objective of
recent research efforts focused on improving gene delivery for both in vitro and in vivo
applications, including tissue engineering7 and cell culture,67,73,74 as well as delivery from
implantable devices such as intravascular stents.7 Progress in the area of delivery from DNA-
containing PEMs has been especially promising given the ability for controlled deposition of
DNA together with various polymers into conformal thin films on geometrically complicated
surfaces. The ability provided by LbL deposition for robust control over nano-scale thin film
composition, and the inherent rigorous control over self-assembly and release that this capacity
allows, makes this approach of significant interest as more complicated systems are engineered.
Prior results in this area have demonstrated that DNA can be deposited by LbL self-assembly
together with a variety of natural and synthetic poly-cations (reviewed in 71). Because DNA is
incorporated directly into these films as a poly-anionic constituent, the LbL approach provides
not only an inherent ability to easily and finely control dosage through variation of deposition
cycle number, but also creates significant opportunities for designing films that efficiently
modulate release and promote efficient transfection through the careful selection of alternative
cationic polymers. For example, the self-assembly of plasmid DNA with various members of the
aforementioned PBAEs serves as an illustrative example. Studies of plasmid self-assembly with
PBAEs demonstrate simple dosage control as film growth and DNA encapsulation are both
linearly correlated with bilayer number.75 In addition, the self-assembly of DNA with PBAEs
(or other degradable cationic polymers) with differing kinetics of hydrolysis has been shown to
allow for rational tuning of the kinetics of DNA release. 75' 76 Finally, PBAEs have been observed
to improve pDNA transfection efficiency relative to naked pDNA and to enhanced immune
response when co-delivered with antigen-encoding plasmid DNA. 7 Therefore, the selection of
these polymers for self-assembly with plasmid DNA may confer these same advantages in an
LbL-based genetic vaccine delivery approach.
1.5.4. Nano-carrier PEM Self-Assembly Enhances PEM Flexibility and Modularity
Despite the success of hydrolytically degradable multi-layer thin films for surface-based
controlled release, this general paradigm for delivery is inherently limited. For example,
although LbL self-assembly has been shown to be generally applicable and extensible to
encapsulation and release of a variety of diverse materials within a broad range of film
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compositions, 62,7 this approach does not provide the generality to apply a single film
architecture to obtain equivalent delivery of chemically diverse species. Instead, independent
design and optimization must be carried out to engineer films capable of encapsulating
chemically or physically distinct materials. Further effort must then be expended in
characterization and control of materials release. This requirement for independent
accommodation of material cargos of interest is a significant obstacle in the development of
multi-layer films capable of delivering multiple materials in combination, an objective of
particular interest in biological and medical applications. Recent approaches have begun to
improve upon this paradigm through incorporation of nano-carriers within multi-layer films
(Figure 1-4). Through the incorporation of cargo-encapsulating micelles, 60,77 liposomes, 78 and
nanoparticles 79 not only can single film architectures provide the flexibility to encapsulate
various diverse materials, but control over release behavior can be achieved independent of
chemical and physical properties of the desired therapeutic cargos. Among these approaches,
nanoparticle-based PEMs are especially promising given that nanoparticle surface functionality
can be easily manipulated independent of cargo, that degradation kinetics can be tuned based on
the choice of degradable polymer, and that structural integrity can be maintained under various
processing conditions. Together, these factors also provide the opportunity for an enhanced
ability for combinatorial encapsulation and delivery of diverse materials with robust and
independent control over release kinetics necessary to address various complex applications.
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Figure 1-4. Nano-carrier PEMs provide additional flexibility and modularity
LbL films encapsulating loaded nano-carriers allow for greater flexibility and con trol, as diverse
materials (i-iii) can be (a) first loaded into particles, and then into films. Thus identical films
can encapsulate various and multiple materials where 'two-stage' loading and (b-c) release are
con trolled by the particle and film design.
1.6. Toll-like Receptor (TLR) Agonists are Effective Vaccine Adjuvants
In order to improve the immunogenicity of peptide or genetic subunit vaccine formulations,
defined molecular adjuvants are frequently co-delivered to provide the necessary innate immune
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stimulus to initiate adaptive immunity. Agonists that stimulate TLRs have been extensively used
for this purpose due to their potency and defined cellular and molecular mechanisms. TLRs
comprise a group of evolutionarily conserved cell-surface and endosomal receptors, which serve
an important role in the regulation of the innate immune response and its interface with adaptive
immunity. Specifically, these receptors recognize compounds conserved among microorganisms
and subsequently activate many diverse cell populations involved in the innate immune
response. Following TLR activation, downstream signaling is mediated by the activation of the
nuclear factor-KB (NFKB) transcription factor8 0 to induce transcription of inflammatory cytokines
such as IL-12, IL-6, IFN-a, and TNF-a. Activation events induced by these cytokines activate
both the innate and adaptive pro-inflammatory immune response. Rapid progress in the
understanding of TLR function in the detection of pathogens by the innate immune system has
indicated the significant promise of TLR agonists for enhancing vaccine efficacy. For example,
certain TLR agonists have been shown to promote DC maturation and antigen presentation,82-84
leading to more effective T cell activation in response to both protein 85 and DNA-based 86
vaccines. As development of non-traditional vaccination strategies continues to progress, the
controlled co-delivery of TLR agonists as vaccine adjuvants should improve immunogenicity in
recombinant vaccines and allow for more rational design of vaccine formulations.
1.7. Scope and Outline of Thesis
This thesis describes the design, development, and application of several strategies for improved
cutaneous delivery using microneedles as a flexible materials platform. Compared to parenteral
injection, microneedle delivery offers many practical advantages including improved safety,
convenience, patient compliance, and cost-effective storage/distribution. Delivery of vaccines to
the skin also provides the ability to more directly target critical immune cell populations which
are densely distributed within the epidermal and dermal tissues and provide pivotal functionality
in the development of effective immunity. Thus, cutaneous vaccination through microneedle
delivery can potentially yield protective immunity that is functionally more potent, and
phenotypically superior to responses elicited by traditional administration. We have explored
several broad hypotheses as a part of this work: (i) that microneedle delivery of recombinant
subunit vaccines should provide additional immunogenicity relative to parenteral administration,
(ii) that greater control over formulation of recombinant multi-component vaccines should
improve microneedle-elicited immunity, (iii) that sustained release of vaccines following
microneedle delivery should allow for additional control over the strength and character of
resulting immune responses, and (iv) that these strategies for engineered vaccines should be
flexible to accommodate various diverse recombinant vaccine platforms (protein, pDNA, virus,
RNA, etc.) with reliable performance in both murine and primate animal models of disease.
Therefore, the broad goal of these studies was the development of new microneedle approaches
for cutaneous vaccination by microneedle delivery of recombinant subunit vaccines and to
evaluate them for preclinical correlates of efficacy.
23
Chapter 2 describes the development of a flexible approach for generating a microneedle
delivery platform using LbL directed-assembly. Fabrication of microneedle arrays was
accomplished using FDA-approved thermoplastics, to ensure safe, cost-effective, and scalable
production for use in humans. Controlled formulation of both pDNA and therapeutic nano-
particles on microneedle patches was achieved through deposition of dried surface coatings using
LbL directed-assembly. These microneedle patches were then shown to be effective in
delivering film-loaded cargos, and in the case of pDNA to produce tunable gene delivery and
expression in mice. These studies serve as a strong proof-of-principle for our directed-assembly
approach, demonstrating the effective control over multiple therapeutic components, effective
transfer into the skin upon microneedle treatment, and controlled release of bio-active delivered
materials in the skin.
Chapter 3 expands upon the results shown in Chapter 2, specifically the design and evaluation of
a materials approach for rapid implantation of controlled-release vaccine films upon microneedle
skin treatment. Here we employed a pH-sensitive polymer to mediate dissolution-based
cutaneous delivery of multilayer films from the surfaces of degradable microneedles upon skin
insertion. We explored the ability of this platform to effectively implant multilayer films, and
control the release of encapsulated vaccine components over time in vivo. These studies
culminated in the demonstration of this approach for eliciting potent cellular and humoral
immunity against a model HIV antigen comparable to the most effective pDNA vaccination
strategies currently in clinical use. Finally, we completed a series of tests in non-human primate
tissues to confirm the ability of microneedle-based cutaneous delivery to mediate successful
pDNA delivery in a model tissue similar to humans. These studies, together with those
described in Chapter 2, serve as a strong indicator of the potential for multilayer delivery to
improve subunit vaccination through microneedle administration, controlled multi-component
vaccine formulation, and sustained release of vaccines.
Chapter 4 continues to explore these concepts for multilayer vaccine formulation and
microneedle delivery within the context of particulate-formulated whole protein vaccines. The
design of pathogen-mimicking synthetic particle-based vaccines has recently shown promise for
enhancing immunity without the potential safety concerns of live or attenuated vaccine vectors.
Building on the success of multilayer delivery described in Chapters 2 and 3, we next designed
an approach for encapsulating lipid nano-capsules into degradable vaccine films on microneedle
surfaces to evaluate the potentially synergistic effects of microneedle delivery, sustained vaccine
release, and particulate vaccine presentation to the immune system. In this case, we observed the
potential for multilayer deposition to generate robust degradable vaccine nano-capsule loaded
films on the surface of microneedles for rapid delivery and sustained release in vivo. In parallel
comparisons to injected particulate vaccines, or microneedle delivered soluble vaccines,
microneedle delivery of vaccine particles gave significantly improved humoral immunity. The
enhanced potency and breadth of the generated antibody repertoire measured here suggests that
cutaneous microneedle delivery, sustained vaccine release from degradable multilayers, and
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particulate vaccine formulation combine synergistically to improve humoral immune responses
in vivo.
Chapters 5 and 6 describe the design and testing of an alternative microneedle delivery approach
utilizing composite structures intended to provide rapid dissolution-based disintegration of skin-
inserted microneedles to implant controlled-release polymer or hydrogel depots within the skin.
Here we continue to explore the effect of sustained vaccine release for enhancing immunity
following microneedle immunization. Composite microneedles were able to rapidly implant
cutaneous polymer or hydrogel depots which persisted in the tissue to sustain vaccine release for
days to weeks. Deployment of this system for the delivery of soluble protein vaccines
demonstrated improved immunity compared to parenteral bolus injection of dose-matched
vaccine formulations again indicating the potential of sustained vaccine exposure to boost
functional immunity in vivo. Further, the ability of these systems to provide varied and sustained
kinetics of antigen and adjuvant exposure was critical for maximizing the potency of elicited
immune responses.
Finally, Chapter 7 describes studies meant to evaluate the clinical potential of microneedles for
cutaneous vaccination through preclinical testing in non-human primates. Although microneedle
vaccination has proven effective in many preclinical rodent models of disease, the potential of
any vaccine system must be established in primate models which more accurately represent
human physiology, immunology, and the human disease state. Here we vaccinated mice and
Rhesus macaques with microneedles bearing vaccine-loaded sugar coatings intended to stabilize
vaccines at room temperature, and rapidly deliver loaded vaccines upon sugar dissolution in
treated skin. The results of these studies indicated that microneedle vaccination induced potent
cellular and humoral immunity in both systemic circulation and mucosal tissues of mice and
primates comparable to those elicited through parenteral injection, indicating the potential of this
approach for effective translation to human clinical trials.
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2. NANO-LAYERED MICRONEEDLES FOR TRANSCUTANEOUS DELIVERY OF POLYMER
NANOPARTICLES AND PLASMID DNA
2.1. Introduction
Current vaccine and therapeutic delivery is largely needle-based,13 but a number of inherent
risks and disadvantages to needle-based delivery have been recognized, such as the need for cold
storage of liquid formulations,11 ' 13 the requirement of trained personnel for administration, and
reduced safety due to needle re-use and needle-based injuries.14 To address these limitations,
vaccination and therapeutics administration through the skin represents a promising alternative
strategy, 20,22,23 and technologies promoting efficient transcutaneous delivery of a variety of drugs
and vaccines has become a significant focus of recent research (reviewed in 87). Recent work in
this area has demonstrated the utility of microneedle arrays for efficient and pain-free disruption
of the stratum corneum (SC), promoting transcutaneous delivery of a variety of bio-active
materials. 46,48 Microneedle delivery is often achieved by coating dried water-soluble drug
formulations directly on the surfaces of solid microneedles. Parallel studies in the area of
polyelectrolyte multilayer (PEM) engineering have demonstrated the potential for simple and
versatile materials encapsulation into conformal thin films, providing robust control over
materials release, solid-state stabilization of environmentally-sensitive encapsulated materials,
and nanometer-scale control over film structure and composition. 60,61,63,64 ,88-90 Prior studies in the
Hammond and Irvine laboratories reported the construction of PEM films loaded with vaccine
components prepared on flexible substrates for transcutaneous vaccine delivery. However,
these planar multilayer patches required prior SC disruption to permit entry of released cargos
from the PEM films into the epidermis. We hypothesized that combining the flexible and highly
tunable nature of PEM thin film coatings with microneedle substrates enabling direct entry of
films into the viable epidermis could provide a versatile platform for single-step transcutaneous
delivery of a broad range of drugs and drug carriers that is effective, generally applicable,
inherently safe and pain-free, and potentially cost effective.
In vitro delivery of plasmid DNA from PEMs has been demonstrated using multilayers that
deconstruct in aqueous conditions via parallel disassembly and degradation of the constituent
polymers. 67,7 We show here that microneedle arrays coated with DNA-carrying PEMs allows
this concept to be translated to in vivo transfection in murine skin, an approach of great interest
for DNA vaccine delivery. Similarly, we show that biodegradable poly(lactide-co-glycolide)
(PLGA) nanoparticles (NPs), ubiquitous in drug delivery, can be embedded within microneedle
PEM coatings, and subsequently deposited in the epidermis following a brief application of
microneedles to unmanipulated skin. Finally, we show that multilayers combining these two
diverse types of therapeutic cargos can be prepared for co-delivery into skin. To our knowledge,
this is the first report of functional coating deposition onto microneedle arrays through the use of
layer-by-layer (LbL) PEM self-assembly. Furthermore, although transcutaneous plasmid DNA
delivery has been demonstrated by topical application to barrier disrupted skin 91,92 and recently
through application of microneedles coated with dried formulations, 93 this is the first reported
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demonstration of in situ DNA delivery from PEM films or PEM-coated microneedles to mediate
in vivo gene delivery and expression.
2.2. Materials and Methods
2.2.1. PLGA Microneedle Fabrication.
PDMS molds (Sylgard 184, Dow Coming) were fabricated by laser ablation using a Clark-MXR,
CPA-2010 micromachining system. PLGA pellets (50:50wt lactide: glycolide, 46 kDa,
Lakeshore Biomaterials) were melted over the molds under vacuum (-25 in. Hg) at 145'C for 40
minutes, and then cooled at -20'C before separating the cast microneedle arrays. Arrays were
characterized using a JEOL 6700F FEG-SEM.
2.2.2. PLGA Nanoparticle Preparation
PLGA nanoparticles were prepared as previously described. 80 Briefly, PLGA (30mg),
DOPC/DOPG lipids (4:1 mol ratio, 5mg, Avanti Polar Lipids), and Dil or DiD (6.4ng,
Invitrogen) were co-dissolved in 1 mL dichloromethane. PBS (200 ptL) was added, the emulsion
was sonicated (7W, 1 min) using a Microson cell disruptor, added to 4mL of Milli-Q (MQ)
water, and sonicated again (12W, 5 min), followed by incubation for 12 hrs at 25'C. The
resulting particles were purified on a sucrose gradient and analyzed using a BIC 90+ light
scattering instrument (Brookhaven Instruments Corp).
2.2.3. Polymer Multilayer Film Preparation
All LbL films were assembled using a Carl Ziess HMS DS50 slide stainer. Films were
constructed on silicon wafers, quartz slides, and PLGA microneedle arrays following treatment
with 02 plasma. To build (PS/SPS) baselayers, substrates were dipped alternatively into PS
(2mg/mL, 1 OOM NaOAc, Sigma-Aldrich) and SPS (5mM, 20mM NaCl, Sigma-Aldrich)
solutions for 10 min separated by two sequential 1 minute rinses in MQ water.94 (Poly-1/pLUC)
multilayers were deposited similarly, alternating 5 min dips in Poly-1 (2mg/mL in 100mM
NaOAc, synthesized according to previous literature 65,69) and pLUC (1 mg/mL, 100mM NaOAc,
a gift from Dr. Daniel Barouch, Beth Israel Deaconess Medical Center) solutions separated by
two sequential rinsing steps in 100mM NaOAc, pH 5.0. Fluorescent pLUC was prepared using
Cy3 Label-IT reagent (Mirus Bio Corporation). All solutions (except pLUC) were adjusted to
pH 5.0 and filtered (0.2ptm) prior to dipping.
2.2.4. Particle Multilayer Film Preparation
Films were assembled using a previously described spray LbL technique.8 ' Briefly, microneedle
arrays were coated with atomized spray solutions using modified air-brushes. Poly-1 (2mg/mL,
100mM NaOAc) and PLGA NP (20mg/mL in MQ water) solutions were sprayed alternatively
for 3 seconds (0.2mL/s, 15 cm range) separated by 6 second rinses with 100mM NaOAc. Film
thickness was measured using a Tencor P-16 surface profilometer. Film delivery was
characterized through CLSM imaging of microneedle arrays using a Zeiss LSM 510 and data
analysis using Image J.95
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2.2.5. In Vivo Transcutaneous Delivery
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state, local,
and NIH guidelines for animal care. Microneedle application experiments were performed on
anesthetized C57BL/6 mice (Jackson Laboratories) and MHC II-GFP transgenic mice (a gift
from Prof. Hidde Ploegh).9 6 Ears were rinsed briefly with PBS on the dorsal side and dried
before application of microneedle arrays by gentle pressure. Microneedles were then removed or
secured in place using Nexcare medical tape (3M). Mice were sacrificed and excised ears were
stained with trypan blue before imaging for needle penetration. Ears collected from mice treated
with Cy3-pLUC- and/or DiI-PLGA-NP-coated microneedle arrays were mounted on glass slides
and imaged by CLSM. Transfection in mice treated with pLUC-coated arrays was measured
using an IVIS Spectrum 200 (Caliper Lifesciences) to detect bioluminescence, following IP
injection of luciferin.
2.3. Results and Discussion
2.3.1. PLGA Microneedle Fabrication
We first used laser micromachining to prepare poly(dimethylsiloxane) (PDMS) slabs with arrays
of tapered pyramidal or conical microscale cavities across their surface, to serve as molds for
polymer microneedle fabrication. Similar to prior reports,5 0 PLGA pellets placed over the molds
were melted under vacuum, cooled, and separated from the PDMS (Supplementary Figure S2-
1) to obtain arrays of microneedles each 250pm in diameter at their base and 900pm in height
(Figure 2-la, Supplementary Figure S2-2). Microneedles of similar dimensions have been
shown to produce negligible pain sensations in humans, while maintaining adequate structural
integrity to efficiently penetrate the SC.97
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Figure 2-1: PLGA microneedle fabrication and LbL coating
(a) SEM micrograph of uncoated PLGA microneedle arrays of pyramidal geometry (scale -
500pm). (b) Film growth (left axis) and absorbance (right axis) for (Poly-J/pLUC, multilayers
assembled on silicon/quartz substrates bearing a (PS/SPS)20 initiating layer (black bar -
(PS/SPS)20 , grey bar - (Poly-1/pLUC)., dashed line - Ab-260 nm). (c, d) Representative
confocal micrographs showing a (c) (PS/SPS)2o-(Poly-1/Cy3-pLUC)24 coated microneedle and a
(d) (PS/SPS)2 -(Poly-1/DiI-PLGA NP)4 coated microneedle (left - transverse section, right -
lateral sections, 200pm intervals, scale - 200 pm). (e) SEM micrograph showing a (PS/SPS)20-
(Poly-1/PLGA NP)4 coated microneedle array (scale - 50pm). (f) Representative confocal
micrographs showing a (PS/SPS)20-(Poly-1/Cy3-pLUC) 24-(Poly-1/DiD-PLGA NP)4 co-coated
microneedle (transverse and lateral sections, left - Cy3-pLUC, right - DiD-PLGA NP, scale -
200 pm).
Polymer Multilayer Deposition
To fabricate a biodegradable PEM coating capable of controlled DNA release in vivo, we
employed a hydrolytically degradable poly(p-amino ester) (PBAE), designated polymer-I (poly-
1, Supplementary Figure S2-3).69 PBAEs have been previously shown to be biocompatible and
degradable, to build multilayers with DNA that transfect cells in vitro, and to have adjuvant
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activity when co-delivered with DNA vaccines. 7,65,67 Poly-1 in particular has been used recently
by our group to fabricate LbL films with controlled erosion and tunable drug release, 64 ,98 ,9 9 and
by others to fabricate DNA-releasing PEM films for potential gene delivery applications. 71' 91 To
provide a uniform initial surface charge density for PEM film growth on the PLGA
microneedles, we first deposited twenty bilayers of poly(4-styrene sulfonate) (SPS), a synthetic
polyanion, and protamine sulfate (PS), a mixture of four related biocompatible, highly cationic
polypeptides of approximately 30 amino acids (Supplementary Figure S2-1).100''01 Onto this
base film, PEMs were built through the alternating adsorption of poly-1 and plasmid DNA
(encoding firefly luciferase, pLUC). Surface profilometry and UV absorbance indicated linear
growth of poly-1/plasmid DNA multilayers (-0.5 ± 0.1 pg pDNA/cm 2/bilayer) when deposited
onto the (PS/SPS) base-layer (Figure 2-1b). Confocal laser scanning microscopy (CLSM) was
used to qualitatively examine microneedles coated with Cy3-labeled pDNA PEMs.
Microneedle arrays coated in this way showed surface-localized fluorescence conformally
coating each microneedle (Figure 2-1c and Supplementary Figure S2-4a), while control
uncoated needles showed no background fluorescence (data not shown).
We next tested whether a similar approach could be used to incorporate biodegradable polymer
NPs into microneedle coatings. Lipid-coated PLGA NPs (244 nm in diameter, PDI 0.15) bearing
a phospholipid surface layer composed of the zwitterionic lipid DOPC, the anionic lipid DOPG,
and containing a lipophilic tracer dye (DiI or DiD) were prepared using an emulsion/solvent
evaporation process we recently described.80 Microneedles were primed with a (PS/SPS) base
layer as before, and then alternating layers of poly- 1 and PLGA NPs were deposited onto the
arrays via spray LbL multilayer self-assembly (Supplementary Figure S2-1).81 CLSM (Figure
2-1d and Supplementary Figure S2-4b) and SEM (Figure 2-le) imaging of the nanoparticle
PEM-coated arrays revealed conformal coatings on the microneedles, similar to the results seen
with poly-1/DNA films. Four (poly-1/NP) bilayers produced a coating approximately 2 pm
thick as measured by profilometry. In addition, serial deposition of (poly-1/pLUC) followed by
(poly-1/NP) bilayers on the same microneedle array permitted the creation of films carrying both
functional components (Figure 2-1f and S2-4c). Thus, PEM-coated microneedles have the
potential to act as multifunctional delivery platforms, carrying cargos with diverse physical
properties.
2.3.3. Microneedle Insertion and Delivery In Vivo
We next analyzed the penetration of microneedle arrays into the dorsal ear skin of C57B1/6 mice
or C57B1/6-MHC II-GFP mice, transgenic animals expressing green fluorescent protein (GFP)
fused to all class II major histocompatibility complex (MHC) molecules. 96 The MHC II-GFP
fusion protein provided an in situ fluorescence marker for the viable epidermis in skin samples
from these mice, as fluorescent epidermal MHC II Langerhans cells (LCs) are readily detected
by CLSM in mouse auricular skin.64 Prior reports have demonstrated that microneedles prepared
from biodegradable polymers with suitable elastic moduli and needle geometries can penetrate
human cadaver skin.97 To confirm that our PLGA arrays could similarly penetrate murine skin,
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uncoated microneedles were applied to dorsal ear skin. Trypan blue staining revealed efficient
and consistent penetration of PLGA microneedle arrays through the SC;48 light microscopic
inspection of arrays before/after application showed some buckling/bending but little breakage of
the needle tips (Figure 2-2a and Supplementary Figure S2-5). CLSM imaging of ear skin
from MHC II-GFP transgenic mice showed that microneedles readily penetrated into the viable
epidermis where LCs were colocalized within the same z-plane (Supplementary Figure S2-6).
To determine if PEM-coated microneedle arrays could deliver pDNA and/or NP cargos into the
skin, we prepared PEM-coated microneedles carrying Cy3-labeled pLUC DNA (Cy3-pLUC) or
Dil-labeled PLGA NPs (DiI-PLGA NPs). These PEM-coated arrays were applied to the ears of
live anesthetized MHC II-GFP mice for 1 min, 5 min or 24 hrs, and then both the freshly
explanted ear skin and the applied microneedles were examined by CLSM. Interestingly, the
cargo delivery properties of these two types of microneedle coatings were quite distinct.
Microneedles carrying (poly-1/pDNA) films examined before and after application to skin
showed very little loss of DNA from the needle surfaces after applications of I or 5 min (Figure
2-2b and Supplementary Figures S2-7a, b, d, and data not shown), and little detectable
transferred DNA in the epidermis (Figure 2-2d and Supplementary Figure S2-8a), but arrays
applied to skin for 24 hours led to nearly complete loss of pDNA from the microneedles (Figure
2-2b and Supplementary Figure S2-7c, d) with a corresponding pronounced accumulation of
DNA in the skin at depths colocalizing with LCs (Figure 2-2e and Supplementary Figure S2-
8b). In contrast, microneedles carrying 4 bilayers of spray-deposited (poly-1/PLGA NP) films
showed immediate transfer of NPs into the epidermis and coincident loss of NP signal from the
microneedles themselves following even a 5 minute application on the skin (Figure 2-2c, 2-2f,
and Supplementary Figures S2-9, S2-10). These disparate results suggest that plasmid DNA-
containing PEM thin films remained intact upon microneedle penetration and subsequently
release DNA over a period of 24 hours, while PLGA NP-containing PEM thin films are likely
deposited in the skin concomitantly with microneedle insertion. It is anticipated that pDNA
undergoes some degree of interpenetration during incorporation in PEMs, consistent with other
polyion species. This would lead to molecular entanglements that would not be present in the
nanoparticle thin films and could account for the relative ease of removal of these films once
inserted into the skin. Thus both PEM multilayer architecture and the nature of the encapsulated
components are parameters controlling the delivery properties of PEM-coated microneedles.
Notably, arrays coated first with (poly-1/pLUC) followed by 4 bilayers of spray-deposited (poly-
1/PLGA NPs) co-delivered DNA and PLGA NPs to the skin of live mice after a 24-hr
application (Figures 2-2g and Supplementary Figure S2-11).
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Figure 2-2. Microneedle delivery of polymer nanoparticles and plasmid DNA
(a) Optical micrograph of ear skin showing microneedle penetration pattern stained using
trypan blue (scale - 100pm). (b) Representative confocal z-stacks and quantification (n = 6) of
(PS/SPS)2 -(Poly-J/Cy3-pLUC)24-coated microneedle arrays (left - brightfield, middle - before
application, right - after 24 hour application, 200pm interval, scale - 200pm). (c)
Representative confocal z-stacks and quantification (n = 6) of (PS/SPS)2 -(Poly-1/DiI-PLGA-
NP)4 coated microneedle arrays (left - brightfield, middle - before application, right - after 5
minute application, 200pm interval, scale - 200pm). Representative confocal micrographs (1 -
MHC-GFP H, 2 - Cy3-pLUC, 3 - DiI/D-PLGA NP, 4 - overlay, scale - 200pm) showing dorsal
ear skin following (d) 5 minute and (e) 24 hour application of a (PS/SPS)20-(Poly-1/Cy3-
pLUC) 24 coated microneedle array, (f) 5 minute (PS/SPS)2o-(Poly-J/DiI-PLGA-NP)4 coated
microneedle application, and (g) 24 hour (PS/SPS)2o-(Poly-J/Cy3-pLUC) 24-(Poly-1/DiD-PLGA
NP)4 coated microneedle application.
Although murine and human skin exhibit a number of structural differences, preclinical mouse
studies of transcutaneous vaccine delivery have been remarkably predictive of clinical trial
results.20 In addition, the mouse model permits a detailed functional analysis of biological
responses to delivered pDNA or NPs. In order to further evaluate the potential of PEM-coated
microneedle arrays for transcutaneous DNA delivery, we assessed the ability of (poly-1/pLUC)-
coated PLGA microneedles to transfect cells in vivo. PEM-coated microneedles were applied to
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the dorsal ear skin of C57BL/6 mice, and in vivo transfection was quantified over time using
whole animal bioluminescence imaging to detect luciferase expression. Mice were treated by
application of a 24 bilayer (poly-1/pLUC)-coated microneedle array to ear skin for 5 minutes
(Figure 2-3a), or a 1- (Figure 2-3b), 5- (Figure 2-3c) or 24-bilayer (Figure 2-3d) array for 24
hrs. Bioluminescence was then monitored in vivo for 7 days. Successful in vivo transfection and
expression of firefly luciferase in the ear skin was detected for both 5 minute and 24 hr
application times, despite the low level of pDNA detected in skin for the former (Figure 2-3e).
In both cases, luciferase expression was detected for over a week, though pLUC-coated
microneedles applied for 24 hours resulted in an increase in the intensity of luciferase
expression, as expected from the CLSM results described above. Additionally, the iterative
nature of LbL film construction is amenable to robust dosage control. Application of
microneedle arrays coated with 1, 5, or 24 bilayers of (poly-1/pLUC) for 24 hrs gave luciferase
expression levels spanning an order of magnitude (Figure 2-3f).
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Figure 2-3. In vivo delivery and transfection of plasmid DNA
In vivo bioluminescent signal observed in C57BL/6 mice (n = 3) following treatment with a
(PS/SPS)20-(Poly-J/pLUCn - coated microneedle array to the right ear: (a) 24 bilayers for 5
minutes, (b) 1 bilayer for 24 hours, (c) 5 bilayers for 24 hours, and (d) 24 bilayers for 24 hours.
The bioluminescent results following treatment are summarize in (e, f) for 7 days together with
the negative control signal (denoted C) collected from the untreated ear, with (e) demonstrating
the effect of application time and (f) showing the result of increasing pLUC dosage.
2.4. Conclusions
In conclusion, as a first step towards the design of a general materials platform for
transcutaneous DNA and therapeutic NP delivery, we have demonstrated for the first time the
application of LbL directed-assembly for the deposition of functional coatings on microneedle
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arrays. We have shown the versatility of this approach, engineering PEM films containing
pDNA and/or degradable polymer NPs, and demonstrating their utility for delivery into the
viable epidermis through microneedle application. Finally, we have shown for the first time to
our knowledge, successful in vivo transfection via DNA released from microneedle-supported
PEM films. These findings suggest the potential utility of these materials for DNA vaccine
delivery and gene therapy, as well as the possibility of co-delivery of therapeutic-loaded
degradable polymer NPs for sustained and controlled release of encapsulated materials in vivo.
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3. POLYMER MULTILAYER TATTOOING FOR ENHANCED DNA VACCINATION
3.1. Introduction
In Chapter 2 we described the design and testing of an approach for therapeutic formulation and
delivery from multilayer films deposited on microneedle surfaces. Despite the success of this
system for effective delivery in vivo important limitations remained unresolved. Prolonged
application times were required in vivo to mediate effective delivery through film degradation,
thus limiting the practicality of administration and limiting the potential use of polymers with
longer degradation kinetics. In Chapter 3, we present the design and testing of an improved
system intended to provide rapid administration and enable the use of slower degrading polymers
for more sustained vaccine release in vivo.
DNA vaccines have been intensively studied due to potential advantages such as ease of GMP
production, lack of anti-vector immunity, and capability to promote both cellular and humoral
immune responses. 4 02 However, plasmid DNA (pDNA) immunization has shown poor efficacy
in non-human primates and human trials, 4'5 and the most promising methods for increasing the
potency of these vaccines have employed involved methods such as in vivo electroporation that
are not attractive for widespread prophylactic vaccination. 0 3 Parallel to the technical challenges
of DNA vaccination, traditional needle-based administration of vaccines has a number of
disadvantages: liquid vaccine formulations typically require refrigeration that raises the cost and
complexity of global distribution (the "cold chain"),12 administration requires trained personnel,
and safety is hampered by needle re-use and needle-based injuries.14 These issues become
particularly acute for vaccine distribution in the developing world.' 3 - 5
We hypothesized that DNA vaccine delivery would be substantially enhanced by an approach
that could simultaneously (i) target DNA to tissues rich in immune-response-governing dendritic
cells, (ii) promote sustained transfection without toxicity, (iii) and provide supporting
inflammatory cues to enhance the induction of a potent immune response. In addition, vaccines
have been shown to vary widely in potency depending on the kinetics of both antigen and
adjuvant exposure, with optimal immunity often stimulated by persistence of antigen and
inflammatory signals for up to one week. 104-107 To meet these design goals, we developed a
strategy using microneedles to rapidly implant into the skin biodegradable polymer films, which
continuously release DNA polyplexes and adjuvant molecules in this immunologically-
competent tissue over a tunable and sustained period of time. We show that skin-implanted
vaccine multilayers allow control over the physical and functional persistence of inflammatory
adjuvants and pDNA, efficiently transfecting cells in murine skin and eliciting cellular and
humoral immune responses comparable to or exceeding in vivo electroporation of pDNA, one of
the most promising current technologies for DNA vaccine delivery.103 We have termed this
approach of implanting persistent polymer films into the skin 'multilayer tattooing', by analogy
to conventional tattooing where persisting inks are deposited in the skin. These multilayer
vaccine formulations allow for dry-state storage of coated microneedle patches at room
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temperature for weeks without loss of activity, an important advantage for decreasing costs and
improving vaccine availability in remote areas. Further, when applied to viable macaque skin ex
vivo, multilayer tattooing elicited 140-fold greater gene expression compared to naked DNA
injection. Thus, this polymer film tattooing approach may offer a route to efficacious DNA
vaccines via a pain-free and self-administrable dry skin-patch platform.
3.2. Materials and Methods
3.2.1. Materials
(b)PNMP (31:59:10 oNBMA:MMA:PEGMA by mol, 17 kDa), poly-1 (15 kDa), and poly-2 (20
kDa) were synthesized as previously reported. 69,08 AL-i1/H-2Kb-peptide-MHC II tetramers
were provided by the NIH tetramer core facility.
3.2.2. PLLA Microneedle Fabrication
PDMS molds (Sylgard 184, Dow-Corning, Midland, Michigan) were prepared using a Clark-
MXR-CPA-2010 (VaxDesign Inc., Orlando, Florida). PLLA (IV 1.9 dL g-', Lakeshore
Biomaterials) was melted over the molds under vacuum (-25 in. Hg, 200'C, 40 min), and then
cooled to -20'C before removal and crystallization at 140'C for 4 hr for solvent resistance.
3.2.3. PNMP Release Layer Deposition
On Si substrates, 3 wt% PNMP in 1,4-dioxane was deposited using a Specialty Coating Systems
P6700 (Indianapolis, Indiana). On PLLA microneedles, 0.25 wt% (b)PNMP was spray deposited
as previously described (0.2 mL s-1, 15 cm range, 10s).81 Films were dried under vacuum at 25'C
for 12 hr. bPNMP release-layers were labeled with Alexafluor-488-conjugated-SAv (10 Ig mL-1
in PBS pH 6.0, Sigma-Aldrich, St. Louis, Missouri).
3.2.4. Polymer Multilayer Film Preparation
LbL films were assembled using a Carl Ziess HMS-DS50 stainer. Films were constructed on Si
wafers and PLLA microneedles following deposition of (b)PNMP and photoswitching via UV-
irradiation (254 nm, 2.25 mW cm-) for 15 min. (PS/SPS) base layers were deposited through
alternative immersion into PS (2 mg mL] , Sigma-Aldrich) and SPS (5 mM, Sigma-Aldrich) for
10 min, separated by two 1 min PBS rinses. (PBAE/nucleic acid) multilayers were deposited
similarly, alternating 5 min dips in poly-1/2 (2 mg mL 1) and either pLUC, pGag, or poly(I:C)
(Invivogen, San Diego, California) solutions (1 mg mL-') separated by two 30 sec PBS rinses.
Fluorescent pLUC and poly(I:C) were prepared using Cy5 and tetramethyl-rhodamine (TMR)
Label-IT reagent (Mirus Bio Corporation, Madison, Wisconsin). All solutions were in PBS,
adjusted to pH 5.0. Films were characterized using a Veeco Dektak profilometer and a Zeiss
LSM510. Data analysis was performed using Image J. Film loading was determined using a
SpectraMax 250 following elution of films in PBS, pH 7.4, 2M NaCl for 24 hours.
3.2.5. In Vitro/In Vivo Delivery
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For in vitro release experiments, (PS/SPS)20(PBAE/nucleic acid)35 films were incubated in PBS
at 37'C and aliquots were assayed for pLUC or poly(I:C) using picogreen or ribogreen assay kits
(Invitrogen). For in vitro delivery, coated microneedles were incubated in PBS, pH 7.4 and
imaged by confocal microscopy. In vivo delivery experiments were performed on anesthetized
C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine) and MHC II-GFP transgenic mice (a
gift from Prof. Hidde Ploegh).96 Ears were rinsed with PBS on the dorsal side and dried before
application of microneedle arrays by gentle pressure. Applied microneedles were imaged by
confocal. Treated skin was excised and stained with trypan blue for needle penetration. Ears
treated with Cy5-pLUC- or TMR-poly(I:C)-coated microneedles (±UV-treatment) were mounted
and imaged by confocal. Clearance of fluorescent poly(I:C) and transfection in mice treated with
pLUC-coated arrays (+UV-treatment) was measured using an IVIS Spectrum 200 (Caliper
Lifesciences, Hopkinton, Massachusetts). For luminescent measurements of pLUC expression,
mice were imaged following IP administration of D-luciferin (150mg kg-1). For luminescent
imaging of MPO-dependent oxidative burst, luminol sodium salt (Santa Cruz Biotech, Santa
Cruz, California) was administered IP (250mg kg'1) before imaging as previously described.10 9
Fluorescence/bioluminescence data was processed using region of interest (ROI) analysis with
background subtraction and internal control ROI comparison to untreated skin using the Living
Image 4.0 software package (Caliper).
3.2.6. Vaccinations
Animal studies were approved by the MIT IUCAC and animals were cared for in the USDA-
inspected MIT Animal Facility under federal, state, local, and NIH guidelines for animal care.
Groups of 4 C57B1/6 mice were immunized with 20 ptg pGag and 10 pg poly(I:C) by
intramuscular injection (15 pl, quadriceps) with or without in vivo electroporation (Harvard
Apparatus ECM830, 2x6Oms pulses, 200V cm-1), intradermal injection (15 ptl, dorsal ear skin,
poly(I:C) mixed with free DNA or DNA/poly-l polyplexes), or by microneedle array (15 min
application of (PS/SPS) 20(poly-1/poly(I:C))35(poly-1/pGag) 35 on uv-PNMP and native-PNMP
coated PLLA arrays). To form poly-1/pDNA polyplexes, pDNA was mixed as previously
described with PBAE (1:1 ratio by mass) in deionized water and vortexed briefly prior to
injection.65 All animals received the same delivered doses of pGag and poly(I:C); microneedle-
delivered dosages were determined by comparison of total eluted pDNA from coated arrays
before and after treatment. Frequencies of Gag-specific CD8+ T-cells and their phenotypes were
determined by flow cytometry analysis of peripheral blood mononuclear cells following staining
with DAPI (live/dead), anti-CD8a, anti-CD44, anti-CD62L, and AL-I l/H-2Kb-peptide-MHC
tetramers. Anti-Gag IgG titers, defined as the dilution of sera at which OD reading was 0.25,
were determined by ELISA using SIV-mac251 (My Biosource, San Diego, California) coated
plates, and UV-Vis detection of peroxidase conversion of tetramethybenzydine (KPL,
Gaithersburg, Maryland) using HRP-conjugated anti-IgG (Jackson Immunoresearch, West
Grove, Pennsylvania). To assess recall responses, microneedle-treated animals were challenged
with 50 pig intramuscular pGag in the quadriceps and cytokine expression was measured by flow
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cytometry in peripheral blood mononuclear cells following stimulation with ALll peptide,
treatment with brefeldin A, and staining with DAPI, anti-CD8 a, and anti-IFN y , anti-TNF a.
3.2.7. Ex Vivo Macaque Skin Culture and Microneedle Testing
Macaque studies were approved by the Harvard Medical School IACUC. Outbred Rhesus
monkeys were housed at New England Primate Research Center. Fresh skin was obtained from
the quadriceps of euthanized Rhesus macaques. Skin was mounted on slides and microneedles
were applied by gentle pressure. Skin was stained using trypan blue for needle insertion,
formaldehyde fixed, and embedded in paraffin for histological sectioning, hemotoxylin and eosin
staining, and optical imaging. To assay ex vivo transfection, pLUC was injected intradermally
(20 pg in 10 pl PBS) or delivered by microneedle in (PS/SPS)20(poly-1/pLUC) 35 multilayers
overlying native or uv-PNMP. Skin was cultured as previously described 1 0 and imaged using an
IVIS Spectrum after addition of 300 ig luciferin to the culture media. Data analysis was
performed as before using the Living Image Software package.
3.2.8. Statistical Analysis
Statistical analysis was performed with Graphpad Prism (La Jolla, California) using two-way
analysis of variance or t-test. Values are reported as mean ± s.e.m.
3.3. Results and Discussion
3.3.1. PLLA Microneedle Fabrication and Multilayer Coating
We first set out to create implantable vaccine coatings using polyelectrolyte multilayers (PEMs,
Figure 3-la), 112 nanostructured films formed by iterative adsorption of alternately-charged
polymers, which embed large weight-fractions of biologic cargos (e.g., DNA, up to 40% of total
film mass),62 stabilize embedded molecules in the dried state,"1"4 and exhibit release kinetics
predetermined by the film architecture/composition. We hypothesized that rapid multilayer
transfer from coated microneedles into the epidermis could be achieved via an underlying
polymer film designed to instantly dissolve when microneedles are applied to the skin (Figure 3-
1b), allowing the kinetics of DNA/adjuvant release in the tissue to be tailored separately from the
time required for a microneedle patch to be kept on the skin. To create such releasable vaccine
coatings, we employed a photo-sensitive and pH-responsive polymer, Poly(o-Nitro-benzyl-
methacrylate-co-Methyl-methacrylate-co-Poly(ethylene-glycol)-methacrylate) (PNMP), for the
release-layer. PNMP is initially organic-soluble, but on brief exposure to UV, cleavage of the o-
nitrobenzyl groups converts the polymer to a weak polyelectrolyte (uv-PNMP) soluble in water
above pH ~6.5.108 As shown below, this photo-switchable solubility provided the means to prove
that PEM film implantation depended on PNMP release-layer dissolution.
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Figure 3-1. Design of quick-release vaccine loaded microneedle coatings
(a) Schematic view of release-layer-mediated multilayer tattooing strategy using coated
microneedles: (1) PLLA microneedles are coated with PNMP release-layer films through spray
deposition; (2) UV-irradiation imparts pH-sensitive aqueous solubility to the PNMP film,
forming a uv-PNMP 'release-layer'; (3) Overlying multilayer films containing nucleic acids are
constructed using LbL deposition at pH 5.0. (b) Mechanism of action for multilayer tattooing:
(1) Microneedle application to skin and exposure to interstitial fluid gives rapid release-layer
dissolution, mediating overlying film delamination and retention in skin following microneedle
removal; (2) Implanted films provide sustained release of nucleic acids through hydrolytic
PBAE degradation and release of in situ-formed PBAE/nucleic acid polyplexes; (3) released
polyplexes mediate local transfection and immune modulation in the tissue.
Skin patches were fabricated by melt-molding poly(L-lactide) (PLLA) on poly(dimethyl-
siloxane) (PDMS) molds to obtain arrays of microneedles each 250 pm in diameter at their base
and 650 pm in height (Supplementary Figure S3-1)."' Biotinylated-PNMP (bPNMP,
Supplementary Figure S3-2a) films were coated on microneedles by spray deposition" from
1,4-dioxane solutions, UV-exposed to trigger the photochemical transition in the film, and then
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stained with fluorescent streptavidin (SAv) to permit visualization of the release-layer by
microscopy. Next, LbL deposition was used to construct an overlying PEM film composed of
Cy5-labeled pDNA encoding luciferase (Cy5-pLUC) and the transfection agent poly-1, a
67,115biodegradable poly(p-amino-ester) (PBAE, Supplementary Figure S3-2b). PEM films
were initiated by depositing 20 bilayers of protamine-sulfate (PS) and poly(4-styrene-sulfonate)
(SPS) to provide a uniform charge density, followed by iterative adsorption of poly- 1 and Cy5-
pLUC (Figure 3-2a). Profilometry measurements performed on PEMs constructed in parallel on
Si substrates showed linear multilayer growth with increasing deposition cycles as previously
reported for (PBAE/pDNA) films (Figure 3-2b).'115 Confocal imaging of microneedles coated
with composite (uv-bPNMP)(PS/SPS) 20(poly-1/Cy5-pLUC) 35 PEM films showed conformal co-
localized fluorescence from SAv-labeled uv-bPNMP and Cy5-pLUC over the surface of each
PLLA microneedle (Figure 3-2c). (Individual uv-bPNMP and PEM films were too thin to
resolve as distinct layers). When analyzed at sequential stages of PEM film deposition, the mean
total SAv-bPNMP fluorescence signal from single microneedles was stable but Cy5-pLUC
fluorescence linearly increased with increasing rounds of bilayer deposition, confirming linear
film growth on microneedles (Figure 3-2d). Measurement of DNA recovered from microneedle
coatings disrupted by treatment with sodium chloride showed ~4.2tg DNA deposited per bilayer
per cm 2 of the microneedle array (Figure 3-2d). Sequential assembly of PEM films comprising
layers of (poly-1/poly(I:C)) followed by layers of (poly-1/pLUC) generated microneedles coated
with complete vaccine multilayers containing pDNA, a transfection agent, and a strong adjuvant
(Figure 3-2e). These composite films showed conformal coating of both vaccine components
(Figure 3-2f) and linear growth of pLUC layers over poly(I:C) layers with increasing number of
deposition cycles (Figure 3-2g, h). Key to this process is that the DNA-containing PEM is never
exposed to UV-irradiation, thus avoiding any potential damage due to UV exposure.
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Figure 3-2. LbL assembly of microneedle coatings carrying DNA, immunostimulatory
RNA, and transfection agents
(a) Film architecture for (uv-PNMP) (PS/SPS),(PBAE/pL UC)n multilayers. (b) Growth of (poly-
1/pLUC)n and (poly-2/pLUC)n multilayers assembled onto (uv-PNMP)(PS/SPS)20films on silicon
substrates as a function of the number of deposited (PBAE/pLUC) bilayers as measured by
surface profilometry. Data represent the mean s.e.m, n = 8. (c) Representative confocal images
of PLLA microneedles coated with (SAv488-bPNMP)(PS/SPS) 2o(poly-1/Cy5-pLUC) 35 films (left
- transverse optical sections, right - lateral sections, 100pum z-intervals, scale bars 200 pm, blue
- Sav488-uv-bPNMP, yellow - Cy5-pLUC). (d) Quantification of Cy5-pLUC and Sav488-
bPNMP incorporated into (SAv488-bPNMP)(PS/SPS)2o(poly-1/Cy5-pLUC)n films on
microneedles through confocal fluorescence intensity analysis (left axis, n = 15) and
measurement of total DNA recovered from dissolved films (right axis, n = 3). Data represent the
mean Ws.e.m. (e) Film architecture for (uv-PNMP)(PS/SPS)2o(poly-1/pLUC)n(poly-1/poly(L-C))n
multilayers. (f) Representative confocal images of microneedles coated with (SAv488-uv-
bPNMP)(PS/SPS)20 (poly-1/TMR-poly(I:C));s(poly-1/Cy5-pLUC)1s films (left - transverse
sections, right - lateral sections, 100,um z-intervals, scale 200 p1m, blue - Sav488-uv-bPNMP,
yellow - Cy5-pL UC, red - TMR-poly(I:C)). (g, h) Quantification of Cy5-pL UC, TMR-poly(I:C),
and SAv488-bPNMP incorporated into (SAv488-bPNMP)(PS/SPS)20 (poly-1/TMR-
poly(I:C))n(poly-1/Cy5-pLUC)n films on microneedles through confocal fluorescence intensity
analysis (g, n = 15) and measurement of total nucleic acids recovered from dissolved films (h, n
= 3). Data represent the mean±s.e.m,
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Lack of toxicity/biocompatibility is critical for materials used in prophylactic vaccines, and the
components of the microneedle system were chosen with biocompatibility in mind: polylactide
used as the microneedle base is a bioresorbable polymer with a long history of clinical use in
resorbable sutures and drug delivery devices. Although we chose to use (PS/SPS) 'base-layer'
films for convenience in lab-scale studies, simplified film architectures composed of only PNMP
and (PBAE/nucleic acids) could be deposited with linear growth per deposition cycle for 20 or
more bilayers (data not shown). Previous studies have demonstrated the biopompatibility of both
PNMP in vitro 08,116 and poly-1 and poly-2 polymers in vitro and in vivo. 66,69,117 Consistent with
these data, we observed no apparent local toxicity in any of the mice treated throughout these
studies.
3.3.2. In Vitro/In Vivo Multilayer Delivery
To test PEM film release from microneedle arrays, dried composite (SAv-labeled uv-
bPNMP)(PS/SPS) 20(poly-1/Cy5-pLUC) 35 coatings (referred to henceforth as PNMP/PEM films)
on microneedles were immersed in pH 7.4 PBS for varying times in vitro and imaged by
confocal microscopy to quantitate uv-bPNMP and Cy5-pLUC fluorescence remaining on the
microneedle surfaces. After 15 minutes incubation in PBS, we observed a significant loss of
both bPNMP and Cy5-pLUC fluorescence from microneedle arrays (Supplementary Figure S3-
3). By contrast, no film release was observed if PEMs were assembled onto PNMP coatings that
had not been irradiated to photo-switch the release-layer's solubility. To determine whether
microneedles coated with releasable films would permit rapid multilayer implantation in vivo, we
applied dry (PNMP/PEM)-coated microneedles to the auricular skin of C57Bl/6-MHC II-GFP
96
mice. Trypan blue staining of treated skin in this case showed consistent microneedle insertion
(Figure 3-3a). Mirroring our in vitro observations, confocal imaging of microneedles after 15
minutes application to murine skin showed that both uv-bPNMP and Cy5-pLUC fluorescence
was rapidly lost from coated microneedles, but only if PNMP films were irradiated before
multilayer assembly to prime for rapid dissolution of the release-layer (Figure 3-3b, c). Confocal
imaging of skin samples following application of (PNMP/PEM)-coated microneedles for 15
minutes showed significant transfer of Cy5-pLUC in the epidermis co-localized with MHC II-
GFP* Langerhans cells (LCs) (Figure 3-3d) and up to 400 ptm deep into the skin (Figure 3-3e),
but only when the PNMP layer was UV-primed. Similarly, microneedles carrying poly(I:C)-
loaded PEM films deposited fluorescently-labeled poly(I:C) into the skin, colocalizing in the
same z-plane with MHC II-GFP-expressing cell populations (Figures 3-3f). Twenty-four hours
after implantation of (poly-1/nucleic acid) multilayers, the degrading films were observed
dispersed into the tissue around the needle insertion site and showed apparent uptake in
colocalized LCs (Figure 3-3g). Thus, the uv-PNMP release-layer promotes rapid transfer of
DNA- or RNA-loaded films from microneedles into the skin.
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Figure 3-3. PNMP release-layers promote rapid implantation of multilayer films at
microneedle penetration sites in vivo
(a) Optical micrograph of ear skin stained with trypan blue to reveal epidermal penetration
following PLLA microneedle application (scale bar, 500pm). (b) Representative confocal images
of (SAv488-bPNMP)(PS/SPS)20(poly-J/Cy5-pLUC)35-coated PLLA microneedles with or without
UV sensitization of the PNMP layer (blue - Sav488-bPNMP; yellow - Cy5-pLUC), before
application, or after 15 min application to murine ear skin (lateral sections, 100 pm z-intervals,
scale bar 200 pm). (c) Quantitation of confocalfluorescence intensities (n = 15) showing loss of
Sav488-uv-bPNMP and Cy5-pLUC films from coated microneedles upon application to skin,
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dependent on UV-induced photo-switching of the PNMP layer solubility. Data represent the
mean±s. e. m, * * *, p< 0.0001, analyzed by unpaired t-test. (d) Representative confocal image of
treated murine skin showing film implantation after 15 min (green - MHC II-GFP; yellow - Cy5-
pLUC; penetration site outlined, scale bar 100um). (e) x-y/x-z/y-z confocal images showing
depth of Cy5-pLUC film deposition after 15 minute microneedle application (green - MHC II-
GFP; yellow - Cy5-pLUC; penetration sites outlined, scale bar 200pim). (f) Representative
confocal image of treated murine skin showing TMR-poly(I.C) film implantation after 15 min
microneedle application (green - MHC II-GFP, red - TMR-poly(I.C); penetration site outlined,
scale bar 100 pm). (g) Colocalization and uptake of TMR-poly(I.C) by MHC II-GFP* LCs at
microneedle insertion site 24 hrsfollowingfilm implantation (green - MHC II-GFP, red - TMR-
poly(IC); yellow - overlay, scale bar 50 pm).
3.3.3. Multilayer Control Over Vaccine Release In Vivo
We next tested whether the in vivo kinetics of nucleic acid release into the surrounding tissue
could be controlled via the composition of multilayers implanted in the skin. Past studies have
demonstrated the ability of multilayers composed of pDNA assembled with the PBAEs poly-I or
poly-2 to mediate release with varying kinetics. 70' 118 Consistent with this prior work,
(PS/SPS)20(poly-1/poly(I:C)) 35 and (PS/SPS) 20(poly-1/pLUC) 35 multilayers constructed on Si
substrates exhibited rapid release at 37'C of ~80% pLUC or poly(I:C) within 24 hours, while
analogous films constructed with poly-2 showed a slower release lasting -1 week
(Supplementary Figure S3-4). To determine whether the composition of PBAE multilayers
implanted via microneedle delivery could mediate similar tunable release of nucleic acid
therapeutics in vivo, we constructed (PBAE/Cy5-poly(I:C)) PEM films on uv-PNMP-coated
microneedles using poly-1 or poly-2 as the PBAE component. Following application of coated
microneedles to the skin of C57B1/6 mice for 15 min, we monitored the fluorescence signal of
implanted Cy5-poly(I:C) over time using whole-animal fluorescence imaging. Similar to the in
vitro trend, films encapsulating poly(I:C) with poly-1 were quickly cleared from the application
site, while (poly-2/poly(I:C)) films persisted for 10 days following application (Figure 3-4a). To
quantify the functional impact of sustained polyl:C adjuvant release in vivo, we applied
microneedles carrying (poly-2/poly(I:C)) multilayers to the auricular skin of mice or injected
equivalent doses of free poly(I:C) intradermally at the same site, and administered the
chemiluminescent probe luminol to trace local inflammation over time. Systemically-injected
luminol emits photons when catabolized by myeloperoxidase (MPO) produced by activated
innate immune cells at sites of inflammation.'09'119 As shown in Figure 3-4b, bolus poly(I:C)
injection elicited a transient burst of inflammation that resolved by 48 hr, while multilayer
implantation resulted in 2-fold higher peak MPO activity at 24 hr that decayed slowly to baseline
over -1 week. Importantly, poly(I:C)-triggered inflammation was highly localized to the
application site, as no elevation of systemic cytokines was observed following multilayer
implantation (data not shown). Thus, the composition of implanted PEM films can directly
control the kinetics of release and local inflammatory response in the skin.
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Figure 3-4. Implanted films control the physical and functional persistence of pDNA and
polyl:C in vivo
(a) Representative whole-animal fluorescence images showing TMR-poly(I:C) retention at the
application site and quantitative analysis of normalized total fluorescence R(t) relative to initial
fluorescence Ro from groups of animals (n = 3) over time following 15 min application of PLLA
microneedles coated with (uv-PNMP)(PS/SPS)2o(PBAE/TMR-poly(I:C))35 multilayers containing
poly-1 or poly-2 as the PBAE component. Data represent the meands.e.m. (b) Representative
whole-animal luminescent images and quantitative analysis of luminol signal from MPO-
dependent oxidative burst in activated phagocytes at the treatment site over time following
intradermal injection of 10 ug poly(I.C) or 15 min application of PLLA microneedles coated
with (uv-PNMP)(PS/SPS)20(poly-2/poly(I:C))35 multilayers. Data represent the mean±s.e.m., n =
4. (c) Representative whole animal bioluminescence images of pLUC expression at the
application site and mean bioluminescence intensity over time following 15 minute application of
microneedles coated with (uv-PNMP)(PS/SPS) 2o(PBAE/pL UC)3 5 multilayers containing poly-]
or poly-2 as the PBAE component. Data represent the mean s.e.m., n = 4 (d) Mean
bioluminescent intensity on day 2 following 15 min application of microneedles coated with (uv-
PNMP)(PS/SPS) 2o(Poly-1/pLUC) 35 multilayers stored dry at 25*C for 0, 14, or 28 days. Data
represent the mean +s.e.m., n = 4.
The selection of poly-1 and poly-2 as biodegradable polycation components of these PEM
coatings was motivated not only by their ability to regulate nucleic acid release, but also to
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directly promote transfection by forming pDNA polyplexes in situ during film degradation.67,120
Dynamic light scattering analysis of supernatants collected from these eroded films in vitro
revealed large aggregates (50-300nm, data not shown), consistent with previous evidence of in
situ polyplex formation/release from degrading (PBAE/pDNA) multilayers. 70'12 0 To determine
whether controlled polyplex release from implanted films would allow gene expression kinetics
to be regulated in vivo, we used bioluminescence imaging to monitor expression of luciferase-
encoding DNA longitudinally in live animals. Although in vivo optical imaging analysis of
bioluminescent signals is limited by variable photon penetration from different tissue depths and
locations, it is useful for accurate comparison of relative signal from identical tissue sites and for
longitudinal analysis of the duration of expression. Microneedles were prepared with
(PNMP/PEM) coatings containing pLUC as before, with or without UV-priming of the PNMP
release-layer. We verified that pDNA released from multilayers in vitro retained bioactivity over
the entire course of film degradation comparable to fresh PBAE/DNA polyplexes
(Supplementary Figure S3-5). In vivo, control microneedles (where the release-layer was not
UV-primed) applied to the skin of mice for 15 min led to no detectable expression of pLUC by
bioluminescence imaging (Supplementary Figure S3-6), consistent with the lack of detectable
film transfer into skin under this condition. By contrast, mice treated with microneedles coated
with (uv-PNMP/PEM) films showed significant levels of bioluminescence one day after
application, demonstrating transfection of cells in situ (Figure 3-4c). Further, the kinetics of
pLUC expression varied greatly depending on the PBAE used: delivery of (poly-1/pLUC)
multilayers led to luciferase expression that peaked after 3 days and declined to background
levels after 10 days, while implantation of slower-degrading (poly-2/pLUC) films showed
prolonged bioluminescence, peaking on day 3 then slowly decreasing to background levels by
day 22 (Figure 3-4c). Together this data shows that, multilayer tattooing can be used to tailor the
duration of both inflammatory signals and antigen-encoding DNA expression in vivo, via
selection of constituent polymers with varying degradation rates.
3.3.4. Stabilization of Vaccines in Multilayer Coatings
Embedding bioactive molecules in multilayer films has previously been shown to enhance their
stability for dry-state storage at room temperature, an attractive feature for vaccines given
the costs and availability limitations imposed by the need for refrigeration of liquid vaccine
formulations. To test whether (PBAE/pDNA) multilayer films coated on microneedles stabilize
their DNA cargo for dry storage, we fabricated microneedle arrays coated with (uv-PNMP/PEM)
films and stored them dry at 25'C for 0, 14, or 28 days before application to the skin of mice as
before. Bioluminescence imaging of these animals after treatment revealed no significant
decrease in transfection resulting from storage, indicating the maintenance of pDNA bioactivity
in multilayers for extended durations (Figure 3-4d). These results suggest that microneedles
coated with vaccine-containing multilayers could be easily packaged for inexpensive dry-state
storage and transportation to remote areas of the world, bypassing the 'cold-chain' requirements
of conventional vaccines.
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3.3.5. Enhanced Vaccination Through Multilayer Tattooing
Previous work has demonstrated DNA uptake in both keratinocytes and local APCs following
delivery to the skin in both humans and mice, both of which can contribute to induction of
immune responses in DNA vaccination (reviewed in 121). To test the ability of multilayer
tattooing with vaccine-loaded polymer films to enhance DNA immunization, we coated
microneedles with (uv-PNMP)(PS/SPS) 20(poly- 1/poly(I:C))35(poly- 1 /pGag) 35  composite
releasable multilayers containing the adjuvant poly(I:C) and pGag, a plasmid encoding the model
HIV antigen SIV-gag (Figure 3-5a). We compared multilayer tattooing to several control
immunizations using the same delivered dose of pGag and poly(I:C): injection of "naked"
pDNA, the most common experimental strategy for DNA immunization in mice and humans;
and in vivo electroporation, where DNA is administered in the presence of an electric field to
promote DNA uptake.103,122 To confirm the importance of the pH-responsive release-layer, we
also tested microneedles where the PNMP layer was not UV-treated, and hence unable to
dissolve upon skin insertion. Finally, we also compared immune responses in mice receiving
intradermal injections of poly-1/pGag polyplexes, to determine the importance of the sustained-
release multilayer film architecture for generating immunity. In all cases we immunized groups
of animals on days 0 and 28 with 20 pg pGag and 10 pg poly(I:C). Multilayer tattooing was
performed with microneedles (MN ± UV) applied to the dorsal ear skin for 15 min. Control
mice were injected intradermally (ID and ID Polyplex) in the ear skin, or intramuscularly with or
without in vivo electroporation (IM ± EP). Peptide-MHC tetramer staining of peripheral blood
mononuclear cells showed that IM and ID ± Polyplex administration produced only weak
antigen-specific CD8+ T cell responses (Figure 3-5b-d). By contrast, microneedle-treated
groups showed robust expansion of Gag-reactive T-cells exceeding 5% of the circulating CD8'
population two weeks following the boost, a response that was quantitatively similar to
frequencies observed for IM + EP immunized mice (Figure 3-5b-d). Notably, the response to
MN vaccination was ablated if the PNMP release-layer was not UV-treated (and was therefore
unable to dissolve on application). Additionally, compared to all of the other vaccination
regimens, microneedle administration generated substantially greater frequencies of
CD44*CD62L* central memory T-cells, a population thought to be important for recall immunity
and long-term protection (Figure 3-5e-f). Following injection of naked pDNA 3.5 months
after the prime to test recall responses, large frequencies of IFN-y-producing CD8* T-cells were
elicited (Figure 3-5g), suggesting the establishment of robust T-cell memory. Finally, two
weeks following the boost, we measured total Gag-specific IgG titers in sera and observed a 10-
fold increase in microneedle treated mice over those given any other immunization regimen (P <
0.01, Figure 3-5h). Thus, DNA vaccination via multilayer tattooing shows the potential to match
(or exceed) the potency of in vivo electroporation, using a skin patch that can be stored in a dry
state, is painlessly applied with no extraneous apparatus, and could be self-applied in minutes.
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Figure 3-5. Microneedle tattooing with multilayer films carrying pDNA and polyl:C
generates potent cellular and humoral immunity against a model HIV antigen
(a) C57Bl/6 mice (n = 4 mice/group) were immunized with 20 pg pGag and 10 pg poly(I.C) on
days 0 and 28 intramuscularly (with or without electroporation (EP)) in the quadriceps,
intradermally in the dorsal ear skin (with free pGag or pGag/poly-1 polyplexes, ID ± Polyplex),
or by 15 minute application of (PNMP)(PS/SPS)20(poly-/poly(I:C))3s(poly-1/pLUC)35-coated
microneedles without or without UV priming of the PNMP release-layer (MN ± UV) to the
dorsal ear skin. (b-d) Frequency of Gag-specific CD8' T-cells in peripheral blood assessed by
flow cytometry analysis of tetramer* CD8' T-cells. Shown are mean±s.e.m. tetramer* values
from (b) day 14 and (c) representative cytometry plots from individual mice and (d) mean±s.e.m.
tetramer* values from day 42. (e-J) Analysis of T-cell effector/central memory phenotypes in
peripheral blood by CD44/CD62L expression of tetramer* cells from peripheral blood. Shown
are e, representative cytometry plots from individual mice at day 49 and f, mean±s.e.m.
percentages of tetramer*CD44*CD62L* among CD8' T cells at day 98. (g) Mice immunized
with microneedles were recalled on day 105 by IM injection of 50 pg pGag, and assessed for
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cytokine production on ex vivo restimulation with ALI] peptide on day 112. Shown is
representative flow cytometry analysis of IFN-y/TNF-a-producing CD8' T-cells. (h) Enzyme-
linked-immunosorbent assay analysis of total Gag-specific IgG in sera at day 42. Data represent
the mean±s.e.m., **, p< 0.005, analyzed by two-way ANO VA.
3.3.6. Multilayer Tattooing in Non-human Primate Skin
While naked DNA injections stimulate immune responses in small animals, responses observed
in non-human primates and humans have been much weaker.4,5 10 2 To determine whether
multilayer tattooing could also enhance the efficacy of DNA delivery in non-human primates, we
tested the ability of PNMP-coated microneedles to deliver (poly-1/pLUC) multilayers into fresh
explanted skin from Rhesus macaques ex vivo. Trypan blue staining and histological sectioning
of macaque skin treated with uncoated PLLA microneedles showed uniform patterns of
microneedle insertion into the superficial layers of the skin without disruption of underlying
dermal layers or capillary vessels (Figure 3-6a, b). We tested the ability of microneedles coated
with (uv-PNMP/PEM) films to transfect ex vivo cultured macaque skin explants compared to
intradermal injections of equivalent doses of naked pDNA. Microneedles coated with
(PNMP/PEM) multilayers effectively transfected macaque skin explants following a 15 min
application period, but as in mice, transfection only occurred if the PNMP release-layer was UV-
primed for dissolution (Figure 3-6c). Bioluminescence imaging of the treated skin samples
showed that microneedle delivery generated consistent expression of luciferase at 140-fold
greater levels compared to intradermally-injected naked DNA controls for several days (P <
0.01, Figure 3-6d). Previous results in mice have indicated that the magnitude of gene
expression following DNA vaccination correlates with the strength of T-cell responses in vivo.7
Thus, although the limitations of ex vivo skin explant culture prevent measurement of the long-
term duration of gene expression, these results indicate that microneedle delivery promotes
strong initial DNA expression in non-human primate skin, where naked DNA injection elicits
very weak transfection only a few fold above background. Although the magnitude of gene
expression is only one parameter determining the ultimate strength of immune responses
following DNA vaccination, the ability to improve expression levels in primates is a significant
result given that poor transfection efficiency is an acknowledged obstacle for improving DNA
immunogenicity in large animal models and humans.12 2" 2 4
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Figure 3-6. Multilayer tattooing enhances transfection in non-human primate skin
(a) Optical micrograph of macaque quadriceps skin showing microneedle penetration pattern
stained using trypan blue (scale bar 500pm). (b) Histological section of microneedle-treated
macaque skin showing epidermal disruption at microneedle insertion sites (boxed, left, scale bar
500pm; right, scale bar 100um). (c) Bioluminescence images of luciferase expression 2 days
following pLUC delivery by ID injection or microneedle tattooing with (PS/SPS)2o(poly-
J/pL UC) 3s films from either uv-PNMP- or non-irradiated PNMP-coated microneedles following
a 15 minute application. (d) Quantification of total bioluminescent signal in cultured skin tissue
explants 1, 2, and 3 days following treatment. Data represent the mean s.e.m., n = 3. p<
0.0001, analyzed by unpaired t-test.
3.4. Conclusions
Microneedles have recently shown substantial promise in vaccine delivery, 25 and several reports
have begun to explore the use of metal microneedles to deliver DNA into the skin. 92,93,126,127
These studies have demonstrated the ability of naked DNA delivery by microneedles to provide
enhanced immune responses compared to intramuscular injection, but only one study compared
microneedle administration to alternative approaches designed to elicit improved transfection; in
that test microneedles elicited T-cell responses comparable to gene gun delivery of DNA if twice
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the DNA dose was given by the microneedle array.93 Here we have demonstrated a new
approach for DNA vaccination via multilayer "tattooing", using microneedles employing a pH-
responsive release-layer to rapidly implant biodegradable vaccine-loaded polymer films into the
skin. (Note that this new approach should not be confused with prior studies of "DNA tattooing",
where DNA solutions are literally applied to the skin using a commercial tattoo device104,122,128_
a completely different method.) Multilayer tattooing simultaneously addresses several issues in
DNA vaccine delivery: implanted multilayers deliver DNA with transfection agents, promoting
transfection in situ; molecular adjuvants are co-delivered to amplify the immune response; and
we have shown that the multilayer structure allows the kinetics of vaccine release to be tailored
over days to weeks. Combined, these features enabled multilayer tattooing to elicit immune
responses in mice far exceeding naked DNA injections. These responses were also comparable
to in vivo electroporation, an approach currently viewed as a gold standard for experimental
DNA vaccine potency but which requires special equipment, elicits pain and discomfort in
recipients, 129,130 and is unlikely to be feasible in widespread prophylactic vaccination. Notably,
vaccines have been shown to vary widely in potency based on the duration of exposure to
antigen and adjuvant combinations. 14-17 Our studies suggest that the continuous release of
polyplexes from implanted multilayers may be critical to the enhanced immunogenicity of
multilayer tattooing, as bolus injection of free polyplexes formed from the same components
elicited very weak immune responses. Finally, we have shown that formulation of DNA
vaccines as multilayer coatings on microneedles provides the opportunity for long term
maintenance of DNA bioactivity in a dried state without refrigeration, addressing cost and
availability limitations imposed by the cold-chain in the global distribution and storage of
vaccines. We focused here on DNA vaccination due to the relevance of needle-free vaccines for
global health and the need for enhanced DNA vaccination strategies. However, the well-known
adaptability of multilayers for incorporation and controlled release of diverse therapeutics 60-
63,88,90,99 suggests this approach should be applicable to diverse drug delivery applications.
Further, the pH-sensitive release-layer strategy employed here is a generalizable approach to
create selectively-released multilayer films. While the true potential of any vaccination strategy
can only be established in human clinical trials, the data shown here suggest that multilayer
tattooing is a promising approach to enhance the efficacy of DNA vaccines, a platform
technology with the potential to be applied universally in vaccine development.
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4. RELEASABLE LAYER-BY-LAYER ASSEMBLY OF STABILIZED LIPID NANOCAPSULES ON
MICRONEEDLES FOR ENHANCED TRANSCUTANEOUS VACCINE DELIVERY
4.1. Introduction
In Chapter 2 we focused on the development of an approach for vaccine and therapeutic
encapsulation into multilayer films for delivery from microneedles. Chapter 3 expanded upon
this concept to design an improved strategy for nucleic acid vaccine delivery. Here, in Chapter 4
we explore further the second theme illustrated in Chapter 2, the loading and delivery of
particulate vaccines from multilayer films for improved transcutaneous vaccination.
The generation of polyelectrolyte multilayers (PEMs) through the iterative and sequential
adsorption of complimentary materials is an attractive approach for nanoscale assembly of
functional systems capable of controlled encapsulation and delivery of diverse therapeutics. The
inherent adaptability of multilayer processing, as well as its biocompatibility, scalability, and
simplicity make it an ideal strategy for the creation of conformal coatings on complex surfaces
(reviewed in 12,131). Recently, multilayers have been optimized for the encapsulation of lipid
vesicles, with the aim of increasing the drug loading capacity of multilayer films, allowing for
biological cargos to be entrapped in films in native aqueous conditions, and providing triggered
materials release through programmed vesicle disruption.78,132-138 A key issue for incorporation
of liposomal carriers in multilayer films is the need for stabilization of vesicles against rupture
during the assembly process or drying of the resulting films. Previous approaches have relied on
vesicle stabilization strategies such as in situ silica polymerization 132,133 or polyelectrolyte
adsorption on the vesicle surface prior to multilayer assembly. 78,134,135 ,137,138 Without such
stabilizing measures, layer-by-layer (LbL) deposition results in spontaneous vesicle disruption
into lipid bilayers on the target substrate.
We recently reported a new approach for lipid vesicle stabilization, where covalent crosslinks are
introduced between adjacent phospholipid bilayers in the walls of multilamellar vesicles to create
robust lipid nanocapsules.1 39'140 These interbilayer-crosslinked multilamellar vesicles (ICMVs)
encapsulate protein cargos within their interior and exhibit enhanced serum stability in
extracellular conditions, but can be readily degraded upon cellular internalization. 139
Vaccination with ICMVs elicited potent cellular and humoral immune responses against the
model antigen ovalbumin (OVA), and enhanced long-term humoral responses to a recombinant
malaria antigen following subcutaneous injection.1 39"140  Given their enhanced stability and
unique potency in the context of protein vaccine delivery, we hypothesized that LbL deposition
of ICMVs would provide an interesting opportunity for the design of ICMV-containing
multilayer delivery systems for subunit vaccination.
In parallel studies, we and others have recently demonstrated the utility of microneedle arrays for
the safe, rapid, and convenient delivery of drugs through the pain-free disruption of the stratum
corneum to access the immune-competent epidermal and dermal tissue.,125,141 Microneedles
have particularly shown promise in vaccine delivery. 15 ,126,142 Microneedle application is known
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to improve safety, eliminate pain upon treatment, and reduce the generation of hazardous
medical waste associated with needle-based delivery. 11,13,143 Further, creation of conformal
surface coatings on microneedle arrays has proven to be an effective method for therapeutic
formulation and delivery into the skin via rapid, topical microneedle application. 15"144 We
therefore set out to design a PEM system for the stable encapsulation and release of ICMVs for
transcutaneous delivery into the skin via microneedle insertion. We envisioned several potential
advantages for such an approach including (i) improved dry state storage through PEM-
embedding of ICMVs, (ii) controlled encapsulation and release of ICMVs from degradable
PEMs implanted in the skin, (iii) delivery of ICMVs to an inherently immunogenic tissue for
enhanced immunity through microneedle application, and (iv) convenient and self-contained
combination of vaccine and administration device for rapid, safe, and painless vaccine delivery
that could potentially be self-administered in minutes.
Here we report studies intended to test these hypotheses, focusing on the generation of a PEM
system capable of stable ICMV encapsulation and release for protein immunization. We first
show the ability of degradable PEMs to stably incorporate ICMV particles, both on flat silicon
substrates as well as poly(lactide-co-glycolide) (PLGA) microneedles, controlling film thickness
and ICMV dosage, and verifying that incorporated ICMVs are intact within dried multilayer
films. We then demonstrate the ability for PEM-coated microneedles to transfer their ICMV-
loaded films into the cutaneous tissue upon brief application to the skin of mice. Following film
degradation and ICMV dispersion in the epidermal tissue, ICMVs were found to be taken up by
resident antigen presenting cells (APCs) within the skin, which were activated in situ by
adjuvants delivered by the particles. Finally, we show that transcutaneous vaccination with
ICMVs embedded in microneedle-based multilayers significantly enhanced humoral immune
responses to a protein antigen, compared to mice vaccinated with either conventional intradermal
bolus injection of antigen or microneedle-mediated delivery of soluble protein antigen.
Together, these results suggest the potential of microneedle-based multilayers for the effective
transcutaneous delivery of functional nanoscale vesicles. In this work, we have improved
protein subunit vaccination by taking advantage of the immunogenicity of ICMVs delivered to
the skin, a site known for high frequency of epidermal and dermal APCs; however, this work
describing vesicle deposition on multilayer-coated microneedles can be readily adapted as a
modular, general strategy for non-invasive drug delivery to the skin.
4.2. Materials and Methods
4.2.1. Materials
Poly-1 (16 kDa) was synthesized according to previous literature. 69 Alexa Fluor 647-conjugated
ovalbumin, and 1,1'-dilinoleyl-3,3,3',3'-tetramethylindocarbocyanine (DiI) were purchased from
Invitrogen (Eugene, OR). PLGA (50:50, IV 1.9 dL/g) was purchased from Lakeshore
Biomaterials (Birmingham, AL). DOPC (1,2-Dioleoyl-sn-Glycero-3-Phosphocholine) and MPB
(1,2 -dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide) were
purchased from Avanti Polar Lipids (Alabaster, AL). MPLA was purchased from Sigma Aldrich
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(St. Louis, MO). PolyI:C was obtained from Invivogen (San Diego, CA). Chromatographically
purified ovalbumin, purchased from Worthington (Lakewood, NJ), was processed through
Detoxi-Gels (Pierce, Rockford, IL) to remove any residual endotoxin.
4.2.2. PLGA Microneedle Fabrication
PDMS molds (Sylgard 184, Dow Coming) were fabricated by laser ablation using a Clark-MXR
CPA-2010 micromachining system (VaxDesign Inc.). PLGA pellets (IV 0.35 dL/g) were melted
over the molds under vacuum (-25 in. Hg) at 140'C for 40 min, and then cooled to -20'C before
separating the cast PLGA microneedles from the PDMS mold. Microneedles were characterized
by SEM using a JEOL 6700F FEG-SEM.
4.2.3. ICMV Synthesis
Synthesis of ICMVs was performed as described previously. 139,140 Briefly, dried films of 1.26
pmol of lipids (DOPC:MPB at 1:1 mol ratio) and 2.9 pg of MPLA were rehydrated in 20 mM
bis-tris propane at pH 7.0 with 325 tg ovalbumin for 1 hr with vortexing every 10 min, and
sonicated in alternating power cycles of 6 watts and 3 watts in 30s intervals for 5 min on ice
(Misonix Microson XL probe tip sonicator, Farmingdale, NY). DTT and Ca were then
sequentially added at final concentrations of 3 mM and 40 mM, respectively, and incubated for 1
hr at 37'C to form ICMVs. The particles were recovered by centrifugation, washed twice,
resuspended in PBS at pH 5.0, and stored at 4"C until usage. In some experiments, ICMVs were
prepared including a lipophilic tracer, Dil, at 0.2 molar % concentration, and 325 pg of Alexa
Fluor 647-conjugated OVA was used to hydrate the lipid films.
4.2.4. Polymer Multilayer Film Preparation
All LbL films were assembled using a Carl Ziess HMS DS50 slide stainer. Films were
constructed on Si wafers and PLGA microneedle arrays. To build (PS/SPS) base layers,
substrates were dipped alternatively into PS (2 mg/mL, PBS, Sigma-Aldrich) and SPS (5 mM,
PBS, Sigma-Aldrich) solutions for 10 min, separated by two sequential 1 min rinses in PBS.
(Poly-1/ICMV) and (Poly-1/MLV) multilayers were deposited similarly, alternating 5 min dips
in Poly-1 (2 mg/mL, PBS) and ICMV/MLV solutions (1 mg/mL, PBS) separated by two
sequential 30 sec rinsing steps in PBS. (Poly-1/OVA) multilayers were deposited by alternating
10 min dips in Poly-1 (2 mg/mL, 0.2M sodium acetate) and OVA solutions (0.1 mg/mL, 0.2M
sodium acetate) separated by two sequential 1 min rinsing steps in deionized water. All solutions
were adjusted to pH 5.0 and filtered (0.2[tm, except ICMV/MLV and OVA) prior to dipping.
4.2.5. Multilayer Film Characterization
Film thickness on Si wafers was characterized using a Veeco Dektak (Plainview, NY) surface
profilometer and a Veeco Dimension 3100 AFM. Film growth and morphology on PLGA
microneedles was characterized by SEM using a JEOL 6700F FEG-SEM and CLSM using a
Carl Zeiss LSM 510. Data analysis was performed using Image J95 and Graphpad Prism (La
Jolla, CA). Film loading was determined for fluorescent cargos using a SpectraMax 250
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spectrophotometer (Molecular Devices, Sunnyvale, CA) following elution of films in PBS, pH
7.4, 2M NaCl for 24 hours.
4.2.6. Characterization of Film Delivery In Vivo
ICMV or soluble OVA delivery was measured in vivo following application of coated
microneedles to the skin of mice. Animals were cared for in the USDA-inspected MIT Animal
Facility under federal, state, local, and NIH guidelines for animal care. Microneedle application
experiments were performed on anesthetized 6-10-week-old female C57BL/6 (Jackson
Laboratories) and C57B1/6-MHC II-GFP transgenic mice (a gift from Prof. Hidde Ploegh, MIT)
at the dorsal ear or flank skin. Skin was rinsed briefly with PBS and dried before application of
microneedle arrays by gentle pressure. Following application, mice were euthanized at
subsequent time points and the application site was dissected. Excised skin was stained with
trypan blue before imaging for needle penetration. In separate experiments treated skin and
applied microneedle arrays were imaged by confocal microscopy to assess transcutaneous
delivery of encapsulated ICMVs or soluble OVA. MHC II-GFP+ cell number and morphology
were analyzed by CLSM in dissected tissue following microneedle treatment. Image analysis
was performed using NIH Image J software.95
4.2.7. Vaccinations and Characterization of Humoral Immune Responses
Groups of 6-10-wk old female C57Bl/6 mice were immunized on days 0, 28, and 56 with 1 pig
OVA, 0.03 ptg MPLA, and 10 ig polyl:C either in suspension or microneedle formulations.
Microneedle coating compositions were chosen so that the dose of antigen/MPLA delivered into
the skin matched the injected cases: MN coatings were dissolved in sodium chloride buffer and
the amount of antigen present was assessed using a spectrofluorimeter for as-prepared and post-
skin-application microneedles; the delivered dose was determined as the difference between
these two values. For intradermal administration, immunogens in 15 p1L PBS were injected
intradermally in the dorsal auricular skin. Transcutaneous administration of microneedles was
performed as described above, following brief rinsing with sterile PBS at the dorsal ear skin. For
multilayers containing OVA/MPLA-loaded ICMVs, polyl:C was administered in 5lI PBS to the
surface of the skin prior to treatment and left in place during the duration of microneedle
application. For multilayers containing soluble OVA, polyl:C and MPLA were similarly
administered to the skin prior to microneedle treatment. Microneedles were secured in place for
5 minutes for both ICMV- and soluble OVA-containing multilayer coating variations. Sera
obtained from immunized mice at various time points were analyzed for IgG, IgG1, and IgG2c
antibodies by ELISA using OVA-coated plates. Anti-OVA IgG titers were defined as the lowest
serum dilution at which the ELISA OD reading was > 0.5.
4.2.8. Statistical Analysis
Data sets were analyzed using one- or two-way analysis of variance (ANOVA), followed by
Tukey's HSD test for multiple comparisons with Prism 5.0 (GraphPad Software, San Diego,
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CA). p-values less than 0.05 were considered statistically significant. All values are reported as
mean ± s.e.m.
4.3. Results and Discussion
4.3.1. ICMV Encapsulation into Degradable Multilayers
In Chapter 2 we demonstrated that microneedles coated with PLGA nanoparticle-loaded PEMs
could be used for rapid implantation of particle-loaded films in skin.115 PLGA particles are
attractive for small-molecule drug delivery but have limitations for delivery of biologics such as
vaccines, due to the low doses of proteins that can be encapsulated and the potential for antigen
denaturation during processing. We hypothesized that the deposition of an ICMV-containing
multilayer coating on the surface of microneedles would provide a solution to these issues and
enable a simple, self-contained, and effective method for recombinant protein vaccine storage
and delivery to the skin, an attractive tissue target due to its dense matrix of resident innate
immune cells (Figure 4-1). 24,145,146 To fabricate an erodible PEM system capable of
encapsulating and delivering intact nanoscale vesicles we selected Poly-1 (Supplementary
Figure S4-1) a biocompatible, hydrolytically degradable polymer from a class of
polyelectrolytes known as poly( B -amino esters) (PBAEs), to serve as a complimentary
degradable partner for ICMV encapsulation in multilayers. Poly-1 has been extensively studied
in a variety of contexts and has been proven effective in generating erodible multilayer films
containing many diverse cargos for controlled drug release. We selected ICMVs
to serve as a stable poly-anionic vesicular partner for Poly-1 in multilayer deposition, taking
advantage of their colloidal stability and potency as vaccine delivery vehicles.' 39'"40 In this
context, ICMVs could serve as a modular delivery vehicle for antigen and adjuvant incorporated
either in the aqueous vesicle core or the hydrophobic lipid capsule walls of ICMVs, and the
covalent inter-bilayer maleimide crosslinks would provide stability for multilayer encapsulation
(Figure 4-la). We hypothesized that (Poly-1/ICMV) multilayers would be deposited into the
skin through brief topical microneedle application (Figure4- 1b), where hydrolytic degradation
of Poly-1 over time would lead to ICMV release (Figure 4-1c) into the surrounding tissue,
followed by uptake into local APCs (Figure 4-id) that would initiate adaptive immunity.
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Figure 4-1. Schematic illustration of ICMV multilayer deposition and delivery
(a) Schematic illustration of (Poly-1/ICMV) multilayers deposited onto PLGA microneedle
surfaces. ICMV lipid nanocapsules are prepared with inter-bilayer covalent crosslinks between
maleimide head groups (M) of adjacent phospholipid lamellae in the walls of multi-lamellar
vesicles. (Poly-1/ICMV) PEMs were constructed on microneedles after (PS/SPS) base layer
deposition. (b) Microneedles transfer (Poly-1/ICMV) coatings into the skin as cutaneous depots
at microneedle insertion points. (c) Hydrolytic degradation of Poly-] leads to PEM
disintegration and ICMV release into the surrounding tissue. (d) ICMV delivery to skin-resident
APCs provides coincident antigen exposure and immunostimulation, leading to initiation of
adaptive immunity.
Negatively-charged ICMVs encapsulating fluorescent ovalbumin (OVA) and composed of
DOPC and maleimide-lipid MPB (Supplementary Figure S4-1) in a 1:1 mole ratio (diam. 240
± 10 nm, 0.19 ± 0.05 polydispersity index, zeta potential -41 ± 1.0 mV, incorporating 0.1 wt%
DiI as a fluorescent tracer in the vesicle walls) were prepared as previously described. 13,14' To
determine whether ICMVs could be stably embedded into degradable multilayer films, we first
synthesized model LbL films on atomically-flat silicon substrates. First, 20 bilayers of
protamine sulfate (PS) and sulfonated poly(styrene) (SPS) were deposited to form a base layer of
uniform surface charge. 101 ' 5 Through subsequent LbL steps, we attempted to construct ICMV-
encapsulating multilayers through sequential immersion in aqueous Poly-1 and ICMV
suspensions of varying concentrations. As shown in Figure 4-2a, when LbL assembly was
performed using ICMVs at 0.5 mg/ml in phosphate buffered saline (PBS) at pH 5.0, we observed
insignificant and irregular film growth, with film thickness remaining steady after 15 deposition
cycles at -400 nm as measured by profilometry. However, using a more concentrated 1 mg/ml
ICMV dispersion, we observed a regular linear increase in measured film thickness (-50
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nm/bilayer) with each deposition cycle up to 35 rounds of LbL deposition, resulting in films
more than 1.5 pm thick (Figure 4-2a). For comparison with the crosslink-stabilized ICMVs, we
also synthesized non-crosslinked multilamellar vesicles (MLVs) via the same process used to
prepare ICMVs, leaving out the final interbilayer crosslinking step. In contrast to ICMVs,
MLVs (diam. 270 ± 17 nm, 0.23 ± 0.014 polydispersity index, zeta potential -33.6 ] 0.9 mV)
displayed inconsistent and irregular film growth plateauing at -500 nm after 15 bilayers (Figure
4-2a). This result is consistent with previous evidence showing ineffective LbL growth of
phospholipid vesicles without sufficient stabilization to prevent spontaneous disruption upon
adsorption.147,148 Spectroscopic measurement of fluorescent signal obtained after (Poly- 1 /ICMV)
film disruption in NaCl for 24 hours indicated a loading of -5 pg OVA/cm 2 and -15 pg
lipids/cm2 for multilayers containing 35 bilayers (-1.6 pm in thickness), consistent with the
known OVA loading density of intact ICMVs; 139 this loading is within the effective dose range
needed for ICMVs to generate potent immune responses in vivo when administered by traditional
routes. 139,140 Further, previous studies have demonstrated enhanced potency of transcutaneously-
administered vaccines, suggesting that additional dose sparing might be possible in this
context.19~21
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Figure 4-2. ICMV multilayer film deposition and characterization
Shown are (poly-J/lipid) film thicknesses determined by profilometry for deposited ICM Vs or
MLVs varying (a) concentration and (b) deposition time (n = 12). (c) CLSM image of
(PS/SPS)20(Poly-1/ICMV)20 or (PS/SPS)2o(Poly-1/MLV)20 multilayers deposited on silicon (scale
bar 20,pm). ICM Vs and MLVs contained AF647-OVA (pink) and were labeled with DiI (red).
(d-g) AFM imaging of a dried (Poly-1/ICMV)s(PS/SPS)2o multilayers built on silicon (scale bar
100 nm). Shown are phase (d), height (e), and 3-D rendered AFM height micrograph data (f) for
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a (Poly-1/ICMV)s(PS/SPS) 20 multilayer (scale bar 100 nm). (g) Height trace data (trace shown
in panel (e)for a single embedded ICMV in a (Poly-1/ICMV)s(PS/SPS)20 multilayer.
Given the success of film growth at these initial conditions, we then measured the effect of
deposition time on the growth of (Poly-1/ICMV) containing films, and observed no significant
increase in film growth per bilayer when the duration for Poly-1 and ICMV adsorption was
increased from 5 to 10 minutes (Figure 4-2b). We thus concluded that 5 minutes was a
sufficient time period to achieve ICMV adsorption and reversal of surface charge for successful
LbL adsorption. To confirm that ICMVs were stably incorporated into Poly-1 films, we
performed confocal laser scanning microscopy (CLSM) on (Poly-1/ICMV) multilayers
constructed using ICMVs labeled with DiI in the lipid phase of the particles and encapsulating
fluorescent AF647-OVA. CLSM imaging showed the presence of overlaid punctate fluorescent
signals indicating colocalization of AF647-OVA and DiI in submicron spherical particles,
suggesting the incorporation of intact, OVA-loaded ICMVs into Poly-1 multilayers (Figure 4-
2c). This punctate fluorescent signal was not observed in films constructed using MLVs formed
in the absence of interbilayer crosslinks, and only low levels of OVA fluorescence were detected
in such films, providing evidence for the importance of the stabilizing inter-bilayer crosslinks of
ICMVs for preventing vesicle disruption during LbL processing (Figure 4-2c). In addition,
large contiguous patches of the DiI lipid tracer were observed in films prepared with non-
crosslinked MLVs, suggesting fusion among vesicles occurring in this case (Figure 4-2c). To
obtain further confirmation of intact ICMV incorporation into multilayers, we performed atomic
force microscopy (AFM) to investigate the surface of (Poly-1/ICMV) films on silicon.
Consistent with previous studies showing intact vesicle incorporation, 78,132,133,137,138 we observed
individual spherical structures 100-300 nm in diameter in height and phase AFM images,
suggesting that multilayer-embedded ICMVs were intact and unchanged following LbL
deposition (Figure 4-2d-e). This was readily apparent upon 3-D rendering of AFM height data
(Figure 4-2f) and in analysis of height traces (Figure 4-2g), suggesting individual ICMVs
embedded within the (Poly- 1 /ICMV) multilayers. The exposed dimensions of particles at the top
of films measured in this way showed diameters of ~100-300 nm and heights of -50-75 nm,
consistent with the previously measured average bilayer thickness and suggesting some
deformation and burial of the particles in underlying Poly-1 layers, as observed in prior studies
of vesicles incorporated in multilayers. 78,135 Additional AFM measurement of dry films stored at
room temperature for 7 days revealed similar punctate patterns with no significant change in
dimension, indicating the potential for multilayer encapsulated ICMVs to maintain their structure
upon dry-state storage (Supplementary Figure S4-2), an attractive feature for potential vaccine
delivery systems in the developing world.
4.3.2. Multilayer Deposition and Delivery from PLGA Microneedles
Given the ability of Poly-1 multilayers to encapsulate intact ICMVs, we next sought to use this
approach for ICMV delivery and release into the skin. In Chapters 2 and 3 we reported the
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successful generation of multilayer films on the surface of microneedle arrays for transcutaneous
delivery in vivo."',"' We hypothesized that a similar approach could allow for ICMV-loaded
multilayer delivery, and given the demonstrated potency of ICMVs for generating adaptive
immunity, 139,140 we anticipated that ICMV delivery to the APC-rich epidermis might provide
enhanced dose sparing immunogenicity. To test whether ICMV-loaded multilayers could be
deposited as surface coatings on microneedles, we first fabricated PLGA microneedles using
poly(dimethyl siloxane) (PDMS) molding as previously described, yielding arrays of conical
microneedles each ~650 ptm in height and 250 im in diameter at the base. Then, following
(PS/SPS) base-layer deposition on these microneedles, we performed LbL assembly using
fluorescently-labeled Dil-ICMVs encapsulating AF647-OVA as before. CLSM on the resulting
multilayer-coated microneedles revealed consistent and uniform fluorescent signal localized to
the surface of each microneedle, indicating effective multilayer deposition as observed for flat
silicon substrates (Figure 4-3a). Using confocal z-scanning, we then performed quantitative
analysis of the total fluorescent signal on individual microneedles following deposition of 10, 20,
or 30 bilayers. This analysis demonstrated a similar linear growth profile for both Dil-labeled
ICMVs and the encapsulated AF647-OVA cargo, consistent with the thickness increase
measured with profilometry on silicon (Figure 4-3b). In addition to confirming the similar
growth of silicon- and microneedle-based films, these results provide additional evidence for
intact ICMV incorporation on microneedle surfaces, consistent with our previous demonstration
of nanoparticle encapsulation on microneedle arrays through spray LbL deposition. 15 Finally,
we imaged the resulting multilayer-coated microneedles using scanning electron microscopy
(SEM) and observed the presence of consistent surface coatings uniformly covering the entire
microneedle array surface (Figure 4-3c).
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Figure 4-3. ICMV multilayer deposition on PLGA microneedles
(a) Representative confocal images of PLGA microneedles coated with (PS/SPS)2o(Poly-
1/ICMV)35 films (left, transverse optical sections; right, lateral sections; 100 pm interval; scale
bar 100 pm; Red, DiI-ICMVs; Pink, AF64 7-0 VA). (b) Quantification of DiI-ICMV and AF647-
OVA incorporation into (PS/SPS)2o(Poly-1/ICMV)n films on microneedles. Analysis was
performed using Image J measurement of total fluorescent signal intensity in confocal z-stacks
collected along the length of microneedles, normalized to the total intensity obtained for 30
bilayer films (results shown are averaged from n = 15 individual microneedles per condition).
(c) SEM micrographs of (PS/SPS)20(Poly-1/ICMV)3s multilayer-coated PLGA microneedles
(scale bars: left 200 pm, right 50 pm).
We next tested whether microneedle-based multilayers encapsulating ICMVs were delivered into
skin following microneedle application in vivo. We have previously shown that microneedles
similar to those used here are effective in providing consistent disruption of the stratum comeum
and insertion into the outer layers of the skin following brief topical application to the skin of
mice.115  We confirmed this result using trypan blue staining of treated skin and observed
uniform staining patterns indicating microneedle insertion as before (data not shown). To test
for transcutaneous delivery, multilayer-coated microneedles carrying AF647-OVA-loaded, DiI-
labeled ICMVs were applied to the dorsal ear or flank skin of C57Bl/6 mice. We then performed
quantitative CLSM image analysis to determine the relative loss of fluorescent signal from
individual microneedles following application. Microneedles applied for only 5 minutes showed
significant losses of both DiI and AF647-OVA fluorescent signal over the entire microneedle
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surface, with -80% reduction in fluorescent intensity observed on the microneedle surfaces
(Figure 4-4a-c). Fluorescent signal reduction was equivalent for both the lipophilic tracer and
protein cargo, suggesting delivery of intact multilayer-embedded ICMVs. These results are
consistent with our previous demonstration of polymer nanoparticle-loaded multilayer delivery,
in which we observed that, unlike multilayers composed only of polymeric materials, PEMs
containing embedded particles were rapidly transferred to the skin after brief application of
microneedle arrays.1 15  This difference in the kinetics of multilayer transfer may reflect a
decreased degree of interpenetrating molecular entanglements between complementary polymer
and nanoparticle pairs, compared to multilayers composed of complementary polymers alone.
The microneedles themselves make up 45% of the total coated surface area on the microneedle
array, meaning that with 80% delivery of the coated material, overall -36% of the vaccine
components coated on the microneedles are estimated to be delivered into the skin. Approaches
to increase this fraction can be readily envisioned by using a hydrophobic base to prevent
wetting of the backing and/or employing strategies to carry out LbL deposition only on the
microneedle tips.49 44
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Figure 4-4. ICMV multilayer delivery following microneedle treatment in vivo
(a-c) Representative confocal images of PLGA microneedles coated with (PS/SPS)20(Poly-
I/ICMV)3 films before application (a) and after a 5 minute application to murine skin in vivo (b)
(lateral sections, 100 pm z-interval; scale bar 100 pm; Red, DiI-ICMVs; Pink, AF647-OVA). (c)
Quantitation of confocalfluorescence intensities (n = 15) showing loss of DiI-ICMV and AF647-
OVA films from coated microneedles upon application to skin. (d-g) Representative confocal
images of mouse skin treated for 5 minutes with (Poly-1/ICMV)35 (PS/SPS)20 multilayer-coated
PLGA microneedles after 6 hr (d) or 24 hr (e) showing ICMV delivery at microneedle insertion
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sites (outlined). Shown is fluorescent signal from (top to bottom) MHC II-GFP (green), DiI-
1CM Vs (red), AF647-OVA (pink), and overlay (yellow) at low (left) and high (right)
magnification (scale bars 100 pm). (f) High magnification CLSM image (field location
highlighted by box in panel (e)) showing colocalization of ICMVs and OVA with APCs in the
skin (scale bar - 20pum). (g) High magnification CLSM image showing APC phagocytosis of
1CMVs with OVA after 24 hr (scale bar 20 pm).
We next examined microneedle-treated skin to observe deposition of ICMV-loaded multilayers
into the tissue. ICMVs were prepared with AF647-OVA loaded in the aqueous core as a model
protein antigen. As adjuvants to provide local inflammatory cues necessary to drive the immune
response, we embedded the Toll like receptor (TLR)-4 agonist monophosphoryl lipid A (MPLA)
in the ICMV capsule walls, and further applied aqueous solutions of the TLR-3 agonist polyI:C
(a double-stranded RNA mimic of viral RNA) directly to the skin just prior to microneedle
application. To observe ICMV delivery in relation to target antigen presenting cell (APC)
populations in the skin, we applied microneedles to the skin of MHC II-GFP mice. These
animals express all major histocompatibility class II (MHC II) molecules as a fusion with green
fluorescent protein (GFP), allowing MHC II+ APCs in the viable epidermis/dermis to be
observed through CLSM imaging in auricular or flank skin. 96 Microneedles were applied to ear
skin for 5 min, which was then dissected 6 or 24 hr later for CLSM imaging. After 6 hr, we
observed AF647-OVA and DiI fluorescence in clusters around microneedle insertion sites; these
signals were colocalized in the same z-plane as epidermal APCs expressing MHC II-GFP and
extended several hundred microns below the skin surface (Figure 4-4d and Supplementary
Figure S4-3). In skin collected 24 hours following treatment, we observed similar fluorescent
signal colocalization (Figure 4-4e) at microneedle insertion sites. However, after 24 hours, low
and high magnification CLSM imaging revealed the emergence of punctate fluorescent signal
dispersed throughout the tissue, similar to that observed for multilayer-embedded ICMVs,
suggesting multilayer disintegration and release/diffusion of ICMVs in situ (Figure 4-4e-f).
This finding is consistent with the known degradation kinetics of Poly-1 multilayers, which
undergo complete breakdown within 24 hours. 75' 115  Dispersed particles were consistently
localized within the viable epidermal layers as evidenced by colocalization within the same z-
plane as MHC II-GFP* APCs (likely Langerhans cells). Further imaging indicated direct
interaction between epidermal APCs and ICMVs within the treated skin, as GFP+ cells were
observed with internal fluorescent signal from both AF647-OVA and DiI (Figure 4-4f). In some
cases, MHC II-GFP APCs were observed with membrane extensions around punctate
fluorescent particles, suggesting that ICMVs released from implanted multilayers were actively
being phagocytosed by resident immune cells in the skin (Figure 4-4g).
4.3.3. Recruitment and Maturation of Cutaneous Antigen Presenting Cells
The presence of TLR-3 and TLR-4 molecular adjuvants triggered striking changes in the APC
populations present in the skin of mice with implanted ICMV multilayers (Figure 4-5). To
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determine the effect of co-delivery of ICMVs with MPLA and polyl:C, mice were treated with
either uncoated microneedles, or microneedle arrays delivering ICMVs with or without MPLA
and polyl:C. A representative series of CLSM images from the 6 and 24 hour timepoints
following treatment were analyzed using Image J software particle analysis algorithms 95 to
determine various phenotypically significant parameters including total cell number per field,
individual cell area and perimeter, and individual cell MHC II-GFP mean fluorescent intensity
(MFI). From representative CLSM fields (Figure 4-5a-b), as well as the dependent quantitative
analysis, we observed a dramatic increase in MHC II+ cells present in the skin tissue between 6
and 24 hours for mice treated with polyl:C and microneedles coated with ICMVs encapsulating
OVA with MPLA, compared to microneedles alone or MN coated with only ICMVs (Figure 4-
5c). This recruitment of antigen presenting cells to the NN application site contrasts with recent
studies using microneedle arrays composed of shorter (100 pm in length) silicon needles (either
bare or coated with antigens and saponin adjuvants), where a slight decrease in the density of
MHC II* cells was observed by 24 hr, suggesting activation and migration of dendritic cells
toward lymphatics following patch application. 1491 50 However, APC accumulation is consistent
with the normal physiological response to inflammation following vaccination, as local
chemokine release from stimulated keratinocytes and innate immune cells triggers both resident
cell division and homing of blood-borne APCs to the inflamed tissue microenvironment.
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Notably, prior studies using adjuvants such as the TLR agonist imiquimod 5 1 or cytokines such
as GM-CSF or FLT-3L 52 , 5 3 have shown similar infiltration of dendritic cells to skin vaccination
sites (including in human trials), which correlates with greater frequencies of antigen-carrying
APCs arriving at draining lymph nodes. Such dramatic APC recruitment to the application site
was not observed for bare microneedles, suggesting that the response observed in this study vs.
the silicon microneedle studies cited above are not simply due to greater wounding of the skin by
the larger microneedles used here.
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Figure 4-5. Cutaneous antigen presenting cell recruitment and maturation
Representative CLSM images of MHC II-GFP* cells in skin dissected 6 (a) or 24 hours (b) after
(PS/SPS)2o(Poly-J/ICMV)35-coated microneedle treatment for 5 minutes (insertion points
outlined); ICMVs were loaded with MPLA and polyI.C was added to the skin directly before
treatment (scale bar 200 pm). (c) Results of quantitative CLSM image analysis to determine
total cell number per field, individual cell area and perimeter, and MHC II-GFP MFI, expressed
as fold change relative to uncoated microneedle treated mice. Mice were either treated with
uncoated microneedles (MN), or microneedles coated with (PS/SPS)2o(Poly-1/ICMV)3s
multilayers with or without added MPLA and polyI.C (MN+ICMV and MN+ICMV+TLRa,
respectively). Data was analyzed for signficance using two-way ANOVA (* - p<0.05, ** -
p<0.01, ***-p<0.001).
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In addition, TLR agonists trigger activation of APCs, which is accompanied by morphological
changes and upregulation of MHC expression,i5 4-5 6 which we also saw reflected in skin treated
with ICMVs with MPLA and polyl:C. Here individual GFP* APCs were observed to take on an
extended dendritic morphology (Figure 4-5a, b) and increase in area (-3x), perimeter (~2x), and
mean MHC II-GFP fluorescence intensity (~10x, Figure 4-5c) as compared to bare microneedle
or ICMV-only treatments. Together these parameters are indicative of a shift towards an
activated phenotype in APCs, as stimulated DCs increase cellular processes to more effectively
capture antigen and increase expression of MHC II for effective communication with naive
lymphocytes in the generation of adaptive immunity. Thus, we have observed the effective
delivery of ICMV-containing multilayers from microneedle arrays into treated skin, the
subsequent disintegration of multilayer depots releasing ICMVs, which are dispersed throughout
the skin for uptake by resident APCs, ultimately resulting in coincident antigen delivery and
activation and maturation of the resident APC population.
4.3.4. Microneedle Delivery of ICM Vs for Enhanced Transcutaneous Vaccination
Finally, we tested whether transcutaneous administration of microneedle-based multilayers
encapsulating ICMVs could elicit immune responses against an antigen incorporated within
ICMVs. Groups of C57B1/6 mice were immunized on day zero and given booster immunizations
after 4 weeks and 8 weeks with 1 ig OVA (model antigen), 0.03 pg MPLA, and 10 ptg polyl:C.
For each immunization, mice received transcutaneous administration of microneedles delivering
Poly-1 multilayers encapsulating either ICMVs (containing OVA and MPLA, OVA-ICMV-MN)
or equivalent doses of soluble OVA (OVA-MN, Figure 4-6a). In both cases microneedle
multilayer delivery was performed in the presence of soluble polyl:C (and MPLA in the case of
OVA multilayers) applied to the skin surface before treatment. Multilayers loaded with soluble
OVA were constructed based upon previously reported methods adapted for microneedle
deposition. 17 Characterization of OVA-multilayer loading and delivery in vivo demonstrated
effective OVA loading into microneedle-based multilayers, and efficient transcutaneous delivery
upon microneedle application (Supplementary Figure S4-4). To further delineate the efficacy
of microneedle-based transcutaneous vaccination from conventional bolus injection of
immunogens, we also vaccinated control groups of mice by intradermal injection of ICMVs
(containing OVA and MPLA, OVA-ICMV-ID) with polyl:C or soluble formulations delivering
the same doses of antigen and adjuvants as in the microneedle treated groups (OVA-ID, Figure
4-6a). All groups received the same total dose of OVA, MPLA, and polyl:C. Notably, following
the first booster immunization all groups responded with increased OVA-specific serum IgG
titers, and the total IgG titer of ICMV vaccines were identical for injected vs. microneedle
formulations by day 56 (Figure 4-6b). However, only mice immunized with microneedle
delivery of ICMV-carrying multilayers responded to the second boost at day 56, with serum IgG
titers showing an additional >10-fold increase for this group, while the other immunization
regimens elicited stable or declining titers at subsequent timepoints. The need for multiple
vaccinations to achieve this high titer is offset by the potential for enhanced protection by such a
substantial increase in strength of the humoral response and the self-administrable nature of
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microneedle patch vaccines. We further analyzed sera obtained on day -110 post-immunization
to determine the isotypes of antibodies generated by transcutaneous vs. intradermal
administration of either soluble or ICMV vaccine formulations. Vaccination with free OVA
protein either via microneedles or intradermal injection resulted in Th2-biased IgGi responses
without any detectable level of Thl-associated IgG2e antibodies (Figure 4-6c, d). In contrast,
ICMVs administered by traditional syringe intradermally or delivered by multilayer-coated
microneedles elicited a more balanced Thl/Th2 response with both IgG1 and IgG 2c titers, with
transcutaneous delivery of ICMV-carrying microneedles achieving 10-fold higher IgG 2e titers
than "free" ICMV injection (Figure 4-6c,d). This is of interest since IgG2 antibody isotypes
have been implicated in enhanced protection in both infectious disease and cancer vaccines. 157-159
Thus, these results suggest that microneedle-based multilayers encapsulating ICMVs are a
promising platform for delivery of vaccine antigen and adjuvant to skin-resident APCs via a non-
invasive, needle-free route for promotion of long-lived, high-titer humoral immune responses.
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Figure 4-6. Microneedle subunit vaccination
(a) Schematic representation of vaccine treatments tested. (b) Anti-OVA serum IgG titers were
measured over time with immunizations on days 0, 28, and 56 with OVA-ICMVs or soluble
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antigen administered via either microneedle-based multilayers or intradermal bolus injection at
dorsal auricular skin. (c, d) Quantification of anti-OVA IgGi (c) and IgG2 (d) subtypes in sera
at day 107. ", p < 0.05 and **, p < 0.01, compared to OVA-ICMV ID, and ***, p < 0.001,
compared to OVA-MN or OVA ID, as analyzed by two-way ANOVA, followed by Tukey's HSD.
*, p < 0.05, as analyzed by one-way ANOVA, followed by Tukey's HSD.
4.4. Conclusions
In summary, we have shown the successful incorporation of intact multilamellar phospholipid
vesicles into erodible multilayer films through the use of an inter-bilayer molecular crosslinking
stabilization strategy. We have further demonstrated the potential utility of such functional
multilayer coatings constructed on microneedle arrays for rapid transfer of particle-carrying
multilayers into microneedle-treated skin, and for the subsequent release of vesicle cargos
through multilayer degradation in situ. Thus, this platform may ultimately serve as a potent
platform for protein vaccination providing enhanced immunogenicity, simple and safe
administration, and the potential for dry-state storage. These advantages provide the opportunity
for more effective and less costly vaccine storage and distribution to the developing world, as
multilayer stabilized formulations could be stored easily without refrigeration until rehydration
upon microneedle insertion into the target tissue. Though we employed an LbL dipping process
in multilayer fabrication for these lab-scale studies for convenience, note that commercial scale
processes could readily employ spray deposition to eliminate loss of precious vaccine materials
during fabrication.8 1 The combination of multilayer deposition with microneedle application for
transcutaneous delivery also addresses the need for a safe, potent, and non-invasive alternative to
hypodermic needle-based administration. The simplicity of microneedle application also
provides the prospect of rapid self-administration potentially streamlining mass vaccination and
eliminating the need for healthcare worker training. 202223 In addition, the ability of ICMVs and
multilayers to incorporate diverse drug compounds and biologics makes this approach of broader
interest for enhanced transcutaneous delivery of therapeutics.
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5. COMPOSITE DISSOLVING MICRONEEDLES FOR COORDINATED CONTROL OF ANTIGEN AND
ADJUVANT DELIVERY KINETICS IN TRANSCUTANEOUS VACCINATION
5.1. Introduction
Chapters 2-4 present the design and preclinical testing of several strategies involving multilayer
formulation of vaccine coatings for microneedle delivery. In Chapters 5-6 we introduce a new
approach for microneedle vaccine design utilizing composite dissolving microneedle structures
to allow for rapid administration, and flexible control over vaccine formulation and sustained
release in vivo.
Recently, microneedle arrays have been employed as an enabling technology for safe and
convenient transcutaneous delivery of diverse bioactive materials, including high molecular
weight hydrophilic biologics, through pain-free mechanical disruption of the stratum corneum.
For such barrier-disruption systems, rapid delivery of therapeutics into the skin by a brief
application of the microneedle array is desirable, to minimize the potential risk of infection. This
strategy has been demonstrated by various approaches, such as the use of microneedles that
rapidly dissolve on entry into skin with release of encapsulated materials over minutes to
57,142,160-168hours. However, while rapid drug release allows a brief microneedle application time,
bolus drug delivery by microneedles, like bolus injections, can lead to rapid clearance of
administered drugs and a need for large drug doses in order for released drug to remain at
therapeutic doses (locally and/or systemically) for a sufficient temporal window to have a
beneficial effect. Sustained or kinetically-controlled drug release is more desirable than bolus
delivery for many therapeutics and is essential to fulfill the full potential of transcutaneous
delivery for sustaining drug levels within a therapeutic window over time. Previous strategies for
obtaining controlled drug release with microneedle systems employed intradermal injection from
hollow microneedles, 169 or delivery from coatings on microneedle surfaces.1 15' 170 Alternatively,
long term delivery has been achieved through encapsulation of drugs directly into biodegradable
microneedles intended to remain in the skin for hours or days. 171,172 In each of these approaches,
the microneedles must remain embedded in the skin, which raises the potential for infection in
the setting of long-term/continuous drug delivery over days or weeks. To overcome this
limitation, several strategies have been developed, including the use of microneedles to generate
physical openings in the epidermis for topically-applied controlled-release particle suspensions
to diffuse into the skin,173 rapid delivery of drug-loaded polymer particles into the skin using
dissolving microneedles,174 or fabrication of solid PLGA microneedles which rapidly fracture
into implanted fragments upon skin insertion due to swelling of embedded hydrogel beads.175
The success of these approaches represents a strong proof of principle for the potential utility of
microneedle platforms providing either rapid delivery or sustained release of therapeutics to the
skin.
Vaccines have been shown to vary widely in potency based on the duration and kinetic profile of
exposure to antigen and adjuvant combinations. 10,106,176-179Recently, we demonstrated that intra-
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lymph node injection of vaccines composed of soluble protein mixed with sustained-release
adjuvant-loaded polymer particles could dramatically enhance the immune response to a model
protein antigen.106 However, intranodal injection is a more complex procedure than traditional
vaccine administration, and is best suited to vaccines against cancer or more specialized settings
such as allergy treatment. 180181 Here, we sought to determine whether control over
antigen/adjuvant exposure kinetics could also enhance immune responses elicited by
microneedle vaccines applicable to widespread prophylactic vaccination. We developed two
parallel approaches for fabrication of composite dissolving microneedles combining a rapid
release phase and sustained release phase for independently controlling the kinetics of antigen
and adjuvant exposure during transcutaneous vaccination. These composite arrays were
composed of poly(acrylic acid) (PAA) and poly(lactide-co-glycolide) (PLGA) in either a
microparticle form or a bulk implant contained in the microneedle tip and intended for
implantation within the skin upon application. PAA forms a glassy hard solid in bulk (E ~ 4
GPa' 82) but also dissolves rapidly in water. Exploiting this duality, we employed bulk solid PAA
as a supportive matrix or pedestal as well as the base of the microneedle array itself. When
inserted into skin, near-instantaneous dissolution of the PAA on hydration by interstitial fluid in
skin provided a mechanism for rapid needle-tip disintegration or release and implantation in the
cutaneous tissue. This approach enables delivery of diverse cargos that are hydrophilic or
hydrophobic including small molecules or macromolecular drugs, either through encapsulation
into PLGA particles or the PAA matrix. The selection of PLGA molecular weight or co-polymer
ratio provides flexibility for tuning the kinetics of sustained cargo release and PAA
encapsulation provides the additional ability for bolus delivery upon dissolution in vivo. These
composite microneedle designs provide the ability for rapid administration leading to cutaneous
implantation of controlled release depots for either bolus or sustained combinatorial release of
therapeutics for various potential applications including vaccine delivery, as demonstrated here.
5.2. Materials and Methods
5.2.1. PLGA Microparticle Synthesis
Polyvinyl alcohol (PVA)-stabilized PLGA microparticles were prepared by a single/double
emulsion/solvent evaporation approach. Briefly, 80 mg PLGA (50:50 lactide:glycolide ratio, IV
0.35 dL/g, Lakeshore Biomaterials or Resomer RG 755 S, IV 0.70 dL/g) was dissolved in 5 ml
dichloromethane. The PLGA solution was then added to 40 ml 0.5% PVA (MW 150,000 Da,
MP Biomedicals) while homogenizing at 12,000rpm using a T-25 Digital Homogenizer (IKA).
Homogenization was performed for 3 minutes following PLGA addition, and solvent was
subsequently removed by stirring overnight. For fluorescently labeled particles 160 ptg 1,1'-
dilinoleyl-3,3,3',3'-tetramethylindocarbocyanine (DiI) or 1,1 '-Dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine (DiD, Invitrogen) were codissolved with PLGA. For poly(I:C)
loaded particles, 3mg Cy3-labeled poly(I:C) (Invivogen, labeled using Mirus LabelIT, according
to the manufacturer's instructions) was dissolved in distilled water and added to the polymer-
containing organic phase while sonicating at 12W with a Microson XL probe tip (Microson).
After sonication for 30 s the resulting emulsion was added to the PVA solution and homogenized
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as before. The resulting particles were collected by centrifugation, washed, and resuspended in
distilled water before lyophilization and storage under desiccation at 4'C until use. Particle size
and zeta potential was determined using a BIC 90+ light scattering instrument (Brookhaven
Instruments Corp).
5.2.2. Composite Microneedle Fabrication
Microneedles encapsulating free PLGA microparticles or bulk PLGA implants were fabricated
from PDMS molds (Sylgard 184, Dow Coming) machined using laser ablation (Clark-MXR,
CPA-2010 micromachining system) to create patterns of micron-scale surface-cavities. First,
PLGA microparticles were deposited into PDMS molds through addition of aqueous particle
suspensions to the mold surface. Following PLGA microparticle addition (0.2-3.0 mg/array),
molds were centrifuged for 20 minutes at rcf ~450 to compact particles into mold cavities.
Following removal of residual material from the mold surface, molds were dried at 25'C. For
microneedles encapsulating free microparticles, addition of 35% poly(acrylic acid) (PAA,
250kDa) to the mold surface was followed by centrifugation (20 minutes, rcf -450) and drying at
25'C (48 hours on the benchtop, followed by 2-14 days under desiccation), before removal.
Microneedles encapsulating multiple distinct particle populations were fabricated similarly
through addition of mixed particle suspensions. For microneedles encapsulating bulk PLGA
implants, PDMS molds encapsulating free microparticles were heated under vacuum (-25 in. Hg)
at 145'C for 40 minutes, and then cooled at -20'C before addition of 35% PAA, centrifugation,
and drying as previously described. For microneedles encapsulating layered PLGA implants,
sequential microparticle deposition, drying, and melting was performed as previously described.
All microneedles were stored under desiccation at 25'C until use. Microneedle arrays were
characterized by scanning electron microscopy (SEM) using a JEOL 6700F FEG-SEM and
confocal microscopy using a Zeiss LSM 510.
5.2.3. Characterization of Microparticle and Implant Delivery
Microparticle and bulk implant release was characterized in vitro through brief (<30 sec)
exposure of fabricated arrays to PBS. Microparticles and bulk implants were then collected
through centrifugation and washed in PBS before application of aqueous suspensions to glass
coverslips. After drying, microparticles and implants were imaged by confocal microscopy.
Similar delivery was measured in vivo following array application to the skin of mice. Animals
were cared for in the USDA-inspected MIT Animal Facility under federal, state, local, and NIH
guidelines for animal care. Microneedle application experiments were performed on
anesthetized C57BL/6 mice (Jackson Laboratories) at the flank or dorsal ear skin. Skin was
rinsed briefly with PBS and dried before application of microneedle arrays by gentle pressure.
Following application mice were euthanized at subsequent time points and the application site
and draining lymph nodes were dissected. Excised skin was stained with trypan blue before
imaging for needle penetration. In separate experiments treated skin and applied microneedle
arrays were imaged by confocal microscopy to assess transcutaneous delivery of encapsulated
microparticles and bulk implants. In some cases, treated skin was excised and fixed in 3.7%
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formaldehyde for 18 hours, then incubated in 30% sucrose/PBS for 2 hours before embedding in
Optimal Cutting Temperature (OCT) medium (Tissue-Tek) for histological sectioning on a
cryotome. Lymph nodes were similarly embedded in OCT and sectioned. Histological sections
were then imaged using confocal microscopy.
5.2.4. In Vivo Imaging
Live whole animal imaging was performed using a Xenogen IVIS Spectrum (Caliper Life
Sciences) on anesthetized mice. Fluorescence data was processed using region of interest (ROI)
analysis with background subtraction and internal control ROI comparison to untreated skin
using the Living Image 4.0 software package (Caliper).
5.2.5. Immunizations
All animal studies were approved by the MIT IUCAC and animals were cared for in the USDA-
inspected MIT Animal Facility under federal, state, local, and NIH guidelines for animal care.
Groups of 4 C57B1/6 mice were immunized on days 0 and 35 with 15 tg ovalbumin and 50 ng
poly(I:C) by intramuscular injection (15 pl in the quadriceps) intradermal injection (15 pl in the
dorsal caudal ear skin) or by microneedle array (5 min application). Frequencies of OVA-
specific CD8' T-cells and their phenotypes elicited by immunization were determined by flow
cytometry analysis of peripheral blood mononuclear cells at selected time points following
staining with DAPI (to discriminate live/dead cells), anti-CD8a, anti-CD44, anti-CD62L (BD
Biosciences), and phycoerythrin-conjugated SIINFEKL/H-2Kb peptide-MHC tetramers
(Beckman Coulter). To assess the functionality of primed CD8* T-cells peripheral blood
mononuclear cells were stimulated ex vivo with 10ug/ml OVA-peptide SIINFEKL for 6 h with
Brefeldin-A (Invitrogen), fixed, permeabilized, stained with anti-IFNy, anti-TNFa, and anti-
CD8a (BD Biosciences), and analyzed by flow cytometry. Anti-Ovalbumin IgG titers, defined
as the dilution of sera at which 450 nm OD reading was 0.25, were determined by ELISA
analysis of sera from immunized mice. Animals were cared for following NIH, state, and local
guidelines.
5.3. Results and Discussion
5.3.1. Fabrication of PLGA-Microparticle-PAA Composite Microneedle Arrays
To create microneedle arrays capable of rapid simultaneous delivery of both soluble and PLGA-
encapsulated cargos, we developed two parallel microneedle approaches intended to deposit
either (1) PLGA microparticles or (2) solid PLGA implants into the superficial layers of the skin
upon the aqueous dissolution of a supportive PAA matrix or pedestal. We hypothesized that
such a platform would provide rapid administration through brief microneedle application while
enabling combined bolus and long-term dosing of cargos released from cutaneously-implanted
PAA and PLGA depots, respectively. To fabricate the polymer composite microneedle
structures needed to achieve these design goals, we employed a molding technique using
polydimethylsiloxane (PDMS) molds. PDMS blocks were patterned with microscale cavities
across their surface by laser micromachining, yielding a negative mold. In this strategy, cavity
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shape and the resulting microneedle geometry are easily controllable through variation of the
laser micro-ablation process.11 5 We selected molds containing conical cavities, approximately
700 ptm in height and 250 pm in width at the base. Microneedles of this size and shape have
been shown to effectively penetrate the murine stratum corneum for cutaneous materials
delivery" 5 and are also appropriate for delivery in humans. To begin the microneedle
fabrication process, PLGA microparticles (1580 ± 95 nm in diameter, -26 ± 2 mV zeta potential)
formed through double-emulsion-solvent-evaporation were applied to the surface of the mold in
aqueous suspension and compacted into the mold cavities through centrifugation (Figure 5-1,
step 1). Excess microparticles were then removed from the PDMS surface and the microparticle-
loaded mold was allowed to dry (Figure 5-1, step 2a). To form dissolving microneedles
carrying dispersible PLGA microparticles, we next added a concentrated aqueous solution of
PAA (35 wt%) to the mold surface and infiltrated the PAA solution into the packed PLGA
particle bed via centrifugation (Figure 5-1, step 3a). The loaded molds were then dried at 25'C
for 48 hr before desiccation under vacuum to obtain solid PLGA-PAA microparticle matrices.
The dry composite microneedles were finally removed from the PDMS mold for characterization
or stored under vacuum at 25'C until use (Figure 5-1, step 4a).
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(1) PLGA MP Deposition
Microparticle-loaded Solid-tipped
(2a) PLGA MP Drying (2b) PLGA MP Melting
(3a) PAA Deposition (3b) PAA Deposition
(4a) Drying/Removal (4b) Drying/Removal
Figure 5-1. Composite microneedle fabrication scheme
Schematic view of composite microparticle and bulk PLGA tip microneedle array fabrication.
PDMS molds were first filled with PLGA microparticles through centrifugation (1). PLGA
microparticles were then either dried in mold cavities (2a) or fused at high temperature to create
a solid tip (2b). Concentrated aq. PAA solution was then centrifuged onto the filled molds to
create a supportive matrix (3a) or pedestal (3b) for rapid dissolution in vivo. After drying
microneedles were removed from PDMS molds (4a, 4b).
To characterize the internal structure of microneedles created in this way, we performed the
described fabrication steps using PLGA microparticles loaded with distinct lipophilic fluorescent
tracers to serve as a model drug cargos: either 1,1 '-dilinoleyl-3,3,3',3'-
tetramethylindocarbocyanine (DiI) or 1,1 -dinoleyl-3,3,3',3'-tetramethylindoc dicarbocyanine
(DiD). Localization of the PAA matrix within the microneedle array was tracked through
encapsulation of Alexafluor-488 (AF488) as a hydrophilic fluorescent tracer in the PAA matrix.
The AF488 dye also served as a model for potential hydrophilic therapeutic compounds that
could be encapsulated for bolus cutaneous delivery upon dissolution of the PAA matrix in vivo.
Confocal imaging of microneedles fabricated using DiD-loaded PLGA microparticles together
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with AF488-loaded PAA showed uniform microneedle formation with DiD fluorescence
localized in the microneedle tip, and AF488 fluorescence throughout the needle length (Figure
5-2a). This indicates the successful deposition of PLGA microparticles to the microneedle tip,
and the effective formation of an encapsulating, supportive PAA matrix surrounding the
microparticles and forming the base of the microneedle array itself. Further, confocal analysis
demonstrated the flexibility of this approach through the similar successful fabrication of
microneedles bearing multiple microparticle populations encapsulating either DiD or DiI in two
different microparticle populations comprised of PLGA with high vs. low molecular weight (to
obtain two distinct kinetics of drug release, Supplementary Figure S5-la). SEM imaging
demonstrated the fidelity of the final composite microneedles to the mold cavity architecture
(Figure 5-2b). Additional imaging of the internal structure of needles intentionally broken after
fabrication also confirmed the confocal imaging results, showing the presence of nodules of
discrete PLGA microparticles surrounded by PAA matrix (Figure 5-2c).
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Figure 5-2. Fabrication of PLGA-microparticle-PAA composite microneedle arrays
(a) Confocal micrographs of PLGA-PAA composite microneedles fabricated to encapsulate DiD-
loaded PLGA microparticles (MP) (right, scale bar 200 pm). SEM micrographs of (b) resulting
microparticle-encapsulating microneedle array (scale bar 200 pm) and (c) high magnification
image of the composite needle interior of a fractured microneedle (scale bar 10 pm).
5.3.2. Fabrication of Solid PLGA-PA A Composite Microneedle Arrays
A similar fabrication approach was developed for the generation of microneedles capable of
implanting solid PLGA tips directly into skin. As previously described, PLGA microparticles
were first deposited into the cavities of a PDMS mold (Figure 5-1, step 1). After drying, the
microparticle-loaded PDMS molds were incubated at 140*C for 40 minutes under vacuum to
fuse the embedded PLGA particles. The molds were then allowed to cool, solidifying the PLGA
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into solid cones at the tips of each mold cavity (Figure 5-1, step 2b). As before, concentrated
PAA was then added and infiltrated into the PDMS molds through centrifugation, before drying
and finally removal of the completed arrays (Figure 5-1, steps 3b and 4b). Confocal imaging of
DiD-loaded PLGA together with AF488-loaded PAA showed the internal composite structure of
the resulting microneedle arrays. In this case fluorescent signal from encapsulated DiD-loaded
PLGA was localized to the tip of the microneedles, while AF488-PAA was only seen forming
the base of the microneedle array (Figure 5-3a), consistent with the melted microparticles
forming a continuous PLGA matrix in the microneedle tip, supported by a PAA pedestal at the
microneedle base. Fabrication in which two distinct PLGA microparticle populations were
sequentially added and melted in sequence yielded a layered microneedle structure in which the
DiD-loaded PLGA added first formed the needle tip, while the remainder of the needle was
composed of the second DiI-loaded PLGA layer, and finally the AF488-loaded PAA pedestal
(Supplementary Figure S5-1b). Fine control over the size of the PLGA "warheads" (and
therefore of encapsulated drug cargos) was readily achieved through simple variation of the mass
of PLGA microparticles added to the mold: Confocal imaging analysis of microneedles
fabricated using varying amounts of PLGA microparticles showed the formation of PLGA tips of
increasing height and correspondingly shorter PAA pedestals as the mass of added PLGA
particles was increased (Figure 5-3b, c). Control over PLGA tip size and PAA pedestal height is
potentially an important parameter not only for controlling cargo dosage, but also for efficiency
of delivery upon insertion to the skin.
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Figure 5-3. Fabrication of solid PLGA-PAA composite microneedle arrays
(a) Confocal micrographs of PLGA-PAA composite microneedles fabricated with a PAA base
and DiD-loaded solid PLGA tip (scale bar 200 pm). Confocal micrographs of microneedles
fabricated with varying amounts of DiD-loaded PLGA microparticles as indicated giving a
range of PLGA tip sizes (b) and PAA pedestal heights (c).
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5.3.3. In Vitro Testing of Composite Microneedle Delivery
To test our hypothesis that PLGA-PAA composite microneedles should be able to rapidly release
either PLGA microparticles or solid PLGA tips upon exposure to interstitial fluids in the skin, we
exposed composite microneedles to phosphate buffered saline (PBS) in vitro for short periods of
time to observe the kinetics of PAA dissolution. When PAA microneedles encapsulating DiD-
loaded PLGA particles were submerged in PBS, PAA dissolution was nearly instantaneous.
After 5 seconds, the remaining microneedle array backing was recovered and the released
microparticles were collected through centrifugation of the PBS solution for confocal imaging.
The recovered particles were identical to those initially used for microneedle fabrication with no
particle aggregation observed (Figure 5-4a). PAA microneedles encapsulating DiD-loaded bulk
PLGA tip implants were similarly exposed to PBS and exhibited equally rapid separation from
the residual PAA base after only 5 seconds. After centrifugation for collection, confocal imaging
of the released PLGA tips showed retention of overall tip morphology (Figure 5-4b). Together
these results suggested that the composite PLGA-PAA microneedle designs we had fabricated
should be capable of rapidly depositing their PLGA payload upon dissolution of the supportive
PAA matrix or pedestal in skin interstitial fluids.
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Figure 5-4. In vitro microneedle disintegration
(a) Schematic of PAA/microparticle composite microneedle dissolution and confocal micrograph
of DiD-loaded PLGA microparticles recovered following 5 sec exposure of composite
microneedles to PBS solution (scale bar 10pm). (b) Schematic of PLGA solid tip microneedle
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dissolution and confocal micrograph of DiD-loaded PLGA microneedle tips recovered following
5 sec exposure of solid tip microneedles to PBS (scale bar - 200pim).
5.3.4. In Vivo Testing of Composite Microneedle Delivery
Given the rapid in vitro release of both PLGA particles and solid PLGA tips from PLGA-PAA
microneedles, we next sought to test the delivery capabilities of these composite designs in vivo.
We hypothesized that composite microneedles encapsulating PLGA particles should have
sufficient strength to penetrate the skin upon application (Figure 5-5a, step 1) before exposure to
fluid in the cutaneous tissue would cause rapid dissolution of the PAA supportive matrix (Figure
5-5a, step 2). This would then lead to disintegration of the microneedle itself, releasing and
implanting the encapsulated microparticles into the epidermis (Figure 5-5a, step 3). Then, after
the residual microneedle backing was removed, implanted microparticles would remain as
cutaneous depots for hydrolytic degradation and sustained release of their encapsulated cargos in
situ (Figure 5-5a, step 4). We first tested AF488-PAA microneedles encapsulating DiD-loaded
PLGA microparticles. To determine the efficiency and timescale of PAA dissolution and PLGA
microparticle release, we applied microneedles to the dorsal ear skin of anesthetized C57Bl/6
mice. Following application to the skin, we performed confocal imaging on the post-application
microneedle arrays to observe residual microneedle morphologies. Similar to the in vitro results,
microneedle application to murine skin in vivo for 5 minutes was sufficient to produce nearly
complete loss of both DiD-PLGA signal and AF488-PAA signal in the microneedle shaft,
indicating rapid dissolution and disintegration of the composite microneedle matrix (Figure 5-
5b). We stained the skin surface over the microneedle application site with trypan blue to
visualize areas of stratum comeum disruption, and found uniform and consistent penetration of
the composite microneedle arrays to the viable epidermis (Figure 5-5c). Confocal imaging
analysis of dissected skin samples immediately following microneedle application indicated the
presence of cutaneous microparticle depots at the sites of microneedle penetration, with
colocalization of fluorescent signal from DiD-loaded PLGA microparticles and AF488 from the
dissolved PAA matrix (Figure 5-5d). Using 3-dimensional rendering of confocal z-stacks, these
depots were observed to extend 300-400pm below the skin surface, consistent with the proposed
paradigm for intact microneedle insertion, followed by PAA dissolution and microneedle
disintegration, leaving depots of implanted material following removal of the microneedle
backing (Figure 5-5e). Notably, we did not observe any short- or long-term local toxicity due to
PAA exposure on the skin of treated animals, despite the relatively large chain length of the
polymers used. This is likely due to the small amount of PAA (>150ug) introduced into the skin
tissue through microneedle application, as well as the known low toxicity of PAA in commercial
topical indications such as in detergents, cosmetics, or pharmaceutical use.183
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Figure 5-5. PLGA-microparticle-PAA composite microneedle insertion and delivery in vivo
(a) Microneedle delivery scheme: (1) Microneedle (MN) arrays are applied briefly to penetrate
skin. (2) Cutaneous microneedle penetration exposes needles to interstitial fluid resulting in
rapid dissolution of the supportive PAA matrix and microneedle disintegration. (3) Following
microneedle base removal, microparticles are left behind at penetration sites where soluble
PAA-encapsulated cargoes are rapidly delivered to the surrounding tissue. (4) Microparticle
deposition into the skin establishes a depot for sustained delivery of PLGA encapsulated cargoes
over time. (b) Confocal micrographs of DiD-microparticle-loaded microneedles before
application (left) and following a 5 minute application to murine skin (right, scale bar 200 um).
(c) Optical micrograph of microneedle-treated skin showing penetration sites stained using
trypan blue (scale bar 500 pm). (d) Confocal micrograph of treated skin, showing deposition of
DiD-loaded PLGA microparticles together with soluble AF488-loaded PAA at needle
penetration sites directly following microneedle application for 5 minutes (scale bar 100 pm,
penetration sites outlined). (e) Reconstructed confocal x-y/x-z/y-z images depicting the
microneedle application site showing deposition of microparticle-cargos within the cutaneous
tissue (scale bar 100 pm).
We hypothesized a similar mechanism for delivery in the case of composite microneedles
bearing bulk PLGA tips. As before, we theorized that intact composite needles would effectively
insert into the outer layers of the skin before dissolution of the PAA pedestal by interstitial fluid,
causing release and implantation of the PLGA tip for degradation and release of encapsulated
cargos over time (Supplementary Figure S5-2a). Using AF488-PAA microneedles bearing
DiD-loaded solid PLGA tips, we performed a similar set of tests to assay composite microneedle
performance in vivo. As in the case of microparticle-loaded microneedles, application of
composite microneedles bearing bulk PLGA tip implants for only 5 minutes to murine skin gave
complete loss of DiD-PLGA signal as well as AF488-PAA signal from the patch backing,
indicating PAA dissolution and needle tip separation (Supplementary Figure S5-2b). Trypan
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blue staining also confirmed that bulk PLGA tipped microneedles were able to penetrate skin
consistently (Supplementary Figure S5-2c) following application for 5 minutes. Finally,
confocal imaging of dissected skin following microneedle array application showed implantation
of the PLGA microneedle tips following removal of the residual microneedle array base
(Supplementary Figure S5-2d). As in the case of microparticle delivery, these bulk PLGA
implants were observed 300-400ptm below the skin surface at the sites of microneedle
penetration, together with fluorescent signal from the dissolved PAA pedestal (Supplementary
Figure S5-2e).
5.3.5. Formation and Retention of Cutaneous Particle Depots for Sustained Cargo Release
We next sought to determine the fate of soluble PAA-loaded cargo and microparticle-loaded
model drugs following deposition into the skin by composite microneedle application. As
previously described, microneedles encapsulating DiD-loaded PLGA microparticles in an
AF488-loaded PAA microneedle matrix were applied to the flank skin of C57Bl/6 mice for 5
minutes. Following treatment, individual animals were euthanized at various time points, and
after dissection of the treatment site, confocal imaging and histological sectioning were
performed to detect the presence of microparticle depots in the skin. Histological sectioning of
tissue collected 24 hours after treatment showed distinct cutaneous depots of microparticles
extending several hundred microns below the skin surface, colocalizing with signal from PAA-
encapsulated AF488 (Figure 5-6a). Similarly, confocal imaging of treated skin 24 hours after
administration indicated the retention of cutaneous microparticle deposits at the sites of
microneedle insertion (Figure 5-6b). Consistent with the histological evidence, optical
sectioning analysis of confocal data indicated the colocalization of DiD-labeled particle depots
extending 300-400 ptm beneath the skin surface. High magnification imaging of the depot site
showed individual particles dispersed within the cutaneous tissue (Figure 5-6b). To determine
whether the microneedle-implanted particles persist in the skin, we performed similar analyses of
treated skin 10 days after microneedle administration. DiD-loaded microparticles were still found
several hundred microns deep within the skin at this timepoint by histology (Figure 5-6c).
However, tissue sections collected after 10 days consistently showed the loss of AF488 signal
within the tissue at the sites of microneedle insertion, indicating the clearance of soluble PAA-
loaded cargo over this time period.
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Figure 5-6. Cutaneous depot formation, controlled release, and systemic delivery
Composite DiD-loaded PLGA microparticle/AF488-loaded PAA microneedles were applied to
the flank or dorsal ear skin of C57Bl/6 mice for 5 min, followed by histological, confocal
microscope, and whole-animal fluorescence analysis at 1-18 days post treatment. (a)
Histological section of treated skin 24 hours following microneedle array application.
Microparticles are shown implanted together with AF488-loaded PAA at a single microneedle
penetration site (scale bar 200pm). (b) Parallel x-y/x-z/y-z confocal reconstruction of the
treatment site at 24 hours post application shows DiD-loaded microparticle depots persisting at
the penetration sites (left, scale bar 100 pm). High magnification imaging at a single
penetration site shows microparticle dispersion within the cutaneous tissue (right, scale bar 20
pm). (c) Histological section of skin 10 days following microneedle application (scale bar 200
pm). (d) Whole animal fluorescence imaging of mice 1, 5, and 18 days after microneedle array
application. Fluorescence signal from released AF488 and DiD-PLGA microparticles is shown.
(e) Quantification of relative AF488 and DiD whole-animal fluorescence signal detected at
microneedle application sites. (f) Histological section of the draining inguinal lymph node 10
days after microneedle application showing persistence of DiD PLGA-loaded cargos in the
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subcapsular sinus (left, scale bar 100 ym), as well as cell-trafficked PLGA particles in the
cortical regions (arrows in inset at right, scale bar 10 pm).
Given the ability of composite microneedles to implant cutaneous microparticle deposits that
were retained at the treatment site for long periods of time, we hypothesized that these
microneedles might serve as an effective platform for sustained delivery of PLGA-loaded drugs,
while also providing an opportunity to rapidly deliver bolus doses of additional cargos
encapsulated in the PAA matrix. To determine the time course for cargo delivery following
microneedle application, we performed composite microneedle treatments on the dorsal ear skin
of C57B1/6 mice as before, to deliver DiD-loaded PLGA microparticles together with PAA-
loaded AF488. Tissue retention and clearance of these fluorescent model drug cargos was then
monitored using whole animal fluorescent imaging. Results of this analysis showed that PAA-
loaded AF488 was rapidly cleared from the site of application within 1 day, while DiD-
fluorescent signal was retained within the ear skin for greater than 20 days following delivery
(Figure 5-6d, e). These results are consistent with the previous confocal and histological
analyses already discussed, and together support the hypothesized mechanism of microneedle
insertion, followed by PAA dissolution, and needle disintegration to form long-lived cutaneous
PLGA particle depots for sustained release over time. Similar whole animal imaging results
obtained following delivery of bulk PLGA implants suggest an equivalent mechanism for
composite microneedles of this variation (Supplementary Figure S5-3).
Nanoparticles and microparticles deposited in skin are known to be phagocytosed over time and
transported to draining lymph nodes by antigen presenting cells1 84-186. This transport process
could affect the biodistribution of particle-released drugs and is an important factor in particle-
based vaccines. To assess transit of particles from microneedle insertion sites to draining lymph
nodes over time, confocal imaging of histologically sectioned draining lymph nodes was
performed to detect the presence of microneedle-delivered cargos 10 days after treatment. These
analyses clearly showed the presence of both AF488 (our model water-soluble PAA-
encapsulated drug) and microparticle-loaded DiD within the subcapsular sinus of sectioned
lymph nodes, suggesting these materials were able to drain through the lymphatics following
release at the cutaneous depot site (Figure 5-6f). Further, intact microparticles were observed by
high magnification imaging within the cortical regions of the lymph nodes, indicating trafficking
of particles by cells from the implantation site. No fluorescent signal was observed in lymph
nodes from untreated animals (data not shown). Together these results support the idea that
cutaneously-delivered soluble materials as well as microparticles themselves are trafficked to
draining lymph nodes.
5.3.6. Composite Microneedle Subunit Vaccine Delivery
As a final test of the ability of composite microneedles to provide effective therapeutic delivery
in vivo, we fabricated arrays for the transcutaneous delivery of a subunit vaccine formulation.
We synthesized PLGA microparticles encapsulating Cy3-labeled poly(I:C) (Cy3-poly(I:C)), a
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synthetic double stranded RNA mimic of viral RNA, as a molecular adjuvant. 187 Microneedles
composed of poly(I:C)-loaded PLGA particles and fluorescently-labeled ovalbumin (AF647-
OVA, model antigen) embedded in a supporting PAA matrix were fabricated following the
approach of Figure 5-1. Characterization of the resulting microneedles using confocal imaging
showed restriction of the Cy3-poly(I:C) microparticles in the microneedle tips, with fluorescent
signal from AF647-OVA throughout the microneedle length (Figure 5-7a). Upon application of
these vaccine-loaded composite microneedles to the dorsal ear skin of mice, we observed
successful deposition of both antigen and adjuvant at the application site using whole-animal
fluorescence imaging (Figure 5-7b), consistent with our previous results using model drug
cargos.
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Figure 5-7. Composite microneedle subunit immunogenicity
(a, b) Composite microneedles were fabricated, comprised of Cy3-labeled poly(I:C)-loaded
PLGA microparticles surrounded by PAA with entrapped AF647-ovalbumin. (a) Confocal
micrographs of composite microneedles (right, scale bar 200 Mm). (b) Whole animal
fluorescence imaging of mice treated with microneedles after 1 day. (c-f) Groups of C57Bl/6
mice (n = 4) were vaccinated with 15 Mg ovalbumin and 50 ng poly(I:C) intramuscularly (IM),
intradermally in the dorsal ear skin (ID), or administered transcutaneously to the ear via
microneedles (MN), with the poly(I:C) entrapped in PLGA microparticles and ovalbumin
entrapped in the PAA phase. Mice were primed on day 0 and boosted on day 35 with identical
formulations. (c) Frequency of SIINFEKL-specific T cells in peripheral blood assessed by flow
cytometry analysis of peptide-MHC tetramer* CD8' T cells. Shown are representative
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cytometry plots from individual mice and mean tetramer*frequencies from day 49. (d) Analysis
of T-cell effector/central memory phenotypes in peripheral blood by CD44/CD62L staining on
tetramer* cells from peripheral blood Shown are mean percentages of
tetramer*CD44*CD62L* among CD8' T cells at day 63. (e) Frequency of tetramer* CD8' T
cells in peripheral blood producing IFN-y and TNF-a following SIINFEKL restimulation
assessed by flow cytometry. Shown are representative cytometry plots from individual mice and
mean cytokine*frequencies for day 56. (f) Enzyme-linked-immunosorbent assay analysis of total
ovalbumin-specific IgG in sera at day 63.
To test the efficacy of these dissolving composite microneedles for vaccination compared to
traditional vaccine administration, mice were immunized on day 0 and boosted on day 35 with
15 pg ovalbumin and 50 ng PLGA-encapsulated poly(I:C) administered either intramuscularly
(IM) in the quadriceps, intradermally (ID) in the dorsal ear skin, or by microneedle application
(MN) for 5 minutes, also at the dorsal ear site. We then monitored the induction of OVA-
specific cellular immunity through the detection of OVA-reactive CD8+ T cells using flow
cytometry. Two weeks following the first immunization we observed expansion of antigen-
specific CD8* T cells to ~2% of the total CD8' population in all treatment groups, suggesting
that microneedle delivery provided similar initial immunogenicity compared with traditional
parenteral immunization strategies (Supplementary Figure S5-4a). Upon contraction of the
antigen-specific T cell population two weeks later, we measured the frequency of antigen-
specific CD44*CD62L* cells, central memory T cells that have been correlated with long-lived
effective protection against re-exposure to pathogens.1 88  On day 28, we observed that
microneedle immunization generated central memory cells much more efficiently than animals
receiving either intramuscular or intradermal vaccination, with greater than 30% of OVA-
specific memory T-cells expressing CD44 and CD62L (Supplementary Figure S5-4b). These
trends were similarly observed after the booster immunization, with antigen-specific T-cells
reaching -5% of the total CD8' population in mice receiving ID or MN dosing (Figure 5-7c, d).
Similar to the pre-boost response, elevated frequencies of central memory CD8+ T cells were
observed in microneedle vaccinated mice after contraction of the response on day 63, compared
to both control IM and ID injected vaccine groups (Figure 5-7e). We also evaluated the
functional capacity of the vaccine-elicited T-cell response through detection of cytokine
production following re-stimulation of peripheral blood mononuclear cells with SIINFEKL
peptide (the immunodominant peptide from OVA in C57Bl/6 mice). These analyses indicated
enhanced cytokine production by T-cells elicited by microneedle vaccination for antigen-
dependent production of both IFN-y and TNF-a, key cytokines for combating viral infection
(Figure 5-7f). Furthermore, microneedle delivery generated a higher frequency of multi-
functional CD8* T cells able to secrete both IFN-y and TNF-a upon peptide stimulation.
Together these results indicate the ability of microneedle immunization with slow-released
adjuvant to elicit phenotypically and functionally superior cellular immunity compared to
traditional vaccine administration. Finally, we measured the level of ovalbumin-specific IgG in
86
the sera of immunized animals to compare the capacity for generating humoral immunity. Here
we observed the presence of similarly high levels of anti-ovalbumin IgG in all immunized
animals on day 63, suggesting that composite microneedle delivery can also generate antibody
responses comparable to traditional immunization strategies (Figure 5-7g). Notably, the
microneedles used in these vaccination studies were fabricated and stored dry at 25'C for
between 4 and 8 weeks before administration for both the prime and boost immunizations,
indicating the potential for long-term maintenance of vaccine potency without the need for cold
storage, a pressing need for the effective distribution of vaccines to remote areas of the
developing world. Taken as a whole, these results demonstrate the strength of our approach for
rapid transcutaneous multi-component delivery using composite PLGA-PAA microneedles.
5.4. Conclusions
Here we have demonstrated an approach for modular cargo encapsulation into composite
dissolving microneedles for rapid delivery of PLGA microparticles or solid tips to form long-
lived cutaneous depots promoting controlled and sustained release over several weeks. The
combination of PLGA-formulated drug with a rapidly water-soluble PAA supporting matrix (in
the case of microparticles) or pedestal (in the case of solid PLGA tips) provides the combined
ability to rapidly and simply deliver the PLGA payload upon application to skin for only 5
minutes and to maintain drug release from implanted PLGA depots long after removal of the
microneedle backing. Additionally, this composite microneedle architecture provides substantial
flexibility in loading of single or multiple diverse cargos either into PLGA through standard
double emulsion particle synthesis, or into the supporting PAA matrix through simple co-
dissolution during fabrication. The composite structure also allows for simple tuning of
extended cargo release kinetics through selection of PLGA copolymer ratio and molecular
weight or bolus delivery upon needle disintegration through encapsulation in the PAA matrix.
We have demonstrated the utility of these microneedle designs for the systemic dispersion of
drugs released upon skin insertion or upon release from implanted PLGA over time. Finally, we
have shown the successful application of this materials platform for encapsulation and delivery
of a protein vaccine formulation generating potent humoral and cellular immunity matching or
exceeding that resulting from traditional needle-based vaccine administration, even after storage
for several weeks at room temperature. Together these results suggest that PLGA-PAA
composite microneedles are an effective platform for straightforward and robust transcutaneous
drug and vaccine delivery. Aside from applications in vaccination, the flexibility and modularity
of this approach suggests its potential to serve as a platform for generalized therapeutics delivery
providing both rapid and convenient administration as well as the potential for controlled and
sustained systemic delivery.
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6. IMPLANTABLE SILK COMPOSITE MICRONEEDLES FOR PROGRAMMABLE VACCINE RELEASE
KINETICS AND ENHANCED IMMUNOGENICITY IN TRANSCUTANEOUS IMMUNIZATION
6.1. Introduction
Chapter 5 introduced an alternative approach for transcutaneous vaccination using composite
dissolvable microneedles to rapidly administer vaccines and control the coordinated release of
antigen and adjuvant over days to weeks for enhanced immunogenicity in soluble protein
vaccines. Here, in Chapter 6, we expand upon this theme to provide additional practical
advantages and more robust controlled release capacities using silk hydrogel matrices to safely
load and release high densities of fragile bio-active vaccine components in vivo.
Immunological studies have begun to reveal the importance of antigen and adjuvant delivery
kinetics in the developing immune response, both within the context of vaccination and natural
responses to infection. 106,189-191 For example, the magnitude, functionality, and phenotype of
elicited CD8' T cell responses following vaccination have been correlated with the kinetic
profile of both antigen and inflammatory signals in vivo. These findings are correlated with
known differences in the natural immunity generated against transient or persistent pathogens,
indicating specific mechanisms of immunity that may be exploited through engineered vaccine
kinetics to yield greater vaccine efficacy.
In Chapter 5 we began to explore the ability of microneedle delivery systems to control vaccine
kinetics. Microneedle patches composed of a single monolithic polymer phase require that
patches remain on the skin for prolonged time periods to achieve extended drug release.
Conversely, our previous composite microneedle structures, based on solid biodegradable
poly(lactide-co-glycolide) (PLGA) polymer tips supported on a water-soluble poly(acrylic acid)
(PAA) base rapidly disintegrate upon skin application, implanting the solid polymer tips into the
skin following a brief -5 min application.192 The implanted polymer tips can subsequently
provide sustained release of encapsulated cargos over a tunable period of days to weeks. In these
previous studies, vaccination utilizing PLGA/PAA composite microneedles implanting persistent
polymer depots for slow cutaneous release of adjuvant following bolus antigen delivery yielded
improved proliferation, stronger antigen-dependent cytokine secretion, and altered memory
phenotypes in assays of CD8' T cell immunity.192 Here we have expanded upon this concept
through the design of a microneedle system based on silk protein, thereby creating implantable
hydrogel microneedle matrices for efficient vaccine loading and highly tailorable vaccine release
kinetics in vivo. Unlike PLGA, loading of biomolecules in silk protein matrices is a simple one-
step process and silk has previously been used as a safe and effective material for high-density
loading of sensitive bio-molecules into non-immunogenic hydrogels under mild aqueous
processing conditions, which subsequently release entrapped cargo for extended periods of
time.191'194 Recent work has demonstrated the ability of dried silk hydrogels to form dense
microneedle structures capable of inserting into murine skin ex vivo. 172,'1 95  The additional
capacity for effective stabilization of vaccines and drugs in silk at room temperature offers an
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attractive opportunity to formulate vaccines which could avoid the cold chain, thus making
vaccines more inexpensive and readily available. 196
Here we sought to combine the advantages of this composite microneedle design with the
beneficial properties of silk as a controlled release matrix for entrapped proteins, and explored
the ability of silk/PAA composite microneedles to regulate the kinetics of vaccine delivery in
skin with the goal of mimicking patterns of antigen and inflammatory signal exposure during
natural infections. Composite microneedles were loaded with a subunit vaccine comprised of a
model protein antigen and the molecular adjuvant polyl:C, a synthetic double-stranded RNA
compound that stimulates immune responses through the danger sensors Toll-like receptor-3
(TLR-3) and melanoma-differentiation associated protein 5 (MDA5).187 Vaccine loaded into the
PAA phase of the microneedles provided a rapid initial bolus of vaccine release, followed by a
slow/sustained release of additional antigen/adjuvant from the implanted silk depots. We
observed dramatic variations in the strength of antigen-specific T cell responses dependent upon
the temporal patterns of bolus and extended vaccine delivery programmed through materials
engineering of the silk-composite structure. This approach allowed for the generation of antigen-
specific T cell responses following a single prime microneedle vaccination that were equivalent
to those measured following a prime-boost parenteral immunization routine, suggesting the
utility of this strategy for streamlined prime-only vaccine delivery. Combined with the recently
demonstrated room temperature stability of vaccines embedded in silk, 196 this controlled-release
microneedle platform has the potential to combine three important features of next-generation
vaccines for use in the developing world: (i) needle-free delivery, (ii) inexpensive long-term
room temperature storage without the need for a 'cold chain', and (iii) effective single-dose
immunization providing potent immunological memory. Additionally, we have confirmed
through these studies the potential for engineering optimal immune responses through
programmed vaccine release kinetics, an important finding supporting the future use of advanced
drug delivery approaches in the progression of vaccine research.
6.2. Materials and Methods
6.2.1. Silk Fibroin Solution Preparation
Cocoons of Bombyx mori silkworm silk were purchased from Aurora Silk (Portland, OR). All
other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and used as received. Silk
fibroin was prepared from cocoons as previously described.197 Briefly, cocoons were boiled for
40 min in a solution of 0.02 M sodium carbonate and then rinsed thoroughly with deionized
water to extract the glue-like sericin protein. After drying, the extracted silk was dissolved in 9
M lithium bromide solution at 600C for 4 hours, and subsequently the salt was removed by
dialysis against deionized water using a Slide-a-Lyzer dialysis cassette (Pierce, Rockford, IL) for
48 hours, changing the water regularly at least six times. The resulting solution was centrifuged
twice at 4"C for 20 min to remove impurities and the aggregates that formed during dialysis. The
supernatant was stored at 40C and filtered through a 450 nm syringe filter prior to use. The final
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concentration of silk fibroin solution was determined by weighing the residual solid of a known
volume of solution after drying.
6.2.2. Fabrication of Silk/PAA Microneedle Arrays
PDMS microneedle molds (Sylgard 184, Dow-Coming, Midland, MI) were prepared using a
Clark-MXR-CPA-2010 laser micromachining instrument (VaxDesign Inc., Orlando, FL).
Soluble ovalbumin (OVA, Worthington, Lakewood, NJ) and polyl:C (Invivogen, San Diego,
CA) were combined with aqueous silk solutions (8% w/v) to give the desired immunogen
concentration (generally ~5 mg/ml OVA, 0.5 mg/ml polyl:C). PDMS molds were then treated
with 02 plasma before addition of silk-vaccine formulations to the mold surface by pipette.
Molds were centrifuged for 30 minutes at rcf ~ 450 and excess silk-vaccine solution was
removed from the mold surface for potential reuse. Molds containing silk-vaccine were then
dried at 25'C for 12 hours and treated with 9:1 (v/v) methanol for 5 minutes or left untreated.
Polyacrylic acid (PAA, 250 kDa, 35%) was then added to soluble OVA and polyl:C at the
desired concentrations (generally -1 mg/ml OVA, ~0.1 mg/ml polyl:C) and mixed well. PAA
pedestals were then formed through addition of 35% PAA to the mold surface, followed by
centrifugation (30 min, rcf ~ 450) and drying at 25'C (48 h on the benchtop, followed by 2-14
days under desiccation), before removal. All microneedles were stored under desiccation at
25'C until use. Microneedle arrays were characterized by optical and confocal microscopy using
a Leica DMXR and a Zeiss LSM 510 respectively.
6.2.3. In vitro Vaccine Release
Silk implant release was characterized in vitro through brief (< 30 s) exposure of fabricated
arrays to deionized water. Implants were then collected through centrifugation and washed
before application of aqueous suspensions to glass coverslips. After drying, implants were
imaged by SEM using a JEOL 6700F FEG-SEM.
To differentiate the release kinetics of OVA loaded in PAA or silk and to evaluate the effect of
methanol treatment on release profiles, in vitro OVA release experiments were performed by
immersing silk/PAA composite microneedles in PBS buffer at pH 7.4 and 37A0.5"C. Dried silk
tips in PDMS were fabricated as described above with or without treatment in 9:1 (v/v)
methanol:water solution for 5 min prior to PAA addition. Three experimental groups (n = 4 for
each group) were designed: AlexaFluor 555 labeled ovalbumin (AF555-OVA) loaded in PAA,
AlexaFluor 647 labeled ovalbumin (AF647-OVA) loaded in non-treated silk tips, AF647-OVA
loaded in methanol-treated silk tips. For AF555-OVA release from the PAA portion of
composite microneedles, 1 ml aliquots were removed from 10 ml volume of release bath at
predetermined time points and replaced with lml of fresh pre-warmed PBS. For AF647-OVA
release from the untreated or methanol-treated silk portion, microneedles were transferred
between 0.5 ml aliquots of fresh pre-warmed PBS at pre-set time points. The concentration of
AF555-OVA and AF647-OVA in each of the release samples was quantified by fluorescence
spectroscopy (M200 Pro, Tecan, Mannedorf, Switzerland). At each time point, samples were
loaded in triplicate and the averaged reading was taken for further quantification.
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6.2.4. In vivo Microneedle Application and Vaccine Release
All animal studies were approved by the MIT IUCAC and animals were cared for in the USDA-
inspected MIT Animal Facility under federal, state, local, and NIH guidelines for animal care.
Microneedle application experiments were performed on anesthetized C57BL/6 mice (Jackson
Laboratories, Bar Harbor, ME) at the flank or dorsal ear skin. Skin was rinsed briefly with PBS
and dried before application of microneedle arrays by gentle pressure. Following application
mice were euthanized at subsequent time points and the application site was dissected. Treated
skin and applied microneedle arrays were imaged by confocal microscopy to assess
transcutaneous delivery of silk implants. In some cases, treated skin was excised and fixed in
3.7% formaldehyde for 18 h, then incubated in 30% sucrose/PBS for 2 h before embedding in
optimal cutting temperature (OCT) medium (Tissue-Tek) for histological sectioning on a
cryotome. Histological sections were then imaged using confocal microscopy. Live whole
animal imaging was performed using a Xenogen IVIS Spectrum (Caliper Life Sciences,
Hopkinton, MA) on anesthetized mice. For luminescent imaging of myeloperoxidase (MPO)-
dependent oxidative burst, luminol sodium salt (Santa Cruz Biotech, Santa Cruz, CA) was
administered i.p. (250 mg kg-1) before imaging. Fluorescence/luminescence data was processed
using region of interest (ROI) analysis with background subtraction and internal control ROI
comparison to untreated skin using the Living Image 4.0 software package (Caliper).
6.2.5. Immunizations
C57B1/6 mice (5/group) were immunized on day 0 with 9 jig ovalbumin and 150 ng polyl:C by
intradermal (i.d.) injection (15 pL in the dorsal caudal ear skin) or by microneedle array (5 min
application). Microneedles contained -98% of the total vaccine dose in the PAA fraction, with
the remaining 2% in the silk implant. Silk implants were either left untreated or cross-linked with
methanol as previously described to give differential vaccine release kinetics. In some cases
microneedles were fabricated to contain vaccine in only silk implants, or otherwise in only the
PAA pedestal. Animals vaccinated by i.d. injection received an identical boost on day 28. Mice
were then mock challenged on day 77 with 10 pg pCl-neo-sOVA (pOVA, Addgene, Cambridge,
MA) encoding soluble OVA, by intramuscular (i.m.) injection (25 ptl, split between both
quadriceps).
6.2.6. In vivo Murine Immunogenicity
Frequencies of OVA-specific CD8' T-cells and their phenotypes elicited by immunization were
determined by flow cytometry analysis of peripheral blood mononuclear cells at selected time
points following staining with DAPI (to discriminate live/dead cells), anti-CD8a , anti-CD44,
anti-CD62L, anti-KLRG1 (BD Biosciences, San Jose, CA), and phycoerythrin-conjugated
SIlNFEKL/H-2Kb peptide-MHC tetramers (Beckman Coulter, Indianapolis, IN). To assess the
functionality of primed CD8' T-cells peripheral blood mononuclear cells were stimulated ex vivo
with 10 ptg/ mL OVA-peptide SIINFEKL for 6 h with Brefeldin-A (Invitrogen, San Diego, CA),
fixed, permeabilized, stained with anti-IFNy, anti-TNFa , and anti-CD8a (BD Biosciences), and
analyzed by flow cytometry. Anti-ovalbumin or anti-silk IgG, IgG1, IgG2c, and IgM titers,
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defined as the dilution of sera at which 450 nm OD reading was 0.25, were determined by
ELISA analysis of sera from immunized mice. To measure avidity index, ELISA was performed
after 10 minute exposure of bound serum to 6M urea, to strip weakly bound immunoglobulins. 198
IgG avidity index was calculated as the ratio of measured titer without urea treatment to titer
measured with urea treatment.
6.3. Results and Discussion
6.3.1. Fabrication of Silk-PAA Composite Microneedles
In Chapter 5 we reported a strategy for the fabrication of composite microneedles based on PAA
and PLGA for microneedle-mediated implantation of solid PLGA microtips or microspheres in
vivo.192 Here we adapted this approach to create microneedles bearing a solid silk tip, supported
by a PAA pedestal intended to rapidly dissolve in cutaneous tissue fluids following needle
insertion, releasing silk tips for retention in the skin following microneedle patch removal. To
fabricate these structures we first generated PDMS molds bearing square pyramidal micro-scale
cavities across their surface using laser ablation as previously described (Figure 6-la, step 1)."5
We then surface treated the molds with 02 plasma to generate a hydrophilic surface and facilitate
infiltration of the mold cavities by the silk-vaccine solution. Silk fibroin protein was co-
dissolved in aqueous solution with ovalbumin protein (OVA, a model antigen) and the TLR-3
agonist polyl:C, a potent double-stranded RNA adjuvant for stimulating anti-viral immune
responses. This solution was added to plasma-treated molds and infiltration of the mold cavities
was further completed through centrifugation (Figure 6-la, step 2). After removing excess silk-
vaccine solution, silk-filled molds were allowed to dry at room temperature for 12 hr to produce
hardened silk hydrogel tips within the PDMS molds (Figure 6-la, step 3).172,195 Silk protein is
known to undergo physical cross-linking upon exposure to methanol, and this results in
prolonged cargo release from rehydrated silk hydrogels.197 Here, we exposed solidified silk tips
to methanol by pipetting solvent onto the mold surface, to introduce physical crosslinking and
retard release of encapsulated vaccine from silk tip implants following implantation in vivo
(Figure 6-la, step 3). Following methanol treatment, we added vaccine-loaded aqueous PAA
solutions carrying co-dissolved OVA and polyl:C to the mold surface and again performed
centrifugation to compact the PAA into the mold cavities forming complete PAA pedestal
structures (Figure 6-la, step 4). Microneedles were then dried in the mold at room temperature
for several days and placed under vacuum to complete the drying process before removal and
storage under vacuum at 25'C (Figure 6-1a, step 5). This process reliably produced arrays of
composite pyramidal microneedles 550pm in height bearing a tip-pedestal structure where
vaccine-containing silk hydrogel tips were supported by vaccine-loaded PAA pedestals (Figure
6-1b). This structure was readily visible by optical microscopy imaging of microneedles
fabricated with Alexafluor 647-labeled OVA (AF647-OVA) and Alexafluor 555-labeled OVA
(AF555-OVA) loaded within the silk tip and PAA pedestal, respectively (Figure 6-1b). We
further confirmed this needle microstructure using confocal microscopy to detect the localization
of the vaccine cargo within the tip or pedestal of the resulting microneedles. This analysis
revealed AF647-OVA restricted to the silk tip of each microneedle with AF555-OVA signal
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observed only in the PAA pedestal (Figure 6-1c). Given our previous results with similar
PLGA/PAA systems, we expected that this composite structure should allow for effective
cutaneous insertion of the hardened composite microneedles, where exposure to interstitial fluids
would rapidly dissolve the PAA pedestals releasing the silk tips, which would remain implanted
in the skin following removal of the array backing. 192
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Figure 6-1. Fabrication and in vitro characterization of silk/PAA composite microneedles.
(a) Schematic of microneedle fabrication: (1) PDMS molds were fabricated using laser ablation,
(2) silk-vaccine formulations were added to plasma treated molds and infiltrated into mold
cavities by centrifugation, (3) silk was dried in mold cavities forming hardened tips and left
untreated or exposed to MeOH, (4) vaccine-loaded PAA was added to the mold and infiltrated
into mold cavities by centrifugation, and (5) arrays were dried before removal. (b) Optical
micrograph of silk/PAA microneedle array encapsulating AF647-OVA (blue) in silk tips, and
AF555-OVA (red) in PAA pedestals (scale bar - 500pm). (c) Confocal micrographs of composite
microneedles showing AF647-OVA (blue) in silk tips and AF555-OVA (red) in PAA pedestals
(scale bar - 500pm). (d) SEM micrographs of a separated silk tip following 30 seconds exposure
of a composite array to deionized water. Micrographs show intact tip structure (left, scale bar -
500pm) and micro-porous silk hydrogel structure (center, scale bar - 20pm, and right, scale bar
- 5pm). (e) Quantitative analysis of fluorescent OVA release from silk and PAA fractions of
composite microneedles over time.
6.3.2. In Vitro Characterization of Silk Tip Release and Vaccine Cargo Delivery
To test our expectation that composite silk/PAA microneedles would rapidly release silk tips
upon exposure to tissue fluids in vivo, we exposed microneedle arrays to deionized water in vitro
for short periods of time to observe PAA dissolution and silk tip release. Here we visually
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observed rapid and complete separation of silk tips from PAA composite microneedle arrays
after only 30 seconds immersion. We then collected the separated silk tips by centrifugation and
imaged them using SEM to observe their structure. Collected tips maintained their pyramidal
geometry with dimensions consistent with the molds used in their fabrication (Figure 6-1d).
Further high magnification SEM imaging of released tips revealed a nano-porous network
structure consistent with bundling of silk proteins to form a cross-linked hydrogel structure
(Figure 6-1d).
To confirm the ability of composite silk/PAA microneedles to provide control over vaccine
release profiles, we fabricated microneedle arrays containing AF647-OVA loaded in the silk
needle tips or AF555-OVA in the PAA pedestals. Silk tips were either left untreated or treated
with methanol as before to introduce additional cross-linking into the silk hydrogels. We then
immersed each array in phosphate buffered saline pH 7.4 (PBS) at 37'C and collected fractions
of the solution at subsequent time points to measure the release of encapsulated AF555-OVA and
AF647-OVA by fluorescence spectroscopy. Consistent with expectations, AF555-OVA loaded
into the PAA pedestal was rapidly dispensed from dissolving PAA pedestals, with complete
release over the course of only 2 hours (Figure 6-le). Conversely, AF555-OVA loaded into silk
hydrogel tips was released more slowly with kinetics further modulated by methanol exposure
during fabrication. For microneedles bearing untreated silk tips, AF647-OVA exhibited a burst
release of -70% over the course of 2 hours with sustained release of the remaining 30% over the
next 5-6 days (Figure 6-le). Delivery from methanol-treated silk was further delayed with only
25% burst release over 2 hours, and sustained near-linear release of the remaining 75% over the
course of 8-12 days (Figure 6-1e). Thus, the combination of rapidly dissolving PAA or slow
swelling of silk hydrogels permits the kinetics of vaccine release to be varied over a wide range
spanning hours to more than a week.
6.3.3. Composite Microneedles Rapidly Implant Silk Tips to Form Cutaneous Vaccine Depots In Vivo
We previously demonstrated that composite PLGA/PAA microneedles penetrate murine skin,
and prior work has also shown the ability of solid silk microneedles to effectively insert into
murine skin. To confirm the ability of composite silk/PAA microneedles to effectively
penetrate skin, we fabricated silk/PAA microneedles encapsulating AF647-OVA and AF555-
OVA in the silk and PAA microneedle phases, respectively, and applied these arrays to the skin
of C57Bl/6 mice for 5 minutes. Confocal imaging of microneedle arrays before and after
application revealed complete loss of both silk- and PAA-associated OVA fluorescent signal
from the length of each microneedle following 5 min insertion in skin (Figure 6-2a). Confocal
imaging on excised skin or skin histological sections where patches were applied revealed
overlaid punctate fluorescent signal from AF647-OVA and AF555-OVA at individual sites of
microneedle insertion indicating the effective delivery of both silk- and PAA-loaded materials
upon microneedle penetration into the cutaneous space (Figure 6-2b-c). In these images
microneedles were observed to insert several hundred microns below the skin surface in the
epidermal space, consistent with previous demonstrations of microneedle delivery.192,199,20
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Three-dimensional rendering of confocal z-stacks to visualize the depth of fluorescent OVA
delivery showed fluorescent signals from AF647- and AF555-OVA from silk and PAA
respectively, extending several hundred microns below the skin surface at sites of microneedle
insertion (Supplementary Figure S6-1). Together these results confirm the ability of silk/PAA
microneedles to effectively insert into murine skin, with rapid dissolution of the PAA pedestal
upon exposure to skin fluids to leave behind vaccine-loaded silk hydrogels.
a Before Application After 5 Min Appieation b c
muwi
d id 2d 3d 4d sd 10d 16d
i.d.-Inj -d.-PAA
5x10, O 
-- Silk
MN-MeOH - MN-PAA
0 6 +MN-Silk
MN+MeOH : OIMN+MOH 3107 MN-PAA
i.d.-Inj x10 
MN-Sk+Me
MN-MeOH 
-7x107 0.maM.0[ 0 2 4 6 3 10 12 14
MN+MeOH 5x10 7  DayPot DeMV
Figure 6-2. Composite microneedles deliver loaded vaccines to murine skin in vivo.
(a) Confocal micrographs of composite microneedles showing AF64 7-OVA (blue) in silk tips and
AF555-OVA (red) in PAA pedestals (scale bar - 500um) before application (left) and following a
5 minutes application to murine auricular skin (right). (b) Confocal micrographs showing OVA
delivery to murine skin following 5 minutes application of composite microneedles (AF647-OVA
in silk tips - blue, andAF555-OVA in PAA pedestals - red, scale bar - 500pm). (c) Confocal
micrograph of histologically sectioned skin treated for 5 minutes with composite microneedles
(AF64 7-OVA in silk tips - blue, and AF555-OVA in PAA pedestals - red, scale bar - 100um). (d)
Whole animal fluorescent images of mice treated (arrows, right ear) with composite
microneedles containing AF64 7-0 VA (blue) in silk tips (±methanol treatment) and AF555-OVA
(red) in PAA pedestals. (e) Quantitative analysis of totalfluorescent OVA signal measured at the
treatment site for mice receiving i.d. injection or microneedle delivery of AF647-OVA in silk tips
(±methanol treatment) and AF555-OVA in PAA pedestals.
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6.3.4. Cutaneous Silk Implants Control Vaccine Release Kinetics In Vivo
We next tested whether microneedle-delivered vaccine release in vivo could be programmed
during array fabrication. Similar to previous experiments, we fabricated microneedles
containing AF647-OVA and AF555-OVA in the silk or PAA needle fraction respectively, and
applied these to the auricular skin of anesthetized C57B1/6 mice. For comparison to parenteral
administration, we performed intradermal (i.d.) injection of dose-matched soluble fluorescent
vaccine formulations in the dorsal ear skin. We then used whole-animal fluorescence imaging to
monitor the persistence of the OVA fluorescent signal at the treatment site and determine the
release characteristics of injected or microneedle-delivered vaccine in vivo. Fluorescence
imaging revealed the rapid loss of AF555-OVA signal in all test groups indicating the clearance
of soluble OVA from the treatment site within 24 hours of delivery either by i.d. injection, or
from the PAA phase of composite microneedles (Figure 6-2d-e). Clearance of AF647-OVA
was similarly rapid in the case of i.d. injection. Conversely, AF647-OVA encapsulated in silk-
implants was retained at the treatment site for days to weeks following microneedle treatment,
depending on whether methanol treatment was performed during fabrication to induce additional
silk hydrogel cross-linking (Figure 6-2d-e). Animals treated with silk/PAA microneedles
without methanol cross-linking showed nearly linear clearance of silk-loaded AF647-OVA over
the course of 4 days following treatment. In the case of microneedles pretreated with methanol,
AF647-OVA fluorescent signal was detectable at the treatment site for >16 days following array
application (Figure 6-2d-e). Notably, these in vivo antigen release profiles showed roughly the
same total duration for complete release as measured in vitro, but showed little or no burst
release as observed in vitro. These results indicate the ability of microneedle-delivered silk tip
implants to control the rate of vaccine release in vivo with a kinetic profile dependent on
methanol treatment during fabrication.
6.3.5. Microneedle Vaccine Release Kinetics Determine the Strength of Cellular Immunity
Many natural infections are characterized by an initially abundant microbe burden lasting a few
days, which is predominantly eliminated by the initial immune response. However in many
"acute" infections, this initial clearance of microbes is followed by a delayed clearance of
residual low levels of the pathogen that persist for a more prolonged period prior to complete
eradication.- 0  Thus the natural immune system is frequently exposed to a large pathogenic
bolus of antigenic and inflammatory stimuli, followed by a prolonged low level exposure which
can persist for days to months following acute infection. Given that such kinetic patterns in
natural infection are often associated with profound T-cell responses and robust immune
memory, we sought to determine whether tailoring vaccine exposure kinetics using silk/PAA
microneedles to mimic this natural progression of infection would impact vaccine
immunogenicity relative to bolus injection or bolus microneedle delivery. We vaccinated mice
with 9 pg OVA and 150 ng polyl:C either by i.d. injection at the dorsal ear site (i.d. Inj.) or by
microneedle administration as before. Microneedles were fabricated with the vaccine dose split
(98% and 2%) between the PAA and silk fractions with or without methanol pretreatment (MN
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PAA(98)/Silk(2) and MN PAA(98)/MeOH-Silk(2)); control microneedles were fabricated with
either 98% of the vaccine dose in the PAA fraction (MN PAA(98)/Silk(0)) or 2% of the dose in
the silk fraction (MN PAA(0)/Silk(2)). To monitor cellular immunity we measured OVA-
specific CD8' T-cell proliferation in peripheral blood using SIINFEKL/H-2Kb peptide-MHC
tetramers (SIINFEKL is the immunodominant peptide epitope of OVA). This analysis revealed
that i.d. injected vaccines elicited extremely weak antigen-specific CD8+ T-cell responses, with
minimal expansion of OVA-specific cells over 4 weeks following a single immunization (-1%
of CD8* T cells, Figure 6-3a-c). Microneedles carrying a fraction of the vaccine dose solely in
the PAA or solely in the silk phase induced stronger CD8+ T-cell proliferation, reaching a few
percent tetramer* CD8' T-cells by 14 days following immunization (Figure 6-3b, c).
Interestingly, for the two microneedle groups containing a small fraction of the vaccine dose in
the silk tips and the bulk of the vaccine in the PAA phase, the T-cell response was stronger than
each of the prior groups (Figure 6-3a-c). Strikingly, methanol-crosslinked silk tip implants that
provided a sustained low dose of the vaccine over 2 weeks after the initial bolus PAA release
resulted in dramatic increases in the frequency of tet* CD8+ T-cells compared to the other
vaccination regimens (Figure 6-3a-c). Two weeks following microneedle patch application,
SIINFEKL-specific CD8* T-cells expanded to 10-20% of all CD8+ T cells in this group. To test
the functionality of these expanded T-cells, we restimulated peripheral blood mononuclear cells
(PBMCs) on day 14 ex vivo with SIINFEKL and assessed production of the inflammatory
cytokines IFN-y and TNF-a using intracellular staining. Flow cytometric analysis revealed high
frequencies of antigen-specific functional cytokine-secreting CD8' T cells in the case of
microneedle vaccination, while i.d. injection treated animals showed only background levels of
activation, as expected from the previous tetramer-staining analysis (Figure 6-3d-e). Sustained
low-level vaccine exposure from methanol cross-linked silk tip implants resulted in significantly
higher frequencies of IFN-y* and IFN-y* TNF-a multi-functional T-cells compared to the other
vaccine groups (Figure 6-3d-e and Supplementary Figure S6-2). Notably, the single silk/PAA
composite microneedle treatment was able to induce CD8* T cell responses of similar magnitude
and cytokine secretion capacity as those observed after a prime + boost regimen administered by
i.d. injection (Supplementary Figure S6-3). These significant increases in the magnitude of
cellular immune responses suggest that both microneedle delivery and prolonged
antigen/adjuvant delivery kinetics can substantially enhance the strength of the adaptive cellular
immune response in transcutaneous vaccination.
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Figure 6-3. Prolonged vaccine release profile elicits increased proliferation of antigen-
specific CD8+ T cells.
Mice were vaccinated on day 0 either by i.d injection, or microneedle treatment (±methanol to
cross-link silk implants) to deliver 9 pg OVA and 150 ngpolyl.C. Microneedles were fabricated
with 98% of the total vaccine dose in the PAA fraction, with the remaining 2% in the silk implant
(MN PAA(98)/Silk(2) and MN PAA(98)/MeOH-Silk(2)); control microneedles were fabricated
with either 98% of the total vaccine dose in the PAA (MN PA A(98)/Silk(0)) or 2% of the total
dose in the silk fraction (MN PAA(0)/Silk(2)). (a-c) Flow cytometry analysis of antigen-specific
CD8' T cell proliferation in peripheral blood. Shown is (a) representative cytometry plots from
day 14, and (b-c) quantitative analysis of SINFEKL-tetramer* CD8' T cell frequencies for 4
weeks following vaccination. (b, * p<0. 05 for MN PAA (98)/Silk(0) versus MN PAA (0)/Silk(2), #
p<0.05 for MN PAA(98)/Silk(0) and MN PAA(O)/Silk(2) versus i.d., c, * p<0.05 for MN
PAA(98)/MeOH-Silk(2) versus MN PAA(98)/MeOH-Silk(2), # p<0.05 for MN PAA(98)/MeOH-
98
Silk(2) and MN PAA(98)/Silk(2) versus i.d). (d-e) Flow cytometry analysis of inflammatory
cytokine expression following ex vivo antigen stimulation. Shown is quantitative analysis of
IFNy* and IFNy*/TNFa* CD8' T cells measured on day 14. (* p< 0.05)
Sustained antigen stimulus has been implicated in controlling memory cell phenotype and
function. 190,191 Thus, we next compared the memory phenotype of CD8' T cells elicited by
single silk/PAA microneedle treatment to prime-boost vaccination administered by i.d. injection,
and observed a significant increase in the frequency of CD44* CD62L* central memory CD8' T
cells on day 63 following microneedle vaccination compared to injection (Figure 6-4a-b).
Central memory T cells have previously been correlated with effective immunological responses
through more rapid recall upon re-exposure to pathogen, and are thought to be important for long
term protection.188 We also characterized the expression patterns of KLRG1, a marker which
indicates effector T cell memory status upon long term exposure to pathogen or antigen.
Cytometric analysis on day 70 showed that animals treated with a single microneedle vaccination
generated similar frequencies of KLRG1* CD8' T cells in peripheral blood relative to mice given
prime and boost vaccine injections (Supplementary Figure S6-4). Finally, we measured the
strength of CD8+ T cell expansion upon recall in vivo with injected OVA-expressing plasmid
DNA (pOVA). Here we observed statistically identical expansion of SIINKEFL reactive,
cytokine-secreting CD8* T cells 14 days following i.m. injection of pOVA in mice vaccinated
with prime-only silk/PAA microneedles or prime-boost i.d. injection, suggesting that a single
immunization by silk/PAA microneedle delivery can provide similar recall immunity compared
to a prime-boost parenteral vaccine (Figure 6-4c-e).
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Figure 6-4. Microneedle vaccination gives enhanced memory CD8*
effector function.
T cell phenotype
Mice were vaccinated on day 0 either by i.d. injection, or microneedle treatment (±methanol to
cross-link silk implants) to deliver 9 pg OVA and 150 ngpolyI.C. Microneedles were fabricated
with 98% of the total vaccine dose in the PAA fraction, with the remaining 2% in the silk implant
(MN PAA (98)/Silk(2) and MN PAA (98)/MeOH-Silk(2)); control microneedles were fabricated
with either 98% of the total vaccine dose in the PAA (MN PA A(98)/Silk(0)) or 2% of the total
dose in the silk fraction (MN PAA (0)/Silk(2)). (a-b) Flow cytometry analysis of antigen-specific
CD8' T cell memory phenotype in peripheral blood. Shown are (a) representative cytometry
and (b) quantitative analysis of CD44 and CD62L on SHNFEKL-tetramer* CD8' T cells for day
63 following vaccination. (c) Single microneedle vaccination gives equivalent recall immunity
relative to prime-boost injection. Mice were then recalled by i.m. injection of 2 0ug pOVA on
day 77. (d-e) Flow cytometry analysis of inflammatory cytokine expression following ex vivo
antigen stimulation of PBMCs. Shown are (d) representative cytometry plots and (e)
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quantitative analysis of IFNy* and IFNy*/TNFai CD8' T cells measured on day 91 (day 14 post
recall).
6.3.6. Microneedle Vaccination Gives More Potent and Balanced Humoral Immunity
To evaluate the antibody response elicited by composite silk/PAA microneedles vaccines, we
collected sera from immunized mice on day 21 following a single i.d. injection of vaccine, MN
PAA(98)/Silk(2) vaccination, MN PAA(98)/MeOH-Silk(2), or MN PAA(98)/Silk(O)
vaccination. ELISA measurements of serum titers of OVA-specific IgM, IgG, IgG1, and IgG2c
showed a consistent increase in the serum titers of class-switched OVA-specific antibodies for
microneedle-immunized animals. Microneedle vaccines induced significant increases in serum
titers for anti-OVA IgG, IgG1, and IgG 2c, while no difference was observed for IgM (Figure 6-
5a-d). The effect on "Thl-like" IgG2c antibody responses was particularly striking, as i.d.
injection elicited no OVA-specific IgG2c response, while both microneedle groups elicited
readily detectable IgG2c titers. These results suggest that microneedle delivery was able to elicit
a more potent, Thl/Th2 balanced antibody repertoire compared to i.d. injection. Further, we
analyzed avidity of the elicited IgG responses using urea exposure before ELISA detection to
strip away weakly binding immunoglobulins.198  This analysis demonstrated significantly
improved IgG avidity for mice receiving microneedle vaccines as compared to i.d. injected
vaccines, with uncross-linked silk microneedles eliciting the greatest increase in avidity (Figure
6-5e). Finally, to further confirm the low immunogenicity of silk protein used in these studies
we measured the presence of silk-specific serum IgG by ELISA. In mice given i.d. injection or
microneedle vaccines, no significant increase in anti-silk IgG was detected following vaccination
relative to naYve levels (Supplementary Figure S6-5). Together, these results indicate that
microneedle vaccines strongly augment the humoral response relative to traditional syringe
injections whether vaccine is given by bolus or release kinetics are prolonged for a few days or a
few weeks.
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Figure 6-5. Delivery route determines the strength and isotype balance of humoral
responses following parenteral i.d. or microneedle vaccination.
Shown are serum OVA-specific antibody titers and avidity indices measured on day 21. Serum
OVA-specific antibody titers are shown for (a) IgM, (b) IgG, (c) IgG1, and (d) IgG2c. (e) Avidity
index for serum IgG , calculated as the ratio of titer measured without urea pretreatment of
bound serum to titer with urea pretreatment. (*p<0.05 compared to i.d.)
6.3.7. Cutaneous Silk Implants Give Sustained Local Inflammatory Activation In Vivo
Having shown the ability of composite silk/PAA microneedles to achieve prolonged vaccine
release, we next sought to determine whether persistent local inflammation in the case of MN
PAA(98)/MeOH-Silk(2) immunizations might be contributing to the enhanced cellular immunity
observed for these microneedle vaccines. To this end, we used whole-animal luminescent
imaging with the chemiluminescent probe luminol to longitudinally measure myeloperoxidase
(MPO)-dependent oxidative flux in locally-recruited inflammatory cells as an indication of
inflammatory activation at the treatment site.'0 9,206 This approach has previously been used to
observe recruitment of activated immune cells such as neutrophils and serves as a general marker
for local innate inflammatory responses. Groups of mice were immunized by i.d. injection of
OVA mixed with polyl:C as before, or treated with microneedles loaded with OVA and the
TLR-3 agonist polyl:C in both the silk (±MeOH) and PAA fractions. Luminescent imaging
indicated that i.d. injection produced only low-level inflammation at the treatment site which
resolved completely after 4 days (Figure 6-6a-b). Conversely, microneedle delivery with either
untreated or methanol-treated silk/PAA microneedles showed a significant burst of inflammation
for 3 days following treatment. After 4 days mice vaccinated with untreated silk showed only
background levels of MPO-dependent chemiluminescence, while methanol treated silk
microneedles gave significant luminescent signal above background on days 4, 5, and 11,
suggesting persistent low level inflammatory activation in these mice, likely resulting from
prolonged release of antigen/adjuvant from silk implants. However, no visible signs of excessive
inflammation or tissue damage were observed in any of the mice in these treatment groups.
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Further, i.d. injection of 5x excess silk doses produced signal similar to i.d. injection alone,
confirming the non-inflammatory nature of purified silk proteins in vivo (data not shown,
reviewed in 193). Together with the previous in vivo OVA delivery results, this indicates the
ability of silk/PAA microneedles to sustain both antigen exposure and inflammatory cues from
days to weeks following treatment in vivo. This sustained low level of inflammation combined
with continuous antigen delivery is likely a key factor in eliciting the potent CD8* T cell
proliferation for microneedle vaccination, specifically cases where methanol cross-linked silk
maintains release over several weeks.
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Figure 6-6. Composite microneedles prolong local inflammation.
(a) Whole animal chemiluminescent images of mice treated (arrows, right ear) with composite
microneedles containing OVA and polyI:C in silk tips (Lmethanol treatment) and PAA pedestals.
Mice were imaged following luminol administration to visualize MPO-dependent oxidative flux
in activated immune cells. (b) Quantitative analysis of total luminescent signal measured at the
treatment site for mice receiving i.d injection or microneedle delivery of OVA and polyI.C in
silk tips (±methanol treatment) and PAA pedestals. (* p<O.05 compared to baseline)
6.4. Conclusions
The development of materials strategies for microneedle fabrication has yielded impressive
progress in the advancement of effective, safe, and convenient delivery of macromolecules for
vaccination in the skin. 199,207,208 These efforts have sought to effectively balance the many
critical features essential for the effective clinical deployment of microneedle patch delivery
systems including (i) suitable mechanical properties, (ii) control over micron-scale needle
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geometry and dimension, (iii) the ability to achieve rapid administration, (iv) effective
encapsulation of sensitive biomolecules, and (v) avoidance of unwanted toxicity (reviewed in
209). Here we have demonstrated the combination of these critical design parameters in the
fabrication of silk/PAA composite microneedle arrays. These structured skin patches readily
penetrate murine skin in vivo, provide rapid deposition of vaccine into the skin over several
minutes, are able to encapsulate fragile protein or nucleic acid vaccine components in densely-
loaded polymer matrices, and exhibited no toxicity in vivo. Further, composite silk/PAA
microneedles provide enhanced flexibility in programming vaccine dosage and long-term
delivery kinetics while retaining the ability to provide rapid and simple administration, a feature
which we have shown to be critical for tuning the potency of immunity.
Previous studies of silk have shown effective loading of sensitive biomolecules including
vaccines for storage at room temperature.193,196,197,210 This is an attractive feature which could
allow for inexpensive and broader global dissemination of vaccines to remote areas of the world.
Here we confirmed the potential for silk to stabilize subunit vaccines during room temperature
storage, as all silk/PAA microneedles used in these studies were stored at room temperature for
>2 months prior to use. Further, as observed previously, our choice of PAA as a water soluble
component in the encapsulation of vaccine during fabrication of silk/PAA microneedles allowed
for similar room temperature storage without loss of in vivo immunogenicity. 192 Prior studies of
silk microneedles have demonstrated effective methods for fabrication as well as consistent
insertion into murine skin.172,195 We have expanded upon these results here to demonstrate a new
approach for silk microneedle fabrication to take advantage of the controlled release capacity for
silk hydrogels while also improving the practicality and speed of microneedle application. These
advances allowed us to perform comprehensive tests of silk microneedle immunogenicity in
vivo, and to demonstrate the utility of silk as a material for effective loading, storage, and
delivery of vaccines. Recently, a similar approach for controlling vaccine release from
microneedles has been described for the dermal implantation of chitosan reservoirs from PLA
pedestals. 21' These embeddable chitosan microneedles showed control over week-long protein
release resulting in enhanced humoral immune responses indicating the potential of this approach
for tuning immunity. Here we have demonstrated that the flexibility of silk fibroin to form
tunable matrices with programmable release of antigen and adjuvant over days to weeks can
provide additional control over elicited cellular and humoral immunity.
It is well established that microneedle delivery of vaccines to the skin can enhance immunity
through targeted delivery of antigen and adjuvant to response-governing antigen presenting cells
present at high density within the skin. The physical disruption of the epidermal/dermal tissues
during microneedle delivery is thought to be an important factor in mediating this enhanced
immunity through the recruitment and maturation of antigen presenting cells.200  Further,
vaccine delivery in the context of epidermal wounding resulting from microneedle treatment may
contribute to a pro-inflammatory microenvironment during cutaneous vaccination as
keratinocytes and other skin-resident cells are known to actively sense and respond to tissue
21adamage as well as pathogen-associate molecular patterns such as TLR-agonists. Thus the
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success of microneedle delivery is likely in part founded in the natural mechanisms of the skin as
a barrier to entry for sensing and responding to natural infections.
Here we have shown that microneedle vaccination can be further enhanced through the adoption
of a similar approach for replicating the natural time course of many diseases in which acute
infection provides initially high levels of antigen and adjuvant stimuli which then rapidly
decrease through immunological mechanisms of pathogen clearance, leading to long-term low
levels of persistent pathogenic stimulus.201-205 In previous studies the presence of protein antigen
or pathogen-derived genetic material has been observed for weeks to months in the local site of
infection and in draining lymph nodes persisting after the relatively rapid clearance of infectious
agent over the course of several days.201,202,214,215 This pattern of sustained antigen exposure
following primary clearance of infection has suggested a potential role for continued
antigen/adjuvant stimulation in the development of primary effector and memory T cell
responses, including effects on T cell migration/homing,203 establishment of T cell memory
phenotypes,216 and maintenance of effective long-lived protective T cell responses.m
Conversely, in some cases, chronic antigen presentation can lead to dysfunctional memory T cell
responses including loss of effector or proliferative functions or poor long-term survival.218 This
dichotomous development of either enhanced or defective long-term protective response is
thought to be determined in part by the relative magnitude of sustained antigen exposure with
chronic high antigen load frequently leading to exhausted or anergic phenotypes, while low level
exposure commonly results in maintenance of protective functions. Thus the ability to finely
tune the level and persistence of antigenic or inflammatory cues following microneedle
vaccination is likely critical for eliciting the desired effect on immunogenicity.
The silk/PAA composite microneedle system we have developed allows for vaccine delivery that
can be tuned to replicate the timing and dosage features of natural infection through the
combination of bolus vaccine release from rapidly soluble PAA, and extended release from
vaccine-loaded silk depots implanted in the skin upon microneedle application. In our studies
this ability to provide bolus vaccine exposure combined with additional multi-week low-level
delivery was able to drastically improve the proliferative capacity of antigen-specific T cells,
yielding increased levels of peripheral antigen-specific, functionally active effector CD8' T cells
greatly exceeding those responses generated through injection. These results indicate the need
for both bolus vaccine delivery and sustained release as individual bolus or sustained release
vaccine components gave much weaker responses. Further, the ability to program the duration
of extended release proved critical as multi-week exposure resulted in 2.8-fold increases in CD8+
T cell responses over shorter multi-day release profiles. Notably, we observed that CD8' T cell
responses to injected vaccines were only able to match single microneedle immunizations
following multiple vaccine doses, suggesting that the combination of microneedle delivery with
programmed vaccine release may eliminate the need for costly and less effective prime-boost
vaccine regimens.
105
Microneedle vaccines have traditionally exploited the naturally endowed immune-functionality
of the skin as a primary barrier to pathogen entry, however further improvements to skin
vaccination can be realized through the design of delivery approaches which similarly mimic the
natural time course of pathogen invasion, recognition, and response. Here we have demonstrated
the potency of this approach by designing a microneedle delivery approach capable of
mimicking the extended kinetic profile for antigen and adjuvant exposure following natural
infection. Composite silk/PAA microneedles were able to rapidly disintegrate after insertion into
the skin releasing vaccine bolus from dissolving PAA pedestals while simultaneously forming
persistent cutaneous silk implants to mediate the sustained low-level delivery of vaccine over
time. The flexibility of this approach for high-density loading and controllable release of
biologically-sensitive vaccine components allowed for programmable vaccine delivery in the
skin to generate potent cellular and humoral immunity superior to prime vaccination by
hypodermic injection. Notably, these responses were elicited following months of microneedle
storage at room temperature and gave equivalent immunity to those following prime-boost
injection regimens. This ability for potent immunity following a single immunization, combined
with the potential for long term room temperature storage, and safe needle-free administration
make this strategy an attractive option for effective global vaccine distribution, and deployment.
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7. IMMUNOGENIC DELIVERY OF ADENOVIRAL VECTORS IN NONHUMAN PRIMATES FROM SKIN
PATCHES ENABLING DRY, REFRIGERATION FREE VACCINE STORAGE
7.1. Introduction
Where Chapters 1-6 focused on the design and initial preclinical testing of novel microneedle
vaccination and delivery approaches, Chapter 7 focuses on more comprehensive preclinical
testing of a simple and robust microneedle strategy for delivery of a clinically advanced viral
vector vaccine in a late-stage primate preclinical model of HIV. Preclinical rodent models are
useful for the development of new vaccination strategies but cannot accurately predict success in
human clinical trials. Therefore, the studies presented here are meant to provide meaningful
preclinical evidence of the potential of microneedle vaccination for translation to human clinical
use.
Transcutaneous drug delivery from planar adhesive skin patches (which adhere to but do not
disrupt the stratum corneum) has been very successful for the delivery of hydrophobic small-
molecule drugs (reviewed in 219) and has been shown to be effective for delivery of skin-
permeable vaccine adjuvants in humans.22 - However, delivery of proteins and other
macromolecular components into the skin requires a means to bypass the barrier posed by the
stratum corneum. To this end, new technologies for cutaneous needle-free vaccination based on
topical patches containing arrays of micron-scale solid projections ('microneedles') that can
penetrate the superficial layers of the skin have shown promise for safe and effective vaccine
delivery. 223 On application to the skin, patch microprojections penetrate the stratum corneum
and enter the viable epidermis, enabling vaccines coated on or encapsulated within the
microneedles to be dispersed into the local tissue. This technology may facilitate a new
paradigm for vaccination which (i) eliminates the risk of blood-borne pathogen transmission or
needle-stick injury, (ii) streamlines vaccine administration for large-scale immunization
campaigns by minimally trained personnel or even self-administration, and (iii) employs dry,
solid-state vaccine formulations that may reduce cold chain requirements for cost-effective
vaccine storage and dissemination, particularly in the developing world. 87,209 Recent studies
have demonstrated the ability of microneedles to effectively deliver vaccines as dried coatings on
the surface of each projection (which dissolve rapidly upon insertion into the skin) or
encapsulated within microneedles which themselves dissolve in the skin, eliciting protective
immunity in mouse models of influenza, 12,142,n4 hepatitis C,93 and West Nile virus.149 However,
this approach has not yet been tested for efficacy in non-human primates, an important large-
animal model that is thought to be more predictive of human immune responses to many
vaccines than small animal models.225 22 7
Given the anatomical and immunological differences between mice or other small animal models
and primates or humans228 and the common failure of small-animal models to predict vaccine
success in humans,229 we set out to test the safety and immunogenicity of a prototypical
microneedle patch vaccine delivering a clinically-relevant vaccine vector in Rhesus macaques.
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We chose for these studies to focus on recombinant replication-incompetent adenoviral vectors,
which have emerged as a potent vaccine platform in non-human primate models of HIV-1
230-234infection. In previous studies, adenovirus serotype 5 (Ad5), as well as less common
serotypes unlikely to trigger pre-existing vector immunity such as Ad26 and Ad35 have yielded
impressive immunogenicity in clinical and preclinical trials.23 -238 To this end, biodegradable
microneedle patches composed of the polymer poly(L-lactic acid) (PLA, used in resorbable
sutures and approved drug delivery formulations, reviewed in 239) were coated with Ad5 vectors
encapsulated in a sucrose sugar-glass matrix. Adenovirus-loaded microneedle patches (Ad-MN)
allowed dry storage of Ad5 for several months at 25'C with no loss in bioactivity in mice.
Similar to traditional syringe injections, Ad-MN delivery of adenovirus SIV vaccines elicited
potent systemic cellular and humoral immunity in both mice and macaques, as well as strong
immunity at mucosal sites typically serving as barriers to entry for SIV/HIV viral transmission.
These results suggest that microneedle patch delivery can enable important practical benefits for
vaccine deployment including solid-state stabilization of vaccine for enhanced long-term room
temperature storage and needle-free administration while maintaining immunogenicity
comparable to traditional needle-and-syringe liquid vaccines.
7.2. Materials and Methods
7.2.1. Adenovirus Vector Preparation
DNA for E1/E3-deleted adenovirus virus was transfected into Per55K cells as previously
described.240 242 After homologous recombination of linearized plasmids, recombinant virus
particles were generated. Transfection lysate was plaque purified, screened for transgene
expression, expanded, purified by Cesium-Chloride gradient centrifugation, and dialyzed in PBS
containing 5% sucrose. Virus was stored at -80 'C until use.
7.2.2. PLA Microneedle Patch Fabrication
PDMS molds (Sylgard 184, Dow-Coming, Midland, MI) were prepared using a Clark-MXR-
CPA-2010 laser micromachining instrument (VaxDesign Inc., Orlando, FL). PLA (IV 1.9 dL g-
, Lakeshore Biomaterials) was melted over the molds under vacuum (-25 in. Hg, 200C, 40
min), and then cooled to -20'C before removal.
7.2.3. Sucrose Microneedle Coating
Adenovirus stocks were thawed and suspended in 5% sucrose/0.01% Tween 20. Coating
solution was pipetted onto the surface of 1 cm2 PLA patches, dried under vacuum for 1 hour at
25'C, and stored at 25'C under desiccation until use. In some cases, AF555 (Invitrogen) was
added to the coating solution to yield labeled coatings.
7.2.4. In Vivo Delivery
Mouse studies were approved by the MIT IUCAC and animals were cared for in the USDA-
inspected MIT Animal Facility under federal, state, local, and NIH guidelines for animal care.
For microneedle treatment, dorsal ear skin of anesthetized C57B1/6 mice (Jackson Laboratories,
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Bar Harbor, ME) was rinsed with PBS and dried before application of microneedle arrays by
gentle pressure. Microneedles were imaged before and after application by optical microscopy
(Leica DMXR). Delivery of AF555 into skin was measured using an IVIS Spectrum 200
(Caliper Lifesciences, Hopkinton, MA). Intradermal injections of control formulations were
performed in the dorsal ear skin (15ptl). For luminescent measurements of luciferase expression,
mice were imaged following i.p. administration of D-luciferin (1 50mg kg 1). Data was processed
using region of interest (ROI) analysis (ROIs were set to include the entire ear site) with
background subtraction and internal control ROI comparison to untreated skin using Living
Image 4.0 software (Caliper).
7.2.5. Murine Vaccinations
Groups of 5 C57B1/6 mice were immunized on day 0 with 1x10 8 vp Ad5-SIV-gag by i.m.
injection (100 pl, quadriceps), i.d. injection (15 pl, dorsal ear skin), or by microneedles (5 min
application). Frequencies of gag-specific CD8' T-cells and their phenotypes were determined by
flow cytometry analysis of PBMCs following staining with DAPI (live/dead), anti-CD8a, anti-
CD44, anti-CD62L, and AL- 11/H-2Kb-peptide-MHC tetramers. Similar analysis was performed
on mononuclear cells isolated from spleen, vaginal tissue, lungs, and intestinal tissues collected
following necropsy. Spleens and lungs were collected, meshed, and strained (70 pm) to obtain
lymphocytes. Vaginal lymphocytes were isolated by digesting tissue in 100 MU/ml collagenase
D (Roche, Branchburg, NJ) at 37'C for 30 min and straining (70 pm). To isolate intra-epithelial
lymphocytes, small intestines were incubated with RPMI 1640 supplemented with 5 mM EDTA
and 0.145 mg/ml dithiothreitol at 37'C; recovered lymphoyctes were isolated by spinning
through a 67% Percoll layer. Cytokine expression in CD8' T-cells was measured by flow
cytometry analysis of PBMCs following stimulation with AL 1I peptide, treatment with brefeldin
A, and staining with DAPI, anti-CD8a, anti-IFNy, and anti-TNFa. Anti-gag IgG titers, defined
as the dilution of sera or vaginal wash at which OD reading was 0.25, were determined by
ELISA using SIV-mac25 1-coated plates (My Biosource, San Diego, CA) using HRP-conjugated
anti-IgG (Jackson Immunoresearch, West Grove, PA).
7.2.6. Ex Vivo Macaque Skin Culture and Microneedle Testing
Macaque studies were approved by the Harvard Medical School IACUC. Outbred Rhesus
monkeys were housed at the New England Primate Research Center (NEPRC). Fresh skin was
obtained from the deltoid of euthanized Rhesus macaques, mounted on slides, and microneedles
were applied by gentle pressure. To evaluate delivery of sucrose coatings, microneedles were
coated with sucrose encapsulating green 100nm carboxylate-modified polystyrene nanoparticles
(Invitrogen) in lieu of viral particles. Treated skin was stained using trypan blue, formaldehyde
fixed, and embedded in paraffin or OCT compound for sectioning and hemotoxylin/eosin
staining. Sections were imaged either using optical microscopy to detect microneedle insertion
or confocal microscopy to observe fluorescent cargo delivery. To assay ex vivo transduction,
1x10 8 Ad5-LUC vp were injected i.d. (15 pl) or delivered by microneedles (5 min application).
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Skin was cultured as previously described 1 0 and imaged using an IVIS Spectrum after addition
of 300 pg luciferin to the culture media.
7.2.7. Rhesus Macaque Vaccinations
All animals were housed at the NEPRC and maintained in accordance with the "Guide for the
Care and Use of Laboratory Animals" of the Institute of Laboratory Animal Resources, NRC.
The facility is AAALAC-accredited and all work was approved by Harvard Medical School's
Standing Committee on Animals. Animals originated form the NEPRC specific-pathogen-free
breeding colony but had been housed in conventional housing prior to this study. Prior to Ad-
MN vaccination, animals were anesthetized with dexdomitor. Hair was removed from the upper
arms and deltoid skin was washed with PBS-soaked gauze. Macaques were immunized on day 0
and day 84 with 4x10 9 vp Ad5-SIV-gag and 7x10 9 vp Ad5-SIV-env by microneedle array (5 min
application, total dose split into 4 identical arrays per vector, applied on the left and right deltoid
respectively). Microneedle patches were applied gently by hand and held in place manually for 5
minutes. Alternatively, a clamp device set to a similar clamping pressure as that obtained
manually was used to secure the microneedles. Animals were allowed to recover from
anesthesia and no side effects of the vaccination procedure were noted. For all procedures,
macaques were sedated with ketamine (10-15 mg/kg IM, FortDodge) or telazol (5 mg/kg,
FortDodge). Blood samples were obtained from the femoral vein using a 22 gauge needle
attached to a vacutainer system. For colorectal biopsies, animals were sedated and biopsies of the
rectal and distal colonic mucosa were obtained using a 1.9mm pinch biopsy forceps and placed
into GIBCO RPMI media. Rectal mucosal secretions were collected using Weck-Cel sponges
and extracted for assays as previously described.
7.2.8. Rhesus Macaque ELISPOT
Gag- and Env-specific cellular immune responses in vaccinated animals were assessed by IFN-y
ELISPOT as described previously. 2 30 ,23 2 Overlapping 15-amino-acid peptide pools from both
SIVmac239 Gag and Env were used to stimulate PBMCs. Following an 18-hr incubation at
370C, plates were washed, incubated with 2 pg/ml biotinylated anti-human IFN-y (BD
Biosciences, San Diego, CA), washed again, and incubated with streptavidin-alkaline
phosphatase (Southern Biotechnology Associates, Birmingham, AL). Plates were then developed
with nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate chromogen (Pierce, Rockford,
IL), stopped with water, dried, and analyzed (Cellular Technology Ltd., Cleveland, OH).
Background levels were typically <15 SFC per 106 cells.
7.2.9. Rhesus Macaque Intracellular Cytokine Staining
The magnitude and phenotype of Gag-specific cellular immune responses in vaccinated rhesus
21232monkeys were assessed by multi-parameter ICS assays as previously described. 3 0' PBMCs
(3x10 6) were incubated for 6 h at 370C with RPMI 1640 containing 10% FBS alone, the
SIVmac239 Gag peptide pool (2 pg/ml), or 10 pg/ml phorbol myristate acetate and 1 gg/ml
ionomycin (Sigma-Aldrich, St. Louis, MO). The cultures contained monensin (BD Biosciences,
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San Diego, CA) and I jg/ml anti-CD49d (BD Biosciences). Cells were then stained with anti-
CD3, anti-CD4, anti-CD8, anti-CD28, and anti-CD95, fixed, and permeabilized. Cells were then
stained intra-cellularly with anti-IFN-y, fixed, and analyzed with an LSR II (BD Biosciences)
using FlowJo software (TreeStar, Ashland, OR). Approximately 500,000 to 1,000,000 events
were collected per sample. Background levels were typically <0.02% of the levels of gated CD8'
or CD4* T lymphocytes.
7.2.10. Rhesus Macaque ELISA
SIV Env-specific antibody titers in serum or rectal mucosal secretions from immunized monkeys
were measured by ELISA as described previously.2 30 2 32 Coated plates (100 l/well of 1 pg/ml
recombinant SIVmac251 gp120 - Immune Technology Corporation) were blocked before serum
addition in serial dilutions. Plates were washed, incubated with peroxidase-conjugated, affinity-
purified rabbit anti-human secondary antibody (Jackson Laboratories, Bar Harbor, ME), washed
again, developed with tetramethylbenzidine (Kirkegaard & Perry Laboratories, Gaithersburg,
MD), and analyzed with a Dynatech MR5000 ELISA plate reader.
7.2.11. Rhesus Macaque Neutralizing Antibody Assays
Serum neutralizing antibody responses were measured using a luciferase-based assay in TZM.bl
cells as previously described.24 3 A neutralization-sensitive SIVmac251 Env pseudovirus clone
was utilized for these assays (SIVmac251.TCLA.15). Briefly, 3-fold serial dilutions of serum
samples were performed in 10% D-MEM. Virus was added to each well and the plates were
incubated for 1 hour at 370 C. TZM.bl cells were then added (1x10 4/well in 100 pl volume) in
10% D-MEM containing DEAE-Dextran (11 ig/ml, Sigma, St. Louis, MO). Assay controls
included TZM.bl cells alone and TZM.bl cells with virus. Following 48 hr at 37* C, Bright-Glo
luciferase reagent (Promega, Madison, WI) was added. Cells were allowed to lyse and cell
lysate was measured using a Victor 3 luminometer (Perkin Elmer). The 50% inhibitory dose
(IDso) titer was calculated as the serum dilution that caused a 50% reduction in relative
luminescence units (RLU) compared to the virus control wells after subtraction of cell control
RLUs.
7.2.12. Statistical Analysis
Statistical analysis was performed with Graphpad Prism (La Jolla, California) using two-way
analysis of variance or t-test. Values are reported as mean ± s.e.m.
7.3. Results and Discussion
7.3.1. Fabrication of Sucrose-coated Polymer Microneedles and Adenovirus Delivery in Murine Skin
Polymer microneedles composed of PLA and its copolymers with glycolic acid are known to
have suitable mechanical properties for effective skin penetration,o,115,200 and in previous
chapters we have reported an approach for fabricating PLA microneedle patches through melt-
molding of PLA polymer on PDMS molds under vacuum. 15 ' 199 Using this process we fabricated
skin patches 1 cm2 in diam. bearing 78 conical PLA microprojections each 650 jim in height and
111
250 pm in diameter at the base. Prior work has suggested that solid state encapsulation of
bioactive materials can provide improved stability against degradation at elevated temperature,
and sugars such as sucrose and trehalose have been used successfully to form dried coatings on
microneedle patches for skin delivery.22,48,49,244-246 Based on these prior findings, adenovirus was
coated by applying a 5% aqueous sucrose solution containing Ad5 vectors (2.5x10 9 - 2.5x10"
vp/mL) and 0.01% Tween-20 surfactant to individual patches to cover the microneedles, and
patches were dried at 25'C under vacuum (Figure 7-1a). This simple process yielded
microneedles coated with a uniform conformal sugar-glass layer on the surface of each
microprojection that retained the sharp tips of the original polymer array (Figure 7-1b). To
confirm the ability of sucrose-coated microneedles to effectively deliver encapsulated cargos in
the skin, we incorporated a fluorescent tracer (Alexafluor 555, AF555) into sucrose coatings and
applied coated microneedles to the dorsal ear skin of C57B1/6 mice. Imaging of coated
microneedles before and after in vivo application showed significant loss of the sucrose coatings
and loaded AF555 after a 5 min treatment, and also indicated some blunting or breaking of
microneedle tips upon treatment (Figure 7-1b), however any PLA fragments remaining in the
skin will harmlessly dissolve over time. Quantification of AF555 remaining on microneedles
following treatment showed that -25% or 60% of encapsulated AF555 was released following a
30 second or 5 min application to skin, respectively (data not shown). The same fraction of
delivered dose was calculated from direct measurements of AF555 fluorescence in the treated
skin measured by whole-animal IVIS imaging relative to a control i.d. injection of the total
coated amount of AF555 (Figure 7-1c-d). To test bioactive delivery of Ad5, we encapsulated
luciferase-expressing Ad5 vectors (Ad5-LUC) in sucrose coatings and applied these patches to
the dorsal ear skin of mice or injected an equivalent dose of Ad5-LUC i.d. by syringe at the same
site as before. Whole-animal bioluminescent imaging of the administration site revealed strong
and persistent expression of the luciferase transgene peaking on day 2 and declining over the
course of 30 days at the site of treatment in both injected and Ad5-MN treatment groups (Figure
7-1e). Quantitation of bioluminescence obtained from Ad-MN vs. i.d. injections suggested that
-12% of the coated dose is functionally delivered to cells in the tissue following a 5 min
application of the microneedles. This value could almost certainly be increased by increasing the
application time or by optimizing coating procedures to coat only the microneedle tips, 48,244 but
we chose to focus on this simple formulation and rapid delivery regimen for these proof-of-
concept studies.
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Figure 7-1. Fabrication, application, and storage of microneedle vaccines
(a) Schematic of microneedle patch (MN) coating strategy in which PLA microneedle patches
are fabricated by PDMS molding (1), followed by application of an aqueous sucrose coating
formulation (2), and drying under vacuum to generate hardened vaccine coatings (3). (b)
Optical micrographs of microneedles bearing AF555-loaded sucrose coatings before application
(top) and following a 5 minute application to murine skin (bottom, scale bar 100 pm). (c-d)
Analysis of sucrose coating delivery following microneedle patch application. (c) Representative
whole-animal fluorescence images of mice directly following treatment with either i.d injection
of AF555 or application of microneedles bearing AF555-loaded sucrose coatings for 5 minutes
or 30 seconds. (d) Quantitative analysis of total AF555 delivery by IVISfluorescence imaging of
treated skin. (e) Quantitative analysis of total bioluminescent signal measured over time
following treatment of mice with either i.d injection or microneedle delivery (1x108 total coated
vp) of Ad5-LUC. (/) Quantitative analysis of day 2 bioluminescent signal collected from mice
treated with either i.d injection or microneedle delivery of Ad5-LUC. Aqueous Ad5-LUC
suspensions and sucrose coated microneedle patches were stored at 25C for 0-56 days before
treatment, and bioluminescent signal was normalized to day 0 values.
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(3) Drying
7.3.2. Enhanced Room Temperature Vaccine Stability of Ad5 Vectors in Sucrose Matrix
To determine the ability of sucrose coatings on microneedles to protect encapsulated Ad5 vectors
during storage at room temperature, we fabricated microneedles with Ad5-LUC/sucrose coatings
and stored them at 25'C for 2 weeks to 2 months under desiccation, then applied the dry patches
to murine auricular skin. For comparison we performed i.d. injections of aqueous coating
solutions stored at 25'C for the same periods of time. Comparison of total measured
bioluminescent signal in mice 2 days after treatment revealed that Ad5-LUC stored in solution
rapidly lost -90% of its initial activity over 14 days as expected,247 while Ad5-LUC encapsulated
on sucrose-coated patches showed no significant loss of activity over 56 days at 25'C (Figure 7-
if). This prolonged dry state stability without refrigeration may be valuable for improving
availability and reducing vaccination costs in the developing world.
7.3.3. Ad-MN Immunization Shows Immunogenicity Comparable to Syringe Injection in Mice
Previous studies have demonstrated that Ad5 vectors are able to elicit potent cellular and
humoral immunity in mice following parenteral injection. 248,249 These vectors elicit systemic
immunity in the peripheral blood and spleen, as well as strong disseminated mucosal
immunity.249 To confirm that the effective transfection observed with Ad-MN was accompanied
by robust immune response induction, we compared the immunogenicity of Ad5 vectors
encoding SIV-gag delivered by Ad-MN, i.d. injections at the same site as MN application, or
standard intramuscular (i.m.) injections, dose-matching the fraction of bioactive delivered vector
from 5 min-applied patches. Cellular immunity in peripheral blood mononuclear cells (PBMCs)
was measured weekly using peptide-MHC tetramers detecting CD8' T-cells specific for the
b 248,249immunodominant gag peptide AL 11 in the context of I-A" class I MHC.249 Consistent with
previous studies, i.m. administration primed strong expansion of antigen-specific CD8' cells,
peaking on day 21 at -20% of the total CD8* cell population, and slowly declining over the next
3 months; i.d. administration elicited a similar pattern of T-cell expansion, at slightly lower
levels (Figure 7-2a-b). Ad-MN elicited statistically identical T-cell responses with a similar
expansion and contraction profile, with peak responses intermediate between i.m. and. i.d.
injections. We also measured the frequency of AL 11-specific CD8+ T cells in spleens collected
on day 21 and similarly observed no statistical difference in the frequency of antigen-specific
cells between groups given parenteral or microneedle-delivered vaccines (~10% of CD8' T cells,
data not shown). Intracellular cytokine staining on ex vivo AL 1-restimulated PBMCs revealed
similar levels of IFN-y- and TNF-a-producing cells in all 3 immunization groups (Figure 7-2c-
d). Interestingly, flow cytometry analysis of homing/memory marker expression by AL 11-
specific T-cells on day 42 revealed an enhanced generation of antigen-specific CD44*CD62L*
lymph node-homing CD8* T cells in microneedle-treated animals relative to those receiving
traditional i.m. injection (Figure 7-2e-f).
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Figure 7-2. Microneedle patch vaccination gives potent immunogenicity in mice similar to
parenteral immunization
C57B1/6 mice (n = 5/group) were immunized with 1xI 08 vp Ad5-SIV-gag on day 0
intramuscularly (100 pl, in the quadriceps), intradermally (15 pl, in the dorsal ear skin), or by 5
minute application of coated microneedles to the dorsal ear skin. (a-b) Frequency of gag-specific
CD8' T-cells in peripheral blood assessed by flow cytometry analysis of AL11I tetramer* CD8'
T-cells. Shown are (a) representative cytometry plots from individual mice on day 14 and (b)
mean+s.e.m. tetramer* values from day 7-91. (c-d) Intracellular cytokine secretion assessed in
peripheral blood upon ex vivo restimulation with ALI] peptide on day 35. Shown is
representative (c) flow cytometry analysis of IFN-y/TNF-a-producing CD8' T-cells and (d)
mean±s.e.m. cytokine* values. (e-J) Analysis of T-cell effector/central memory phenotypes in
peripheral blood by CD44/CD62L expression of tetramer* cells from peripheral blood. Shown
are (e) representative cytometry plots from individual mice at day 49 and (f) mean±s.e.m.
percentages of tetramer*CD44*CD62L* among CD8' T cells at day 49. (g-h) Enzyme-linked-
immunosorbent assay analysis of total gag-specific IgG in sera (g) and vaginal wash (h) at day
42. Data represent the mean~s.e.m., *, p< 0.005, analyzed by two-way ANO VA.
Parenteral administration of Ad5 vectors has been reported to induce strong CD8* proliferation
in mucosal tissues in mice, a potentially attractive feature for generating protective responses
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against mucosal exposure in the case of sexual transmission of HIV.248,249 To determine the
relative ability of microneedle vaccination to stimulate mucosal cellular immunity, mice were
vaccinated by skin patches or by i.m. or i.d. injection and mucosal tissues were harvested 21 days
later. ALll tetramer staining analysis indicated strong mucosal responses across all treatment
groups (Supplemental Figure S7-1). Equivalent frequencies of AL 11-specific CD8* T cells
were elicited by Ad-MN or i.m. or i.d. injections in the lungs (-30% ALll ), vaginal tissues
(~25% AL 11*), and gut intraepithelial compartments (-10% AL 11*).
Finally, to compare humoral immunity stimulated by the skin patch vaccine vs. syringe injection,
we measured gag-specific serum IgG titers, and found that microneedle delivery produced
statistically equivalent levels of systemic anti-gag IgG compared to either i.m. or i.d. vaccination
(Figure 7-2g). We also measured levels of gag-specific IgG in vaginal wash collected on day 42
and observed elevated antibody levels in mice receiving i.d. injection or microneedle treatment
relative to i.m. administration (Figure 7-2h). These results suggest that microneedle patch
vaccination can produce equivalent systemic antigen-specific antibody responses compared with
i.m. or i.d. treatment, and elicits enhanced mucosal antibody titers relative to parenteral i.m.
vaccination.
7.3.4. Insertion and Adenovirus Delivery in Primate Skin
Although mouse models provide an effective context for the development of new vaccination
approaches, skin physiology and immunity in mice has many differences from humans.223 To
evaluate the feasibility of coated microneedle vaccines in a model closer to humans, we set out to
evaluate the immunogenicity of Ad-MN vaccines in Rhesus macaques, an accepted preclinical
model for HIV and many other infectious diseases.93,12s,142,149,224 We first tested whether
microneedles provide similar delivery in macaque skin compared to our previous results in mice.
Patches were applied manually to the shaved deltoid skin of recently euthanized macaques and
secured in place for 5 min. Treated skin was then excised and stained with trypan blue to
visualize areas of microneedle insertion. Optical microscopic imaging of skin treated before
dissection revealed consistent patterns of microneedle penetration (Figure 7-3a). Histological
analysis of patch-treated skin showed uniform sites of microneedle insertion accessing the
superficial epidermis while leaving the underlying dermal tissues undisturbed (Figure 7-3b-c).
To determine the pattern of vaccine deposition, we treated macaque skin with patches coated
with sucrose carrying 100 nm fluorescent carboxylated polystyrene nanoparticles as a surrogate
for viral particles. Confocal imaging of treated skin revealed the consistent presence of punctate
fluorescent signal from particles at sites of microneedle insertion, suggesting successful
penetration of microneedles and dissolution-mediated delivery of sucrose-loaded cargos
following a 5 minute application period (Figure 7-3d). Further, histological sections of treated
skin showed permeation of nanoparticles several hundred microns into the surrounding
epidermis at sites of microneedle penetration (Figure 7-3e). To assess the local bioactivity of
Ad5 vectors delivered into macaque skin, we applied Ad-MN delivering 1x10 8 vp Ad5-LUC to
freshly explanted macaque skin ex vivo. Following treatment, skin samples were cultured in
116
vitro and expression of luciferase was measured using whole-tissue bioluminescent imaging.
Here we observed strong luciferase expression for several days following treatment for both
microneedle-treated skin and skin treated by i.d. injection of a dose-matched aqueous solution of
the patch coating formulation (Figure 7-3f-g). In both treatment groups, statistically equivalent
levels of luciferase expression were measured for multiple days following treatment, with peak
expression observed on day 2 after administration (Figure 7-3g). Altogether, these results
suggested effective epidermal delivery from sucrose-coated polymer microneedles in the skin of
Rhesus macaques.
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Figure 7-3. Microneedles penetrate primate skin to deliver vaccine coatings
(a) Optical micrographs of macaque deltoid skin stained with trypan blue to reveal epidermal
penetration following PLA microneedle patch application (one example penetration site
indicated by arrow; scale bar, 500 pm). (b-c) Histological sections of microneedle-treated
macaque skin showing epidermal disruption at microneedle insertion sites (scale bars: b, 500
pm; c, 200 pm with insertion site denoted by arrow). (d) Representative confocal micrograph of
microneedle-treated deltoid skin showing delivery of 100nm carboxylate modified polystyrene
nanoparticles (green) from sucrose coatings at microneedle insertion sites (circled). (e)
Histological section of similarly treated macaque skin showing epidermal delivery of 100nm
carboxylate modified polystyrene nanoparticles (green) from sucrose coatings at microneedle
insertion site (arrow); scale bar 200 pm. (f-g) Analysis ofAd5-LUC delivery to macaque skin ex
vivo. (f) Representative whole-tissue bioluminescent images of macaque deltoid skin treated with
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lx]O vp Ad5-LUC by i.d injection or microneedle patch delivery (1x10 9 total coated vp). (g)
Quantitative analysis of total bioluminescent signal measured on day 2 following delivery.
7.3.5. Peripheral and Mucosal Immunogenicity ofAd-MN in Primates
To evaluate the functional immunogenicity of adenovirus delivery from microneedles, we
formulated patches coated with sucrose-encapsulated Ad5 vectors encoding SIV gag or env. We
then applied four patches for each vector (total delivered dose 4x10 9 vp Ad5-SIV-gag and 7x10 9
vp Ad5-SIV-env) to the shaved deltoid skin of anesthetized macaques (n = 4) for 5 min to deliver
the vaccines; animals were boosted by the same patch administration regimen at 12 weeks. No
adverse reactions were noted at the application sites in any animals and visible redness resolved
after only 30 minutes. As shown in Figure 7-4a, microneedle delivery of Ad vectors elicited
robust ELISPOT responses against gag and env peptide pools, with gag responses maintained at
high levels for at least 16 weeks. T-cell responses to env epitopes were initially weaker but were
clearly boosted following the Ad-MN vaccination at week 12 (Figure 7-4b). Intracellular
cytokine staining on restimulated T-cells from blood or colorectal biopsy samples at week 16
showed readily detectable CD8* and CD4* T-cells, suggesting the induction of both systemic and
mucosal immune responses by the microneedle vaccines (Figure 7-4c). Analysis of env-specific
antibody titers in serum over time showed the induction of gp120-specific humoral responses
following priming which was further increased by more than a log following boosting (Figure
74d). Anti-env IgG was also detected in rectal mucosal secretions at week 16 (Figure 7-4e). By
4 weeks post prime, skin patch vaccines had induced high neutralizing antibody titers against a
neutralization sensitive clone of SIVmac251 virus (Figure 7-4f). Thus, microneedle delivery of
adenovirus vectors induces strong cellular and humoral immunity in line with results expected
from traditional needle and syringe intramuscular vaccination, and promotes both systemic and
mucosal immune responses.
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Figure 7-4. Microneedle patch vaccination is immunogenic in Rhesus macaques
Four macaques were immunized with 4x10 9Ad5-SIV-gag vp and 7x10 9 vp Ad5-SIV-env vp by
microneedle patch application for 5 min at week 0 and week 12. (a-b) ELISPOT analysis of
peripheral blood mononuclear cell secretion of IFNy following ex vivo restimulation with
representative overlapping peptide epitopes for SIV-gag and SIV-env. Shown are IFNy spot
forming cells (SFC) per 1xI 06 PBMCs for each timepoint following stimulation with (a) SIV-gag
or (b) SIV-env pooled peptides. (c) Week 16 flow cytometric analysis of IFNy* cells isolated
from peripheral blood or colorectal biopsy following ex vivo stimulation with media or SIV-gag
peptide. Shown are responses for CD8' and CD4' T cells. (d-e) Anti-SIV-env antibody titers in
serum and colorectal mucosal secretions. Shown are (d) anti-env serum IgG titers as measured
at each timepoint and (e) anti-env IgG titers measured in colorectal secretions at week 16. (f)
Serum neutralizing antibody titer analysis for SIVmac251 homologous virus. Shown are ID50
neutralizing titers at each timepoint following vaccination.
7.4. Conclusions
The goal of this study was to evaluate the potential for microneedle patch delivery of a
prototypical non-replicating adenovirus vaccine to generate immunity in mice and non-human
primates. Microneedle vaccination could provide many practical advantages over the use of
traditional hypodermic needles in vaccine delivery, including improved safety, simplified
administration, and the potential for non-refrigerated, dry-state storage.25 0 ,251 Further,
microneedles localize vaccine delivery to the skin, thereby targeting potent epidermal and dermal
antigen-presenting cells, which in some small-animal models has led to enhanced
immunogenicity compared to traditional parenteral immunization.23,125,142,25 2,253 The potency and
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protective efficacy of microneedle vaccines has been demonstrated in a variety of disease models
in rodents.93,142,149,199,254,255 However, to our knowledge the immunogenicity of microneedle
vaccines in non-human primates, an important step in preclinical vaccine development for
advancement to human clinical trials, has not been tested.
A great variety of solid microneedle designs have been tested for delivery of vaccines in rodent
models, ranging from simple metal microprojections coated with dried vaccine to polymer
microneedles that encapsulate vaccine and dissolve in the skin.142,192,200 Here we developed and
tested a prototypical system representative of the most common microneedle strategy in vaccine
delivery, where vaccines are encapsulated in a protective dissolving matrix coated on solid
microneedle arrays. We employed FDA-approved PLA as the microneedle base for low-cost,
high-throughput (melt-molding) fabrication, and used sucrose as a protective coating matrix for
the adenoviral vector, based on its known ability to stabilize diverse biologics in a dried state,
including viruses.247 This patch composition provided substantial stabilization of Ad5 vectors for
extended storage without refrigeration, and showed robust immunogenicity equivalent to
traditional syringe injections in mice.
In Rhesus macaques, Ad-N4Ns provided reproducible skin penetration and delivery of sucrose
coatings into the epidermis following brief applications of only 5 minutes. Local gene expression
in the skin of macaques following patch application was quantitatively indistinguishable from an
intradermal syringe injection. Skin patch vaccination elicited robust CD4* and CD8* T-cell
responses as measured by ELISPOT and intracellular cytokine staining in both blood and
mucosal tissues. Sustained anti-env IgG responses were elicited in the serum and mucosal sites,
and sera from immunized macaques neutralized autologous SIVmac251 virus. Supporting the
robustness and reproducibility of microneedle vaccination, both T-cell and antibody responses
were clearly increased following boosting at 12 weeks. These responses are all in line with
expectations for the response to this adenovirus vector from prior studies in our laboratory using
traditional intramuscular injections of similar vector doses. Overall, these results demonstrate the
potential for microneedle delivery to effectively deliver adenovirus vectors in non-human
primates, an important step in establishing this technology as an attractive alternative to
traditional syringe administration. Together with the many known practical advantages of
microneedles, the results shown here indicate the significant promise of microneedle patch
vaccination to improve immunization, particularly in the developing world.
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8. CONCLUSIONS AND FUTURE WORK
8.1. Conclusions
Here we have shown the development and testing of several novel approaches for microneedle
formulation of subunit vaccines to enable effective and non-invasive transcutaneous delivery.
Our goal throughout these studies was to employ innovative materials engineering approaches to
the design of vaccination platforms capable of combining the numerous practical advantages of
transcutaneous delivery, with systems capable of modular and tunable control over
multicomponent vaccine formulation, delivery, and contextual presentation to the immune
response. Although prior work has explored the use of microneedles for effective transcutaneous
vaccination, much of this work has focused on the simple adaptation of existing parenteral
vaccine formulations for delivery by microneedle array. Conversely, the results reported here
have demonstrated the potential of microneedle delivery to enable several forms of recombinant
subunit vaccination, including the delivery of defined antigenic and adjuvanting nucleic acids,
proteins, and viral vectors. Furthermore, we have demonstrated the significant potential of
advanced materials science concepts for control over vaccine loading, delivery, and release for
enhancing immunity, thus providing a platform supporting the rational design of vaccines
combining immunogenic cues to optimize immunity.
LbL directed assembly has previously been shown to be a robust and controllable approach for
biological therapeutics formulation, enabling complex programming of multicomponent loading
and release, and providing the potential for the design of responsive behaviors through selection
of polymeric constituents. Given the need for more potent subunit vaccination strategies driven
by the limitations of conventional killed/attenuated pathogen approaches for safely addressing
emerging diseases such as HIV, we were motivated to explore the use of LbL for the rational and
complex formulation and delivery of genetic vaccines. The adaptation of this strategy to enable
controlled vaccine formulation into microneedle surface coatings allowed for tunable antigen-
encoding nucleic acid encapsulation together with hydrolytic cationic polymers capable of
mediating both controlled pDNA release, and in situ polyplex formation. LbL assembly also
proved to be a modular approach allowing for defined incorporation of nucleic acid adjuvants
together with antigenic pDNA, thus providing a coating capable of delivering a complete subunit
vaccine. Finally, LbL assembly was able to interface with a pH-responsive polymer to allow for
rapid film implantation upon microneedle application. Testing of this approach in mice using a
model HIV antigen, showed promising induction of both cellular CD8+ T cell and systemic
humoral immunity comparable to electroporation, one of the most promising current clinical
strategies for pDNA delivery in humans. Further, ex vivo LbL microneedle treatment of viable
non-human primate skin showed >100x increased expression of a model protein compared to
injection, an important result indicating the promise of microneedle delivery for effective
translation to large animals and humans.
Given the inherent adaptability of LbL assembly we next explored the potential of this approach
for incorporation and delivery of lipid nanocapsules from LbL-assembled microneedle surface
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coatings. The ICMV delivery system has previously been shown to potently induce systemic
CD8+ T cell responses following parenteral vaccination. Therefore we were motivated to test
the potential of this platform for triggering similar immunity following non-invasive cutaneous
immunization. Although, previous studies have introduced the concept of incorporating lipid
particles into LbL-assemblies, these have largely been limited by the instability of native lipid
particles exhibited during the adsorption process. ICMVs provide a unique opportunity to
overcome this challenge by leveraging their enhanced physical stability endowed by inter-bilayer
molecular crosslinks within the lipid lamellae. These studies proved the utility of this approach,
which generated controllable ICMV-loaded microneedle coatings capable of rapidly dispersing
into treated skin and effectively delivering immunogenic cargos to recruited APCs. These results
also indicated a promising role for microneedle delivery of defined molecular adjuvants in
recruiting cutaneous APCs and driving their concomitant uptake of vaccine and maturation for
effective interaction with scanning naive lymphocytes. Finally, transcutaneous delivery of LbL
formulated ICMVs resulted in a more potent and diversified functional antibody response
compared to parenteral administration, or microneedle delivery of soluble vaccine components,
suggesting a synergistic combination of ICMV-mediated cellular delivery following
microneedle-enabled transfer into the skin.
Control over the persistence of antigenic or inflammatory stimulus within the context of
infection or vaccination is emerging as a deterministic variable in the shaping of effector and
memory adaptive immune responses. To explore this concept in combination with the practical
and immunological advantages of transcutaneous delivery we designed and constructed several
parallel microneedle approaches able to mediate rapid implantation of controlled release matrices
for programming vaccine persistence. These strategies were based upon the use of composite
responsive structures which rapidly deliver bolus or controlled release vaccine formulations
through dissolution mediated disintegration within the skin. Although previous studies have
explored the use of rapidly dissolving microneedles, these studies were the first to combine rapid
needle dissolution with the delivery of long-lived vaccine depots. The results of these studies,
either using persistent PLGA or silk protein matrices in combination with dissolvable PAA,
demonstrated the ability to program vaccine delivery and release over time depending on the
combination of materials used for microneedle fabrication. This ability proved critical for tuning
the duration and magnitude of subunit vaccine exposure in vivo and optimization of these
features resulted in greatly enhanced cellular and humoral immunity. Furthermore, these
approaches demonstrated a promising potential for enabling simple and cost effective room
temperature storage, an important advance for improving vaccine economics and availability.
Finally, to complement our various studies for the development of sophisticated materials
approaches to microneedle vaccine formulation, we were motivated to explore the potential for
microneedle delivery to enable safe, reliable, and effective delivery of an advanced recombinant
viral vector vaccine to elicit immunity in both preclinical mouse and nonhuman primate models
of HIV. Although many reports have indicated the promise of microneedle vaccination in small
animal models, no previous study has robustly characterized the potential for microneedle
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delivery to induce immunity in large animal models thought to be more predictive of success in
human clinical testing. In this work, we also developed a new approach for biologics
encapsulation into sugar-glass coatings on the surface of polymer microneedle arrays through
simple co-suspension of vaccine with sugar followed by liquid application and drying on the
surface of the microneedle array. In these studies we demonstrated the effective loading, stable
storage, and delivery of replication incompetent Ad5 viral vectors giving robust transgene
expression in the treated tissues resulting in potent cellular and humoral immunity against SIV-
gag in mice comparable to that elicited by parenteral injection. We then translated this approach
for the treatment of Rhesus macaques, and observed strong, boostable, systemic and mucosal
cellular responses against SIV-gag and SIV-env. Further, we detected potent and boostable
serum antibody responses targeting SIV-env, which correlated with the development of similar
responses within mucosal tissues at sites sensitive to sexual viral transmission. Together these
results indicate the potential for microneedles to provide a viable alternative to parenteral
injection of a clinically advanced recombinant vaccine platform in primates and potentially
humans.
To conclude, we have successfully demonstrated several parallel approaches for the formulation
and delivery of recombinant subunit vaccines for transcutaneous delivery using microneedle skin
patches. These strategies represent a portfolio of materials platforms suggesting the promise of
microneedle delivery technology to enable safer, more cost-effective, and more potent non-
invasive vaccination based on a variety of next-generation recombinant vaccine technologies
including pDNA, RNA, proteins, synthetic particles, and viral vectors. Further the flexibility and
modularity of these approaches should support the increased success of such emerging vaccine
technologies by facilitating greater control and rational design of vaccines to enhance
immunological response.
8.2. Future Work
8.2.1. LbL Coated Microneedle Vaccine Delivery
Based on our studies so far, microneedle delivery of LbL-formulated pDNA vaccines can induce
potent cellular and humoral antigen-specific immunity comparable to the most promising clinical
approaches for DNA delivery. Given the many attractive features of pDNA-based
immunization, including ease of good manufacturing practice production, lack of anti-vector
immunity, greater stability in storage, and the capability to promote both cellular and humoral
immune responses, future work should focus on (i) elucidating the mechanisms leading to this
improved performance, (ii) development of streamlined fabrication approaches with improved
throughput, efficiency, and consistency, and (iii) validation studies in large animal models of
disease to support potential clinical translation.
Our current results indicate that the improved immunogenicity achieved by multilayer tattooing
is mediated by a combination of microneedle delivery and multilayer pDNA formulation, as
injected naked pDNA or polyplexes give very little measureable immunity. In other studies,
microneedle delivery of naked pDNA resulted in similarly weak immunogenicity at similar
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doses. Future work should work towards a more detailed understanding of the enhancement
mediated by the combination of cutaneous delivery and multilayer formulation. Potential areas
of exploration include (i) testing of various multilayer architectures to determine the design rules
governing multilayer elicited immunity, (ii) more comprehensive measurement of both local
pDNA cellular delivery, and local immune cell recruitment/response, and (iii) extension of these
studies to nonhuman primates to validate potential mechanisms in a context more similar to
humans. Variables of interest for exploring multilayer architecture include hydrolytic versus
non-degradable polymer constituents, degradation kinetics, co-delivery of adjuvants, and overall
inflammatory capacity. Characterization of local delivery and innate/adaptive immunity might
reasonably focus on first determining which local cell populations are transfected in vivo, the
timescale for antigenic gene expression, and second, the detailed profile of innate cell
recruitment, activation, maturation, and finally interaction with the naYve adaptive response.
Although mouse models will serve as a valuable context for preliminary exploration of these
questions, study in explanted primate tissues or live animals will likely be critical given the
known differences between murine and primate transfection mechanisms.
Further development of the LbL coating process for microneedles should also be a priority for
future study. These efforts should focus on improving throughput, efficiency, and reliability in
support of larger preclinical studies. These goals might be addressed through the development of
an automated LbL process employing liquid handling robots to enable LbL in small volumes to
increase efficiency. An ideal process will improve the efficient use of vaccine materials by
facilitating reuse, and decreasing the total volume/concentration needed during adsorption. One
potential option is shown in Figure 8-1, in which liquid handling robots manipulate small liquid
volumes applied only to the surface of each array. This approach should decrease the total
volume needed per array from ~750ptl per 30 bilayers to ~75pl per 30 bilayers. Given, the
preapproval of relevant robotic handling equipment by the FDA for good manufacturing
practice, adoption of this approach would also allow for simple translation to production at scale
in the event of clinical translation.
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Figure 8-1. High throughput liquid handling assisted LbL
Schematic showing a potential approach for high throughput LbL using liquid handling robots to
pipette coating solutions in small volumes onto only the surface of individual microneedle
arrays.
Finally, although our current work suggests that microneedle tattooing promotes enhanced
expression of pDNA in primate skin, antigen expression is only one of many variable
determining immunogenicity. Therefore, future work must provide additional validation of
efficacy in primates in order to be considered a viable platform for use in humans.
8.2.2. Sucrose Coated Microneedle Vaccine Delivery
Encapsulating vaccines in sucrose has proven to be a simple and flexible process enabling
successful preclinical vaccine testing in both mice and primates. Further, sugar-glasses are
known to improve the stability of sensitive biological molecules and vaccines stored at room
temperature, a valuable feature for future vaccine deployment in remote areas of the world.
Future work in this area should focus on (i) the further optimization of the microneedle coating
process, and (ii) testing for effective vaccination with more advanced viral vector serotypes
currently being developed for clinical trials.
Although microneedle coatings encapsulating recombinant viral vectors gave effective immunity
in both mice and primates, there is significant room for improvement in the efficiency of vaccine
delivery. For example, approaches enabling the coating of microneedles only should improve
delivery efficiency by eliminating wasted material coated onto the base of the array.
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Given the success of microneedle delivery of Ad5-SIV-gag and Ad5-SIV-env, future work
should begin to explore the delivery of more advanced clinical grade vectors engineered to avoid
pre-existing vector immunity, and to express mosaic antigens enabling global vaccination to
address many sub-clades of HIV isolates prevalent in various regions. This work should enable
more comprehensive testing of protective immunity following microneedle vaccination in
primate models of S(H)IV challenge. Additionally, larger scale primate tests should aim to
directly compare microneedle immunization with dose-matched parenteral treatments to
establish potential differences resulting from microneedle delivery. Ultimately these studies
should provide pivotal preclinical results to determine whether microneedle vaccination would
be a valuable clinical candidate for testing in humans.
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9. APPENDIX A: SUPPLEMENTARY FIGURES
9.1. Nano-layered Microneedles for Transcutaneous Delivery of Polymer Nanoparticles and
Plasmid DNA
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Supplementary Figure S2-1. Schematic of PLGA microneedle fabrication process.
(a) PDMS slabs were machined using laser ablation to create micron scale cavities before (b)
application of PLGA to the surface of the mold. (c) PLGA was then melted under vacuum and
cooled before (d) removal from the PDMS mold. (e) Schematic showing the LbL directed-
assembly process of iterative deposition of oppositely charged polymers through immersion. ()
Initial multilayers were deposited using alternating immersion of PLGA microneedle arrays in
solutions of polycationic protamine sulfate and polyanionic poly(4-styrene sulfate). (g)
Additional multilayers were then deposited through alternating deposition of polycationic
polymer-] and polyanionic plasmid DNA or PLGA NP to give pDNA or PLGA NP coated arrays
respectively. Microneedle arrays coated with both pDNA and PLGA NP were constructed in a
similar way first depositing (PS/SPS) base layers, followed by (poly-J/pDNA) multilayers and
finally (poly-1/PLGA NP) multilayers.
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Supplementary Figure S2-2. SEM micrograph of PLGA microneedle array
SEM micrograph of uncoated PLGA microneedle arrays of conical geometry (scale - 500pfm).
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Supplementary Figure S2-3. Chemical structure of Poly-1
Chemical structure ofpoly-1 used in this study (molecular weight -8,000 - 10,000 g/mol).
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Supplementary Figure S2-4. Multilayer deposition on PLGA microneedles
(a) Representative CLSM z-stacks of a (PS/SPS)20-(Poly-1/Cy3-pLUC)24 coated microneedle
array and (b) a (PS/SPS)2o-(Poly-1/DiI-PLGA NP)4 coated microneedle array. (c) CLSM z-
stack of dual coated microneedle array (PS/SPS)20-(Poly-1/Cy3-pL UC)24-(Poly-1/DiD-PLGA
NP)4 (scale bar - 100 pm).
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Supplementary Figure S2-5. In vivo murine skin penetration with PLGA microneedles
In vivo skin penetration results for microneedle arrays with (a) pyramidal geometry and (b)
conical geometry (left-optical micrographs of microneedle arrays before and after application,
right -trypan blue staining of microneedle penetration patterns).
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Supplementary Figure S2-6. In vivo murine skin penetration
In vivo skin penetration results for microneedle application to MHC II-GFP mice. CLSM
images showing microneedle penetration colocalized with Langerhans DCs in the epidermis
(scale bar - 100pm).
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Supplementary Figure S2-7. In vivo delivery of microneedle-based pDNA multilayers
Representative CLSM z-stacks of a (PS/SPS)20-(Poly-1/Cy3-pLUC)24 coated microneedle array
(a) before application, (b) after a 5 minute application, and (c) after a 24 hour application in
vivo. (d) Quantification (n = 6) of relative integrated Cy3 signal on both the microneedle
surface and the base of the array before and after application.
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Supplementary Figure S2-8. In vivo delivery of pDNA multilayers from coated
microneedles
In vivo delivery of Cy3-pLUC to ear skin of MHC II-GFP mice. CLSM images of MHC II-GFP
ear skin following application of a (PS/SPS)20-(Poly-1/Cy3-pLUC)2 4 coated microneedle array
for (a) 5 minutes and (b) 24 hours (scale bar - 200um).
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Supplementary Figure S2-9. In vivo delivery of microneedle-based polymer nanoparticle
multilayers
Representative CLSM z-stacks of a (PS/SPS)20-(Poly-1/DiI-PLGA NP)4 coated microneedle
array (a) before application, and (b) after a 5 minute application. (c) Quantification (n = 6) of
relative integrated DiI signal on both the microneedle surface and the base of the array before
and after application.
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Supplementary Figure S2-10. In vivo delivery of polymer nanoparticle multilayers from
coated microneedles
In vivo delivery of DiI-PLGA NP to ear skin of MHC II-GFP mice. CLSM images of MHC II-
GFP ear skin following (PS/SPS)20-(Poly-1/DiI-PLGA NP)4 coated microneedle array
application for 5 minutes indicates effective transfer of PEMfilms and delivery of PLGA NP to
epidermal LCs (scale bar 100 pm).
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Supplementary Figure S2-11. In vivo delivery of pDNA and polymer nanoparticles
multilayers from dual coated microneedles
In vivo co-delivery of Cy3-pLUC and DiD-PLGA NP to ear skin of MHC II-GFP mice. CLSM
z-stack images of MHC II-GFP ear skin following (PS/SPS)2o-(Poly-1/Cy3-pLUC) 24-(Poly-
J/DiD-PLGA NP)4 coated microneedle array application for 24 hours indicates effective transfer
of PEMfilms and delivery ofpLUC and PLGA NP to epidermal LCs (scale bar 100 pm).
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9.2. Polymer Multilayer Tattooing for Enhanced DNA Vaccination
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Supplementary Figure S3-1. PLLA microneedle fabrication
(a) PDMS is laser ablated to form micron-scale cavities. (b) PLLA is added to the surface of the
PDMS mold. (c) PLLA is melted under vacuum and then cooled before (d) removal of PLLA
microneedle arrays. (e) SEM and (f) optical micrograph of PLLA microneedle arrays produced
through PDMS melt-casting (scale bar - 500pm).
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Supplementary Figure S3-2. Chemical structure of PNMP and PBAEs
(a) Structure of biotinylated-PNMP (bPNMP, MIW~17,000 Da, x.y.z - 31:59:10) in which a
pendant biotin is conjugated to the free hydroxyl terminus of the PEG-methacrylate monomer
unit. (b) Chemical structure ofpoly-J (MW~15, 000 Da) and (c) poly-2 (MW-21, 000 Da) used in
this study.
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Figure S3-3. In vitro release of polymer multilayers from coated
(a) Representative confocal images of a (SAv488-bPNMP)(PS/SPS) 20(poly-1/Cy5-pLUC) 35-
coated PLLA microneedle prepared with UV treatment of the PNMP release layer, before
immersion in pH 7.4 PBS (left lateral sections - 100pm interval; scale 200um; blue - Sav488-
bPNMP; yellow - Cy5-pLUC) and after 15 min in PBS (middle); this is compared to an identical
multilayer-coated needle immersed in PBS for 15 min, where the PNMP release layer was not
primed with UVprior to multilayer assembly (right). (b) Quantitation of confocal imaging (n =
15 microneedles) showing UV-dependent loss of SAv488-bPNMP and Cy5-pLUC signal
following PBS exposure.
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Supplementary Figure S3-4. In vitro release of pDNA and RNA from polymer multilayers
In vitro release of pLUC and poly(I.C) from (PS/SPS)2o(PBAE/pLUC) 35 and
(PS/SPS)20(PBA E/poly(I:C))s films on silicon.
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Supplementary Figure S3-5. Bioactivity of multilayer released pDNA in vivo
(PS/SPS)2o(PBAE/pLUC) 2s films were constructed using either poly-] or poly-2 as the PBAE
component. Films were then incubated in PBS at 3 7'C for 7 days and release fractions were
collected after 2 or 7 days. Release fractions were normalized for concentration and injected
intradermally (1pg) in the auricular skin. Fresh PBAE/pLUCpolyplexes were formed by mixing
poly-1 and poly-2 with fresh pLUC and these were similarly injected for comparison with
polyplexes released from degrading (PS/SPS)2o(PBAE/pLUC) 2sfilms.
139
a105
104
Supplementary Figure S3-6. Expression of pDNA following pDNA microneedle tattooing
Whole animal bioluminescence images of pLUC expression at application site 1, 3, 10, or 20
days following a 15 min application of (SAv488-bPNMP)((PS/SPS)20 (poly-1/pLUC)35 coated
microneedle array without UV pretreatment of the PNMP release layer. No bioluminescence
signal was detected in the treated ears (marked by white arrows).
9.3. Releasable Layer-by-Layer Assembly of Stabilized Lipid Nanocapsules
Enhanced Transcutaneous Vaccine Delivery
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Supplementary Figure S4-1. Chemical structures of PBAE and MBP lipid
Chemical structures of (a) poly(3-amino ester) poly-1 and (b) maleimide MBP lipid used in this
study.
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Supplementary Figure S4-2. AFM characterization of room temperature stored ICMV
multilayers
AFM phase (a) and height (b) micrographs of a (PS/SPS)2o(poly-1/ICMV)s multilayer built on
silicon after 7 days at room temperature (scale bar 100nm). (c) 3-D rendered AFM height
micrograph data for a (PS/SPS)2o(poly-1/ICMV)s multilayer after storage for 7 days (scale bar
100nm). (d) Height trace data (trace shown in e) for a single embedded ICMV in a
(PS/SPS)20(poly-1/ICMV)s multilayer following room temperature storage.
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Supplementary Figure S4-3. In vivo microneedle delivery of ICMV multilayers
Representative confocal image of mouse skin treated for 5 minutes with (PS/SPS)2o(poly-
1/ICMV)3 5 multilayer-coated PLGA microneedles after 6 hours showing ICMV delivery at
microneedle insertion sites (outlined) colocalized with APCs and in depots several hundred
microns below the skin surface. Shown is fluorescent signal from MHC II-GFP (green), DiI-
ICMVs (red), AF647-OVA (pink), and overlay (yellow) (scale bar 100pm).
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Supplementary Figure S4-4. Microneedle deposition and delivery of OVA multilayers
(a) Growth curve for (poly-1/OVA), multilayers on (PS/SPS)20 on silicon, as assessed by surface
profilometry. (b) Representative confocal images of PLGA microneedles coated with
(PS/SPS)2o(poly-1/AF647-OVA) 45 films (left - transverse optical sections; right - lateral
sections, 100pm interval; scale bar 100 pm; pink - AF647-OVA). (c) Quantification of AF647-
OVA incorporation into (PS/SPS)2o(poly-1/AF647-OVA), films on microneedles through
confocal fluorescence intensity analysis (n = 15). Representative confocal images of PLGA
microneedles coated with (PS/SPS)20(poly-1/O VA) 45 films (lateral sections, 100pm interval;
scale bar 100 pm; pink - AF647-OVA) (d) before application and (e) after a 120 minute
application to murine skin in vivo. (f) Quantitation of confocal fluorescence intensities (n = 15)
showing loss of AF647-OVA films from coated microneedles upon application to skin for 5, 60,
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or 120 minutes. Representative confocal images of mouse skin treated for 5 minutes with
(PS/SPS)20(poly-1/O VA) 45 multilayer-coated PLGA microneedles after (g) 6 hours showing
ICMV delivery at microneedle insertion sites (outlined). Shown is fluorescent signal from (top to
bottom) MHC II-GFP (green), AF647-OVA (pink), and overlay (scale bar 100pm).
9.4. Composite Dissolving Microneedles for Coordinated Control of Antigen and Adjuvant
Delivery Kinetics in Transcutaneous Vaccination
a b
Supplementary Figure S5-1. Characterization of composite microneedles encapsulating
multiple cargos
(a) Confocal micrographs of PLGA-PAA composite microneedles fabricated to encapsulate both
DiD- and DiI-loaded PLGA microparticles of high molecular weight (HWM) or low molecular
weight (LWM) respectively (right, scale bar 200 pm) (b) Confocal micrographs of resulting
PLGA-PAA composite microneedles fabricated to encapsulate a layered DiL/DiD-loaded PLGA
tip implant (scale bar 200 pm). DiD and DiI were encapsulated in PLGA microparticles
synthesized from PLGA with IV 0.35 (LMW) or 0.70 (HMW).
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Supplementary Figure S5-2. In vivo delivery of solid PLGA-PAA composite microneedles
(a) Microneedle delivery scheme: (1) Microneedle arrays are applied briefly to penetrate murine
skin. (2) Cutaneous microneedle penetration exposes needles to interstitial fluid resulting in
rapid dissolution of the supportive PAA pedestal. (3) Following microneedle base removal,
released PLGA tips are left behind at penetration sites where soluble PAA-encapsulated cargoes
are rapidly delivered to the surround tissue. (4) PLGA deposition into the skin establishes a
depot for sustained delivery of encapsulated cargoes over time. (b) Confocal micrographs of
solid DiD-loaded PLGA tip microneedles before application (left) and following a 5 minute
application to murine skin (right, scale bar 200 pm). (c) Optical micrograph of microneedle
treated skin showing penetration sites stained using trypan blue (scale bar 500 pm). (d)
Confocal micrograph of treated skin, showing deposition of DiD-loaded PLGA tip implants
together with soluble AF488-loaded PAA at needle penetration sites directly following
microneedle application for 5 minutes (right, scale bar 100 pm, penetration sites outlined). (e)
Reconstructed confocal z-stack depicting the microneedle application site showing deposition of
PLGA-loaded cargoes within the cutaneous tissue (right, scale bar 100 pm).
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Supplementary Figure S5-3. In vivo control over cargo release following solid PLGA-PAA
microneedle treatment
(a) Whole animal fluorescence imaging of mice treated with DiD-loaded solid PLGA tip
microneedles with AF488-loaded PAA pedestals after 1, 5, and 18 days. Fluorescence signal
from AF488-PAA and DiD-PLGA implants is shown. (b) Quantification of relative fluorescent
signal detected at microneedle application site for bulk implant delivery.
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Supplementary Figure S5-4. In vivo cellular immunogenicity for composite microneedle
subunit vaccination
(a) Frequency of SIINFEKL-specific T cells in peripheral blood assessed by flow cytometry
analysis of tetramer* CD8' T cells. Shown are representative cytometry plots from individual
mice and mean tetramer* frequencies from day 14. (b) Analysis of T-cell effector/central
memory phenotypes in peripheral blood by CD44/CD62L staining on tetramer+ cells from
peripheral blood Shown are mean percentages of tetramer*CD44*CD62L* among CD8' T
cells at day 28.
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9.5. Implantable Silk Composite Microneedles for Programmable Vaccine Release Kinetics and
Enhanced Immunogenicity in Transcutaneous Immunization
Supplementary Figure S6-1. Composite microneedles give effective cutaneous delivery.
Reconstructed confocal x-y/x-z/y-z image depicting the microneedle application site showing
deposition of microparticle-cargos within the cutaneous tissue (AF647-OVA - blue, AF555-OVA
- red, overlay -pink, scale bar 100 u m).
MN
PAA(0)/Silk(2)
MN
PAA(98)/Silk(O)
MN MN
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Supplementary Figure S6-2. Microneedle vaccination gives enhanced effector function.
Flow cytometry analysis of inflammatory cytokine expression following ex vivo antigen
stimulation of PBMCs. Shown are representative cytometry plots of IFNy*/TNFa* CD8' T cells
measured on day 14.
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Supplementary Figure S6-3. Single microneedle vaccination gives comparable cellular
immunity relative to prime-boost injection.
Mice were vaccinated on day 0 and 35 by i.d injection, or on day 0 by microneedle treatment
(+methanol to cross-link silk implants) to deliver 9 pug OVA and 150 ng polyl:C. . Microneedles
were fabricated with 98% of the total vaccine dose in the PA A fraction, with the remaining 2% in
the silk implant (MN PAA(98)/MeOH-Silk(2)). Flow cytometry analysis of antigen-specific
CD8' T cell proliferation and cytokine secretion in peripheral blood. Shown is quantitative
analysis of peak SIINFEKL-tetramer+ CD8' T cell frequencies for 14 days following either
prime or boost immunization (left) and frequencies of IFNy* among CD8' T cells on day 14 post
prime/boost following in vitro restimulation with SIJNFEKL (right).
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Supplementary Figure S6-4. Single microneedle vaccination gives prolonged antigen
exposure.
Mice were vaccinated on day 0 and 35 by i.d injection, or on day 0 by microneedle treatment
(+methanol to cross-link silk implants) to deliver 9 pg OVA and 150 ng polyI:C. Microneedles
were fabricated with 98% of the total vaccine dose in the PAA fraction, with the remaining 2% in
the silk implant (MN PAA(98)/MeOH-Silk(2)). Flow cytometry analysis of antigen-specific
CD8' T cell KLRG] expression in peripheral blood Shown is quantitative analysis of KLRGJ
expression on SIINFEKL-tetramer+ CD8' T cells for day 70following vaccination.
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Supplementary Figure S6-5. Silk is non-immunogenic.
Mice were vaccinated on day 0 by i.d injection or microneedle treatment (+methanol to cross-
link silk implants) to deliver 9 pg OVA and 150 ngpolyI.C. Microneedles were fabricated with
98% of the total vaccine dose in the PAA fraction, with the remaining 2% in the silk implant (MN
PAA(98)/Silk(2) and MN PAA(98)/MeOH-Silk(2)). Shown are anti-Silk serum IgG levels for
day 21 as measured by ELISA.
9.6. Immunogenic Delivery of Adenoviral Vectors in Nonhuman
Enabling Dry, Refrigeration Free Vaccine Storage
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Figure 7-1. Microneedles induce potent mucosal cellular immune responses
(a-c) Frequencies of gag-specific CD8+ T-cells in mucosal tissues as assessed by flow cytometry
analysis of tetramer* CD8' T-cells. Shown are meands.e.m. tetramer+ values from day 21 for (a)
lungs (b) vaginal tissues, and (c) intraepithelial small intestinal tissues.
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